NZ782254A - Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof - Google Patents
Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereofInfo
- Publication number
- NZ782254A NZ782254A NZ782254A NZ78225416A NZ782254A NZ 782254 A NZ782254 A NZ 782254A NZ 782254 A NZ782254 A NZ 782254A NZ 78225416 A NZ78225416 A NZ 78225416A NZ 782254 A NZ782254 A NZ 782254A
- Authority
- NZ
- New Zealand
- Prior art keywords
- seq
- cancer
- ctla
- domain
- binding
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract description 44
- 229940045513 CTLA4 antagonist Drugs 0.000 claims abstract description 533
- 230000027455 binding Effects 0.000 claims abstract description 505
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims abstract description 490
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims abstract description 490
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 105
- 201000011510 cancer Diseases 0.000 claims abstract description 66
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 36
- 201000010099 disease Diseases 0.000 claims abstract description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 382
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 342
- 229920001184 polypeptide Polymers 0.000 claims description 339
- 210000004027 cell Anatomy 0.000 claims description 191
- 241000282414 Homo sapiens Species 0.000 claims description 118
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 64
- 238000006467 substitution reaction Methods 0.000 claims description 56
- 230000004048 modification Effects 0.000 claims description 26
- 238000012986 modification Methods 0.000 claims description 26
- 230000000638 stimulation Effects 0.000 claims description 24
- 238000004519 manufacturing process Methods 0.000 claims description 21
- 230000001404 mediated effect Effects 0.000 claims description 21
- 210000002966 serum Anatomy 0.000 claims description 20
- 230000004044 response Effects 0.000 claims description 19
- 208000015181 infectious disease Diseases 0.000 claims description 18
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 14
- 206010009944 Colon cancer Diseases 0.000 claims description 13
- 206010039491 Sarcoma Diseases 0.000 claims description 12
- 230000003612 virological effect Effects 0.000 claims description 11
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 9
- 206010017758 gastric cancer Diseases 0.000 claims description 9
- 201000011549 stomach cancer Diseases 0.000 claims description 9
- 208000008732 thymoma Diseases 0.000 claims description 9
- 206010005003 Bladder cancer Diseases 0.000 claims description 8
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 8
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 206010038389 Renal cancer Diseases 0.000 claims description 8
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 8
- 201000010982 kidney cancer Diseases 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 8
- 206010029260 Neuroblastoma Diseases 0.000 claims description 7
- 206010033128 Ovarian cancer Diseases 0.000 claims description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 7
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 7
- 208000037819 metastatic cancer Diseases 0.000 claims description 7
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 7
- 230000001737 promoting effect Effects 0.000 claims description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 6
- 230000002538 fungal effect Effects 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 208000034578 Multiple myelomas Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- -1 amino acid cations Chemical class 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 208000037540 Alveolar soft tissue sarcoma Diseases 0.000 claims description 4
- 206010003571 Astrocytoma Diseases 0.000 claims description 4
- 206010004593 Bile duct cancer Diseases 0.000 claims description 4
- 206010005949 Bone cancer Diseases 0.000 claims description 4
- 208000018084 Bone neoplasm Diseases 0.000 claims description 4
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 4
- 208000001843 Carotid Body Tumor Diseases 0.000 claims description 4
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 4
- 201000009047 Chordoma Diseases 0.000 claims description 4
- 208000008743 Desmoplastic Small Round Cell Tumor Diseases 0.000 claims description 4
- 206010064581 Desmoplastic small round cell tumour Diseases 0.000 claims description 4
- 206010014967 Ependymoma Diseases 0.000 claims description 4
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 4
- 208000021309 Germ cell tumor Diseases 0.000 claims description 4
- 208000009164 Islet Cell Adenoma Diseases 0.000 claims description 4
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 4
- 206010024612 Lipoma Diseases 0.000 claims description 4
- 208000000172 Medulloblastoma Diseases 0.000 claims description 4
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 206010033963 Parathyroid tumour Diseases 0.000 claims description 4
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 4
- 206010057644 Testis cancer Diseases 0.000 claims description 4
- 201000009365 Thymic carcinoma Diseases 0.000 claims description 4
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 4
- 208000008524 alveolar soft part sarcoma Diseases 0.000 claims description 4
- 208000012080 benign lipomatous neoplasm Diseases 0.000 claims description 4
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 4
- 210000000988 bone and bone Anatomy 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 4
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 4
- 201000010240 chromophobe renal cell carcinoma Diseases 0.000 claims description 4
- 208000009060 clear cell adenocarcinoma Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 210000000232 gallbladder Anatomy 0.000 claims description 4
- 201000010175 gallbladder cancer Diseases 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 201000002529 islet cell tumor Diseases 0.000 claims description 4
- 201000005252 lipomatous cancer Diseases 0.000 claims description 4
- 206010024627 liposarcoma Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 208000030883 malignant astrocytoma Diseases 0.000 claims description 4
- 206010051747 multiple endocrine neoplasia Diseases 0.000 claims description 4
- 208000023833 nerve sheath neoplasm Diseases 0.000 claims description 4
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 claims description 4
- 208000010916 pituitary tumor Diseases 0.000 claims description 4
- 201000002267 posterior uveal melanoma Diseases 0.000 claims description 4
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 201000011096 spinal cancer Diseases 0.000 claims description 4
- 208000014618 spinal cord cancer Diseases 0.000 claims description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 4
- 208000017572 squamous cell neoplasm Diseases 0.000 claims description 4
- 201000003120 testicular cancer Diseases 0.000 claims description 4
- 210000001685 thyroid gland Anatomy 0.000 claims description 4
- 208000025443 tumor of adipose tissue Diseases 0.000 claims description 4
- 208000017997 tumor of parathyroid gland Diseases 0.000 claims description 4
- 206010046766 uterine cancer Diseases 0.000 claims description 4
- 208000030507 AIDS Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 206010053717 Fibrous histiocytoma Diseases 0.000 claims description 3
- 208000032612 Glial tumor Diseases 0.000 claims description 3
- 206010018338 Glioma Diseases 0.000 claims description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
- 208000008938 Rhabdoid tumor Diseases 0.000 claims description 3
- 206010073334 Rhabdoid tumour Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 3
- 244000052616 bacterial pathogen Species 0.000 claims description 3
- 208000001119 benign fibrous histiocytoma Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 201000010073 fibrogenesis imperfecta ossium Diseases 0.000 claims description 3
- 201000010103 fibrous dysplasia Diseases 0.000 claims description 3
- 244000053095 fungal pathogen Species 0.000 claims description 3
- 206010027191 meningioma Diseases 0.000 claims description 3
- 230000001394 metastastic effect Effects 0.000 claims description 3
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 3
- 201000011519 neuroendocrine tumor Diseases 0.000 claims description 3
- 244000079416 protozoan pathogen Species 0.000 claims description 3
- 206010038038 rectal cancer Diseases 0.000 claims description 3
- 201000001275 rectum cancer Diseases 0.000 claims description 3
- 244000052613 viral pathogen Species 0.000 claims description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 2
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 208000028591 pheochromocytoma Diseases 0.000 claims description 2
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims description 2
- 230000001573 trophoblastic effect Effects 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 34
- 230000028993 immune response Effects 0.000 abstract description 14
- 210000005260 human cell Anatomy 0.000 abstract description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 107
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 99
- 238000012063 dual-affinity re-targeting Methods 0.000 description 96
- 238000000375 direct analysis in real time Methods 0.000 description 94
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 93
- 102100023374 Forkhead box protein M1 Human genes 0.000 description 59
- 101000907578 Homo sapiens Forkhead box protein M1 Proteins 0.000 description 59
- 235000001014 amino acid Nutrition 0.000 description 47
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 47
- 230000006870 function Effects 0.000 description 44
- 230000014509 gene expression Effects 0.000 description 44
- 230000000694 effects Effects 0.000 description 43
- 108090000623 proteins and genes Proteins 0.000 description 41
- 239000000427 antigen Substances 0.000 description 40
- 210000002865 immune cell Anatomy 0.000 description 40
- 229940024606 amino acid Drugs 0.000 description 38
- 102000036639 antigens Human genes 0.000 description 38
- 108091007433 antigens Proteins 0.000 description 38
- 150000001413 amino acids Chemical class 0.000 description 36
- 238000003556 assay Methods 0.000 description 35
- 210000000987 immune system Anatomy 0.000 description 34
- 239000000203 mixture Substances 0.000 description 33
- 235000018417 cysteine Nutrition 0.000 description 32
- 235000018102 proteins Nutrition 0.000 description 32
- 102000004169 proteins and genes Human genes 0.000 description 32
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 31
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 31
- 210000004899 c-terminal region Anatomy 0.000 description 31
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 31
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 31
- 101800001707 Spacer peptide Proteins 0.000 description 30
- 239000012636 effector Substances 0.000 description 25
- 150000002500 ions Chemical class 0.000 description 24
- 239000003446 ligand Substances 0.000 description 24
- 230000002401 inhibitory effect Effects 0.000 description 23
- 230000004913 activation Effects 0.000 description 22
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 22
- 102000005962 receptors Human genes 0.000 description 22
- 108020003175 receptors Proteins 0.000 description 22
- 230000003993 interaction Effects 0.000 description 20
- 230000000903 blocking effect Effects 0.000 description 19
- 239000012634 fragment Substances 0.000 description 19
- 102100034428 Dual specificity protein phosphatase 1 Human genes 0.000 description 17
- 108060003951 Immunoglobulin Proteins 0.000 description 17
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 17
- 239000004472 Lysine Substances 0.000 description 17
- 102000018358 immunoglobulin Human genes 0.000 description 17
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 17
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 16
- 102000004127 Cytokines Human genes 0.000 description 16
- 108090000695 Cytokines Proteins 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 239000000872 buffer Substances 0.000 description 16
- 238000011156 evaluation Methods 0.000 description 16
- 102000017578 LAG3 Human genes 0.000 description 15
- 101150030213 Lag3 gene Proteins 0.000 description 15
- 108020001507 fusion proteins Proteins 0.000 description 15
- 102000037865 fusion proteins Human genes 0.000 description 14
- 230000036039 immunity Effects 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 14
- 108091033319 polynucleotide Proteins 0.000 description 14
- 102000040430 polynucleotide Human genes 0.000 description 14
- 239000002157 polynucleotide Substances 0.000 description 14
- 102100027088 Dual specificity protein phosphatase 5 Human genes 0.000 description 13
- 239000012082 adaptor molecule Substances 0.000 description 13
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 13
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 12
- 230000003213 activating effect Effects 0.000 description 12
- 125000000539 amino acid group Chemical group 0.000 description 12
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 230000003834 intracellular effect Effects 0.000 description 12
- 210000001616 monocyte Anatomy 0.000 description 12
- 230000035755 proliferation Effects 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 230000006044 T cell activation Effects 0.000 description 11
- 108091008874 T cell receptors Proteins 0.000 description 11
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 11
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 101100291853 Caenorhabditis briggsae uba-4 gene Proteins 0.000 description 10
- 101100291854 Caenorhabditis elegans moc-3 gene Proteins 0.000 description 10
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 10
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 10
- 241000282567 Macaca fascicularis Species 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 230000037361 pathway Effects 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 9
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 9
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 9
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 9
- 230000006052 T cell proliferation Effects 0.000 description 9
- 230000005867 T cell response Effects 0.000 description 9
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 9
- 230000004927 fusion Effects 0.000 description 9
- 238000005734 heterodimerization reaction Methods 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 101100262441 Caenorhabditis elegans rfl-1 gene Proteins 0.000 description 8
- 210000000612 antigen-presenting cell Anatomy 0.000 description 8
- 230000004940 costimulation Effects 0.000 description 8
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 8
- 210000004698 lymphocyte Anatomy 0.000 description 8
- 230000011664 signaling Effects 0.000 description 8
- 241000894007 species Species 0.000 description 8
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 7
- 101100256089 Caenorhabditis elegans uba-2 gene Proteins 0.000 description 7
- 108010002350 Interleukin-2 Proteins 0.000 description 7
- 241000288906 Primates Species 0.000 description 7
- 241000283984 Rodentia Species 0.000 description 7
- 210000004443 dendritic cell Anatomy 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 230000002708 enhancing effect Effects 0.000 description 7
- 102000043321 human CTLA4 Human genes 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 210000000822 natural killer cell Anatomy 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 230000003389 potentiating effect Effects 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 230000004936 stimulating effect Effects 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 241000283707 Capra Species 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 241000711549 Hepacivirus C Species 0.000 description 6
- 241000709721 Hepatovirus A Species 0.000 description 6
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 6
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- 101710094000 Programmed cell death 1 ligand 1 Proteins 0.000 description 6
- 241000711975 Vesicular stomatitis virus Species 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 229960002685 biotin Drugs 0.000 description 6
- 239000011616 biotin Substances 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 230000000139 costimulatory effect Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000002519 immonomodulatory effect Effects 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 210000003289 regulatory T cell Anatomy 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 6
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 108010044091 Globulins Proteins 0.000 description 5
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000000182 cd11c+cd123- dc Anatomy 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000006471 dimerization reaction Methods 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000005746 immune checkpoint blockade Effects 0.000 description 5
- 230000003832 immune regulation Effects 0.000 description 5
- 229940072221 immunoglobulins Drugs 0.000 description 5
- 230000004807 localization Effects 0.000 description 5
- 230000002101 lytic effect Effects 0.000 description 5
- 239000003226 mitogen Substances 0.000 description 5
- 101150033518 uba-5 gene Proteins 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 4
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 4
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 4
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 4
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 4
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 230000000735 allogeneic effect Effects 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 230000016396 cytokine production Effects 0.000 description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 239000000710 homodimer Substances 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 229960003301 nivolumab Drugs 0.000 description 4
- 238000011275 oncology therapy Methods 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 230000000087 stabilizing effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 101150034533 ATIC gene Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 241001465677 Ancylostomatoidea Species 0.000 description 3
- 241000228212 Aspergillus Species 0.000 description 3
- 241000228245 Aspergillus niger Species 0.000 description 3
- 241000304886 Bacilli Species 0.000 description 3
- 208000019838 Blood disease Diseases 0.000 description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 3
- 241000242722 Cestoda Species 0.000 description 3
- 206010008631 Cholera Diseases 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 201000007336 Cryptococcosis Diseases 0.000 description 3
- 241000221204 Cryptococcus neoformans Species 0.000 description 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102000001301 EGF receptor Human genes 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- 241000588914 Enterobacter Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 208000006168 Ewing Sarcoma Diseases 0.000 description 3
- 108010087819 Fc receptors Proteins 0.000 description 3
- 102000009109 Fc receptors Human genes 0.000 description 3
- 229920001917 Ficoll Polymers 0.000 description 3
- 102000006395 Globulins Human genes 0.000 description 3
- 101800000194 Growth hormone-binding protein Proteins 0.000 description 3
- 102400001066 Growth hormone-binding protein Human genes 0.000 description 3
- 241000700721 Hepatitis B virus Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
- 241000701027 Human herpesvirus 6 Species 0.000 description 3
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 3
- 241000588748 Klebsiella Species 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- 241000222727 Leishmania donovani Species 0.000 description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 3
- 241000282560 Macaca mulatta Species 0.000 description 3
- 241000235395 Mucor Species 0.000 description 3
- 241000235388 Mucorales Species 0.000 description 3
- 108091007960 PI3Ks Proteins 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 3
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 3
- 241000242594 Platyhelminthes Species 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 241000589516 Pseudomonas Species 0.000 description 3
- 241000235527 Rhizopus Species 0.000 description 3
- 241000606701 Rickettsia Species 0.000 description 3
- 241000607142 Salmonella Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 102000004584 Somatomedin Receptors Human genes 0.000 description 3
- 108010017622 Somatomedin Receptors Proteins 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 206010043376 Tetanus Diseases 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 238000003782 apoptosis assay Methods 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000002619 cancer immunotherapy Methods 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 206010013023 diphtheria Diseases 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 230000005714 functional activity Effects 0.000 description 3
- 244000000013 helminth Species 0.000 description 3
- 208000014951 hematologic disease Diseases 0.000 description 3
- 239000000833 heterodimer Substances 0.000 description 3
- 102000048362 human PDCD1 Human genes 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 108091008042 inhibitory receptors Proteins 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 229960002621 pembrolizumab Drugs 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 230000005522 programmed cell death Effects 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 206010042863 synovial sarcoma Diseases 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 241001529453 unidentified herpesvirus Species 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- WLJWJOQWLPAHIE-YLXLXVFQSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]pentanedioic acid Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O WLJWJOQWLPAHIE-YLXLXVFQSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 241001225321 Aspergillus fumigatus Species 0.000 description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- 229940122738 CD3 agonist Drugs 0.000 description 2
- 208000016778 CD4+/CD56+ hematodermic neoplasm Diseases 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 241000157306 Dientamoeba fragilis Species 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 2
- 201000003364 Extraskeletal myxoid chondrosarcoma Diseases 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 241000224466 Giardia Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 241000228402 Histoplasma Species 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 2
- 101100334515 Homo sapiens FCGR3A gene Proteins 0.000 description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 108010073807 IgG Receptors Proteins 0.000 description 2
- 102000009490 IgG Receptors Human genes 0.000 description 2
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 241000589248 Legionella Species 0.000 description 2
- 208000007764 Legionnaires' Disease Diseases 0.000 description 2
- 206010024238 Leptospirosis Diseases 0.000 description 2
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 2
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 102220482767 Mitochondrial coenzyme A diphosphatase NUDT8_D79A_mutation Human genes 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 241000526686 Paracoccidioides brasiliensis Species 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 108010047620 Phytohemagglutinins Proteins 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241000607720 Serratia Species 0.000 description 2
- 241000295644 Staphylococcaceae Species 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 241000242541 Trematoda Species 0.000 description 2
- 241000223105 Trypanosoma brucei Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002494 anti-cea effect Effects 0.000 description 2
- 230000001130 anti-lysozyme effect Effects 0.000 description 2
- 102000025171 antigen binding proteins Human genes 0.000 description 2
- 108091000831 antigen binding proteins Proteins 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 230000000536 complexating effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 108091008034 costimulatory receptors Proteins 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 208000003884 gestational trophoblastic disease Diseases 0.000 description 2
- 108091022928 glucosylglycerol-phosphate synthase Proteins 0.000 description 2
- 201000009277 hairy cell leukemia Diseases 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 238000011577 humanized mouse model Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000005917 in vivo anti-tumor Effects 0.000 description 2
- 229960005386 ipilimumab Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229930192851 perforin Natural products 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000001885 phytohemagglutinin Effects 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000000163 radioactive labelling Methods 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- FGDZQCVHDSGLHJ-UHFFFAOYSA-M rubidium chloride Chemical compound [Cl-].[Rb+] FGDZQCVHDSGLHJ-UHFFFAOYSA-M 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 229950007217 tremelimumab Drugs 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- WLKSPGHQGFFKGE-UHFFFAOYSA-N 1-chloropropan-2-yl n-(3-chlorophenyl)carbamate Chemical compound ClCC(C)OC(=O)NC1=CC=CC(Cl)=C1 WLKSPGHQGFFKGE-UHFFFAOYSA-N 0.000 description 1
- 241000235389 Absidia Species 0.000 description 1
- REAQAWSENITKJL-DDWPSWQVSA-N Ala-Met-Asp-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O REAQAWSENITKJL-DDWPSWQVSA-N 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- 101150076489 B gene Proteins 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000228405 Blastomyces dermatitidis Species 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- 101000741929 Caenorhabditis elegans Serine/threonine-protein phosphatase 2A catalytic subunit Proteins 0.000 description 1
- 101100279186 Caenorhabditis elegans efn-4 gene Proteins 0.000 description 1
- 101100069857 Caenorhabditis elegans hil-4 gene Proteins 0.000 description 1
- 101100022187 Caenorhabditis elegans mab-10 gene Proteins 0.000 description 1
- 101100346155 Caenorhabditis elegans oma-2 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 244000197813 Camelina sativa Species 0.000 description 1
- 241000222178 Candida tropicalis Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000588923 Citrobacter Species 0.000 description 1
- 102000035183 Clathrin adaptor proteins Human genes 0.000 description 1
- 108091005769 Clathrin adaptor proteins Proteins 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 229920002911 Colestipol Polymers 0.000 description 1
- 102100030886 Complement receptor type 1 Human genes 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000004243 E-number Substances 0.000 description 1
- 235000019227 E-number Nutrition 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000237537 Ensis Species 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- 101100061678 Homo sapiens CTLA4 gene Proteins 0.000 description 1
- 101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 102100034980 ICOS ligand Human genes 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102220478985 Interleukin-4 receptor subunit alpha_L64A_mutation Human genes 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241001245510 Lambia <signal fly> Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
- 101100400378 Mus musculus Marveld2 gene Proteins 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- AFQNEJIPKKLOCL-UHFFFAOYSA-N N-{1-amino-6-[(5-nitro-2-furoyl)amino]-1-oxohexan-2-yl}-26-(indol-3-yl)-23-oxo-4,7,10,13,16,19-hexaoxa-22-azahexacosan-1-amide Chemical compound C=1NC2=CC=CC=C2C=1CCCC(=O)NCCOCCOCCOCCOCCOCCOCCC(=O)NC(C(=O)N)CCCCNC(=O)C1=CC=C([N+]([O-])=O)O1 AFQNEJIPKKLOCL-UHFFFAOYSA-N 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 102000017954 Nuclear factor of activated T cells (NFAT) Human genes 0.000 description 1
- 108050007058 Nuclear factor of activated T cells (NFAT) Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102220473319 PCNA-associated factor_I65A_mutation Human genes 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 240000007643 Phytolacca americana Species 0.000 description 1
- 235000009074 Phytolacca americana Nutrition 0.000 description 1
- 241000235645 Pichia kudriavzevii Species 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000010362 Protozoan Infections Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229940125647 RAED Drugs 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 102000014400 SH2 domains Human genes 0.000 description 1
- 108050003452 SH2 domains Proteins 0.000 description 1
- 101100378956 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) AMD2 gene Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010029180 Sialic Acid Binding Ig-like Lectin 3 Proteins 0.000 description 1
- 102000001555 Sialic Acid Binding Ig-like Lectin 3 Human genes 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 241001149962 Sporothrix Species 0.000 description 1
- 101001057121 Staphylococcus aureus Enterotoxin type B Proteins 0.000 description 1
- 108700011201 Streptococcus IgG Fc-binding Proteins 0.000 description 1
- 102000000551 Syk Kinase Human genes 0.000 description 1
- 108010016672 Syk Kinase Proteins 0.000 description 1
- 201000008736 Systemic mastocytosis Diseases 0.000 description 1
- 229940126530 T cell activator Drugs 0.000 description 1
- 230000020385 T cell costimulation Effects 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 241000243774 Trichinella Species 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 1
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000000961 alloantigen Effects 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 238000002841 anti-cancer assay Methods 0.000 description 1
- 230000005911 anti-cytotoxic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000006041 cell recruitment Effects 0.000 description 1
- 230000015861 cell surface binding Effects 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000004041 dendritic cell maturation Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000006334 disulfide bridging Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 229940096118 ella Drugs 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000003174 enzyme fragment complementation Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- SXXHYAMKYMNIHI-UHFFFAOYSA-N fluoroimino(sulfanylidene)methane Chemical compound FN=C=S SXXHYAMKYMNIHI-UHFFFAOYSA-N 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000012817 gel-diffusion technique Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 102000055229 human IL4 Human genes 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000011502 immune monitoring Methods 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000006028 immune-suppresssive effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000011575 immunodeficient mouse model Methods 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 230000003259 immunoinhibitory effect Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000009500 myxoid chondrosarcoma Diseases 0.000 description 1
- 210000004296 naive t lymphocyte Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 108010068617 neonatal Fc receptor Proteins 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 101710135378 pH 6 antigen Proteins 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229950010773 pidilizumab Drugs 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000027317 positive regulation of immune response Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 208000030925 respiratory syncytial virus infectious disease Diseases 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229940102127 rubidium chloride Drugs 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- KISFEBPWFCGRGN-UHFFFAOYSA-M sodium;2-(2,4-dichlorophenoxy)ethyl sulfate Chemical compound [Na+].[O-]S(=O)(=O)OCCOC1=CC=C(Cl)C=C1Cl KISFEBPWFCGRGN-UHFFFAOYSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 231100000617 superantigen Toxicity 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000003211 trypan blue cell staining Methods 0.000 description 1
- 210000004926 tubular epithelial cell Anatomy 0.000 description 1
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 229940055760 yervoy Drugs 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention is directed to bispecific molecules (e.g., diabodies, bispecific antibodies, trivalent binding molecules, etc.) that possess at least one epitope-binding site that is immunospecific for an epitope of PD-1 and at least one epitope-binding site that is immunospecific for an epitope of CTLA-4 (i.e., a “PD-1 x CTLA-4 bispecific molecule”). The PD-1 x CTLA-4 bispecific molecules of the present invention are capable of simultaneously binding to PD-1 and to CTLA-4, particularly as such molecules are arrayed on the surfaces of human cells. The invention is directed to pharmaceutical compositions that contain such PD-1 x CTLA-4 bispecific molecules, and to methods involving the use of such bispecific molecules in the treatment of cancer and other diseases and conditions. The present invention also pertains to methods of using such PD-1 x CTLA-4 bispecific molecules to stimulate an immune response.
Description
TITLE OF THE INVENTION:
Bispecific Molecules Having Immunoreactivity with PD-1 and
CTLA-4, and Methods of Use Thereof
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a divisional of New Zealand Application No. , filed on
1 June 2018, and is related to International Patent Application No. , filed
on 12 December 2016 and claims priority to, U.S. Patent Appln. Serial No. 62/266,944 (filed:
December 14, 2015; pending), which application is incorporated herein in its entirety.
REFERENCE TO SEQUENCE G
This application includes one or more Sequence Listings pursuant to 37 C.F.R.
1.821 et seq., which are disclosed in computer-readable media (file name:
1301_0134PCT_ST25.txt, created on December 4, 2016, and having a size of 186,040 bytes),
which file is herein incorporated by reference in its entirety.
FIELD OF THE INVENTION
The present invention is directed to ific molecules (e.g., diabodies,
bispecific dies, ent binding les, etc.) that possess at least one epitope-binding
site that is immunospecific for an epitope of PD-1 and at least one epitope-binding site that is
immunospecific for an epitope of CTLA-4 (i.e., a “PD-1 x CTLA-4 bispecific molecule”). The
present invention concerns such PD-1 x CTLA-4 bispecific molecules that possess two
epitope-binding sites that are immunospecific for one (or two) epitope(s) of PD-1 and two
epitope-binding sites that are specific for one (or two) epitope(s) of CTLA-4. The
present ion also is directed to such PD-1 x CTLA-4 ific molecules that additionally
comprise an globulin Fc Region. The PD-1 x CTLA-4 bispecific molecules of the
present invention are capable of simultaneously binding to PD-1 and to CTLA-4, particularly
as such molecules are arrayed on the surfaces of human cells. The invention is directed to
pharmaceutical compositions that contain such PD-1 x CTLA-4 bispecific molecules, and to
methods involving the use of such bispecific molecules in the ent of cancer and other
diseases and conditions. The present invention also ns to methods of using such PD-1 x
CTLA-4 bispecific molecules to stimulate an immune response.
BACKGROUND OF THE ION
1. The Immune System Response to Cancer
The mammalian immune system is lly poised to recognize and eliminate
cancerous cells (Topalian, S.L. et al. (2015) “Immune Checkpoint Blockade: A Common
Denominator ch to Cancer Therapy,” Cancer Cell 271450-461). In y duals,
the immune system is in a quiescent state, inhibited by a repertoire of diverse inhibitory
receptors and ligands. Such immune “checkpoint” pathways are important in maintaining self-
tolerance (i.e., in preventing a subject from mounting an immune system attack against his/her
own cells (an “autoimmune” reaction) and in ng collateral tissue damage during anti-
microbial or anti-allergic immune responses. Upon recognition of a cancer antigen, detection
of a microbial pathogen, or the presence of an allergen, an array of activating receptors and
ligands induce the activation of the immune system. Such activation leads to the activation of
macrophages, Natural Killer (NK) cells and antigen-specific, cytotoxic, T—cells, and promotes
the release of various cytokines, all of which act to counter the perceived threat to the health
ofthe subject (Dong, C. et al. (2003) “Immune Regulation by Novel Costimulatory Molecules,”
Immunolog. Res. 28(1):39-48; tta, V. et al. (2007) “Modulating Co-Stimulation,”
herapeutics 41666-675; Korman, AJ. et al. (2007) “Checkpoint Blockade in Cancer
Immunotherapy,” Adv. Immunol. 90:297-339). The immune system is capable of returning to
its normal quiescent state when the countervailing inhibitory immune signals outweigh the
activating immune s.
Thus, the disease state of cancer (and indeed the disease states of infectious
diseases) may be considered to reflect a failure to adequately activate a subject’s immune
system. Such failure may reflect an inadequate presentation of activating immune signals, or
it may reflect an inadequate ability to ate inhibitory immune s in the subject. In
some instances, researchers have determined that cancer cells can co-opt the immune system
to evade being detected by the immune system (Topalian, S.L. et al. (2015) “Immune
Checkpoint Blockade: A Common Denominator Approach to Cancer y,” Cancer Cell
-461).
Of particular importance is binding between the B7.1 (CD80) and B72 (CD86)
ligands of the Antigen-Presenting Cell and the CD28 and CTLA-4 receptors of the CD4+ T
lymphocyte (Sharpe, A.H. et al. (2002) “The B7-CD28 Superfamily,” Nature Rev. Immunol.
2:116-126; Dong, C. et al. (2003) “Immune Regulation by Novel ulatory Molecules,”
Immunolog. Res. 28(1):39—48, Lindley, P.S. et al. (2009) “Ihe Clinical Utility biting
CD28-Mediated ulation,” Immunol. Rev. 229:307-321), Binding of B7,] or of B72 to
CD28 ates T-cell activation; binding ofB71 or B72 to CTLA-4 inhibits such activation
(Dong, C. et al. (2003) “Immune Regulation by Novel Costimulatory Molecules,” Immunolog.
Res. 28(1):39-48, Lindley, P.S. et al. (2009) “The Clinical Utility OfInhibiting CD28-Mediated
Costimulation,” Immunol. Rev. 229:307-321; Greenwald, R]. et al. (2005) “Ihe B7 Family
Revisited,” Ann. Rev. Immunol. 23:515-548). CD28 is constitutively expressed on the surface
of T-cells (Gross, J., et al. (1992) “Identification And Distribution Of Ihe Costimulatory
Receptor CD28 In The Mouse,” J. Immunol. 149:380—388), whereas CTLA-4 expression is
rapidly upregulated following T-cell activation (Linsley, P. et al. (1996) “Intracellular
Trafiicking OfCTLA4 AndFocal Localization Towards Sites OfTCR Engagement,” Immunity
4:535—543). Since CTLA-4 is the higher affinity receptor (Sharpe, AH. et al. (2002) “The B 7-
CD28 amily,” Nature Rev. Immunol. 2: 1 , an, S.L. et al. (2015) “Immune
oint Blockade: A Common Denominator Approach to Cancer Therapy,” Cancer Cell
27:450-461), binding first initiates T-cell proliferation (via CD28) and then inhibits it (via
nascent expression of CTLA-4), thereby dampening the effect when proliferation is no longer
needed.
II. CTLA-4
Cytotoxic T-lymphocyte associated n—4 (CTLA-4; CD152) is a single pass
type I ne protein that forms a de linked homo-dimer rtz J.C,, et al. (2001)
“Structural Basis For Co—Stimulation By The Human CTLA-4/B7-2 Complex,” Nature
410:604-608). Alternate splice variants, encoding ent isoforms, have been characterized
including a soluble isoform which functions as a monomer (Magistrelli G., et al. (1999) “A
Soluble Form OfCTLA-4 Generated By Alternative Splicing Is sed By Nonstimulated
Human T Cells,” Eur. J. l. 29:3596-3602, Oaks MK. et al. (2000) “A Native Soluble
Form OfCTLA-4,” Cell Immunol 201:144-153).
CTLA-4 is primarily an intracellular antigen whose surface expression is tightly
regulated by restricted trafficking to the cell e and rapid internalization (Alegre M-L, et
al. AndIntracellular Expression OfCTLA4 OnMouse TCells,”
, (1996) “Regulation OfSurface
J. Immunol. 157:4762—4770; y, P.S. et al. (1996) “Intracellular Trayficking OfCTLA-4
AndFocal Localization Towards Sites Of TCR Engagement,” Immunity 4:53 5—543). CTLA-
4 is expressed at low levels on the surface of naive effector T-cells (Alegre, M.L., et al. (1996)
“Regulation Of Surface And Intracellular Expression Of CTLA4 On Mouse T Cells,” J
Immunol 157:4762-70), and constitutively expressed on T regulatory cells (Wang, X.B., et al.
(2002) “Expression OfCTLA-4 By Human Monocytes,” Scand. J. Immunol. 55:53-60).
The extracellular region of CTLA-4 comprises a single extracellular Ig(V)
domain, followed by a embrane (TM) region and a small intracellular cytoplasmic tail
(37 amino acids). The intracellular tail ns two tyrosine-based motifs, which interact with
several ellular proteins, including the lipid kinase phosphatidylinositol 3-kinase (PI3K),
the phosphatases SHP-2 and PP2A and clathrin adaptor proteins AP-l and AP-2 (Rudd, C.E.
et al. (2003) “Unifi/ing Concepts In CD28, ICOS And CTLA4 Co-Receptor Signalling,” Nat
Rev l. 3:544-56). CTLA-4 is related to CD28, with the two proteins having
approximately 29% identity at the amino acid level (Harper, K. (1991) “CTLA-4 And CD28
Activated Lymphocyte Molecules Are Closely d In Mouse AndHuman As T0 ce,
Message Expression, Gene Structure, And Chromosomal Location,” J. Immunol. 147:1037-
1044)
When a naive T effector cell is activated through its T-cell receptors (TCRs),
CTLA-4 is recruited to the cell surface (Linsley, P.S., et al. (1996) “Intracellular Trajficking
OfCTLA-4 AndFocal Localization Towards Sites OfTCR Engagement,” Immunity 4:53 5-43).
Once CTLA—4 is expressed on the T-cell surface, it competes with CD28 (constitutively
expressed on T-cells) for CD80/CD86, thereby shutting off further signaling through the TCR
and thus down—regulating any further T—cell response by TCR signaling (Carreno, B.M., et al.
(2000) “CTLA-4 ) Can Inhibit T Cell Activation By Two Dierrent Mechanisms
Depending On Its Level OfCell Surface Expression,” J l 165: 13 52-6;Chuang, E., et al.
(1999) “Regulation Of Cytotoxic T cyte-Associated Molecule-4 By Src Kinases,” J
Immunol 162: 1270-7). Thus, CTLA-4 acts as a negative regulator of T effector cell activation
that diminishes effector function and dictates the efficacy and duration of a T-cell response
(Linsley, P.S., et al. (1996) cellular Traficking Of CTLA-4 And Focal Localization
Towards Sites OfTCR Engagement,” ty 43).
[001 1] In addition, CTLA-4 may play a role in enhancing the negative effect of
regulatory T—cells on the immune response to cancer (Tai, Y.T., et al., (2012) “Potent in vitro
And in vivo Activity OfAn Fc-Engineered HumanizedAnti-HM1.24 Antibody AgainstMultiple
a viaAugmentedEjfector Function,” Blood 1 4-82). CTLA-4 has a much higher
ty for members of the B7 family than for CD28, and therefore its expression on a T-cell
dictates a dominant negative regulation of the T-cell (Allison, J.P., et al. (1995) “Manipulation
Of Costimulatory Signals To Enhance Antitumor T-Cell Responses,” Curr Opin Immunol
7 :682-6). The ism by which CTLA-4 contributes to the suppressor on of T
regulatory cells is incompletely understood, but the expression of CTLA-4 on T regulatory
cells enhances the suppressive function of these cells (Tai, Y.T., et al, (2012) “Potent in vitro
And in vivo ty OfAn Fc-Engineered HumanizedAnti-HMI. 24 Antibody tMultiple
Myeloma via Augmented Effector Function,” Blood 1 19:2074-82).
Blockage of CTLA-4 is ed to enhance T-cell responses in vitro (Walunas,
T.L., et al. (1994) “CTLA-4 Can Function As A Negative Regulator Of T Cell Activation,”
Immunity 1:405-413) and in vivo (Kearney, E.R., et al. (1995) “Antigen-Dependent Clonal
Expansion OfA Trace Population OfAntigen-Specific CD4+ T Cells in vivo Is Dependent On
CD28 Costimulation And Inhibited By CTLA-4,” J. Immunol. 155:1032-1036) and also to
increase mor immunity , D.R. et al. (1996) “Enhancement OfAntitumor Immunity
By CTLA-4 Blockade,” Science 271:1734-1736). Thus, blockage of CTLA—4 using anti-
CTLA-4 antibodies has been proposed to provide new treatments for disease, especially human
diseases where immune stimulation might be beneficial such as for treatment of cancers and
infectious diseases (see, Leach, D.R., et al. (1996) “Enhancement OfAntitumor Immunity By
CTLA-4 Blockade,” Science. 271:1734-1736, and PCT Publications No. WO 01/14424; WO
04). Development of blockers of CTLA-4 function has focused on the use of
monoclonal antibodies such as umab (see, e. g., Hodi, F.S., et al., (2003) “Biologic
Activity Of xic T Lymphocyte-Associated Antigen 4 Antibody Blockade In Previously
Vaccinated Metastatic Melanoma And Ovarian Carcinoma ts,” Proc. Natl. Acad. Sci.
(USA) 100:4717-4717) and tremelimumab (Ribas, A. et al. (2005) “Antitumor Activity In
MelanomaAndAnti-SelfResponses InA Phase I Trial With The Anti-Cytotoxic TLymphocyte-
AssociatedAntigen 4 Monoclonal Antibody CP-675,206,” Oncologist 12: 3).
111. Programmed Death-1 (“PD-1”)
Programmed Death-1 (“PD-1,” also known as “CD279”) is type I membrane
protein member of the extended CD28/CTLA-4 family of T-cell regulators that broadly
negatively tes immune ses (Ishida, Y. et al. (1992) “Induced sion OfPD-
1, A Novel Member Of The Immunoglobulin Gene Superfamily, Upon Programmed Cell
Death,” EMBO J. 11:3887-3895; United States Patent Application Publications No.
2007/0202100, 311117, 2009/00110667; United States Patents No. 6,808,710,
550, 7,488,802, 7,635,757; 7,722,868; PCT Publication No. wo 01/14557).
The receptor-ligand ctions of the PD-l system appear to be even more
complex than those of the CD28/CTLA-4 system. PD-1 is expressed on the cell surface of
activated T-cells, B-cells, and monocytes (Agata, Y. et al. (1996) “Expression Of The PD-I
Antigen On The Surface OfStimulatedMouse TAndB Lymphocytes,” Int. Immunol. 8(5):765-
772; Yamazaki, T. et al. (2002) “Expression OfProgrammed Death 1 Ligands By Murine T-
Cells AndAPC,” J. Immunol. 169:5538-5545) and at low levels in l killer (NK) T-cells
(Nishimura, H. et al. (2000) “Facilitation Of Beta Selection And Modification Of Positive
Selection In The Thymus -DeficientMice,” J . Exp. Med. 191 :891-898, Martin-Orozco,
N. et al. (2007) “Inhibitory Costimulation And Anti-Tumor Immunity,” Semin. Cancer Biol.
17(4):288-298).
The ellular region of PD-l consists of a single immunoglobulin (Ig)V
domain with 23% identity to the equivalent domain in CTLA-4 (Martin-Orozco, N. et al.
(2007) “Inhibitory Costimulation AndAnti-Tumor Immunity,” Semin. Cancer Biol. 17(4):288-
298). The extracellular IgV domain is followed by a transmembrane region and an intracellular
tail. The intracellular tail ns two phosphorylation sites d in an immunoreceptor
tyrosine-based inhibitory motif and an immunoreceptor tyrosine—based switch motif, which
suggests that PD-l negatively regulates TCR signals (Ishida, Y. et al. (1992) “Induced
Expression Of PD-I, A Novel Member Of The Immunoglobulin Gene Superfamily, Upon
Programmed Cell Death,” E1Vfl30 J. 11:3887-3895, Blank, C. et al. (2006) “Contribution Of
The PD-LI/PD-I Pathway To T-Cell Exhaustion: An Update On Implications For c
Infections And Tumor n Cancer,” Immunol. Immunother. 56(5):739—745).
PD-l mediates its inhibition of the immune system by binding to B7—H1 and B7-
DC (also known as PD-Ll and PD-L2, Flies, D.B. et al. (2007) “The New B 7s: Playing a
Pivotal Role in Tumor ty,” J. Immunother. 30(3):251-260; United States Patents Nos.
6,803,192, 7,794,710, United States Patent Application Publication Nos. 059051,
2009/0055944, 2009/0274666, 2009/0313687, PCT Publication Nos. WO 01/39722; WO
02/086083).
B7-H1 and B7-DC are broadly expressed on the surfaces of many types of human
and murine tissues, such as heart, placenta, muscle, fetal liver, spleen, lymph nodes, and thymus
as well as murine liver, lung, kidney, islets cells of the pancreas and small intestine (Martin-
Orozco, N. et al. (2007) “Inhibitory Costimulation AndAnti-Tumor Immunity,” Semin. Cancer
Biol. 17(4):288-298). In humans, B7-H1 protein expression has been found in human
endothelial cells (Chen, Y. et al. (2005) “Expression ofB7-HI in Inflammatory Renal Tubular
Epithelial ” n. Exp. Nephrol. 102ze81-e92; de Haij, S. et al. (2005) “Renal
Tubular Epithelial Cells te T-Cell Responses Via ICOS—L And B7—HI” Kidney Int.
68:2091-2102; Mazanet, M.M. et al. (2002) “B 7-H] Is ExpressedBy Human Endothelial Cells
And Suppresses T-Cell Cytokine Synthesis,” J. Immunol. 169:3581-3588), dium
(Brown, J.A. et al. (2003) “Blockade OfProgrammed Death-1 Ligands On Dendritic Cells
Enhances T-Cell Activation And Cytokine Production,” J. Immunol. 170: 1257-1266),
syncyciotrophoblasts (Petroff, M.G. et al. (2002) “B7 Family Molecules: Novel
Immunomodulators At The Maternal-Fetal Interface,” Placenta 23:895-8101). The molecules
are also expressed by nt macrophages of some tissues, by macrophages that have been
activated with eron (IFN)-y or tumor necrosis factor (TNF)—u (Latchman, Y. et al. (2001)
“PD-L2 Is A Second Ligand For PD-I And Inhibits T-Cell Activation,” Nat. Immunol 2:261-
268), and in tumors (Dong, H. (2003) “B7—HI Pathway And Its Role In The Evasion OfTumor
Immunity,” J. Mol. Med. 81:281-287).
The interaction between B7-H1 and PD-l has been found to provide a crucial
negative costimulatory signal to T and B-cells (Martin-Orozco, N. et al. (2007) “Inhibitory
Costimulation AndAnti-Tumor Immunity,” Semin. Cancer Biol. 17(4):288-298) and functions
as a cell death inducer a, Y. et al. (1992) “InducedExpression OfPD-I, A NovelMember
Of The globulin Gene Superfamily, Upon Programmed Cell Death,” EMBO J.
11:3887-3 895, Subudhi, S.K. et al. (2005) “The Balance OfImmune Responses: Costimulation
Verse Coinhibition,” J . Molec. Med. 83:193—202). More specifically, interaction between low
concentrations of the PD-l receptor and the B7-H1 ligand has been found to result in the
transmission of an inhibitory signal that strongly inhibits the proliferation of antigen-specific
CD8+ T-cells, at higher concentrations the interactions with PD-l do not inhibit T—cell
proliferation but ly reduce the tion of multiple cytokines e, AH. et al.
(2002) “The B7-CD28 Superfamily,” Nature Rev. Immunol. 2:116—126). T-cell eration
and cytokine production by both resting and previously ted CD4 and CD8 s, and
even naive T—cells from umbilical-cord blood, have been found to be ted by soluble B7-
Hl-Fc fusion proteins (Freeman, G.J. et al. (2000) “Engagement Of The PD-I
Immunoinhibitory Receptor By A Novel B7 Family Member Leads To Negative Regulation Of
Lymphocyte tion,” J. Exp. Med. 192: 1-9, Latchman, Y. et al. (2001) “PD-L2 Is A Second
Ligand For PD-I And Inhibits T-Cell Activation,” Nature Immunol. 2:261—268; Carter, L. et
al. (2002) “PD-I.'PD-L Inhibitory Pathway Aflects Both CD4(+) and CD8(+) T-cells And Is
Overcome By IL-2,” Eur. J. l. 32(3):634-643; , A.H. et al. (2002) “The B 7-CD28
Superfamily,” Nature Rev. Immunol. 2: 1 16—126).
The role of B7-H1 and PD-l in inhibiting T-cell activation and proliferation has
suggested that these biomolecules might serve as therapeutic targets for treatments of
inflammation and cancer. Thus, the use of anti-PD—l antibodies to treat infections and tumors
and to up-modulate an adaptive immune response has been proposed (see, United States Patent
Application Publication Nos. 2010/0040614, 2010/0028330, 2004/0241745, 2008/0311117,
2009/0217401, United States Patent Nos. 7,521,051, 7,563,869, 7,595,048, PCT Publication
1 have been reported by Agata, T. et al. (1996) “Expression Of The PD-I Antigen On The
Surface OfStimulatedMouse TAnd8 Lymphocytes,” Int. Immunol. 8(5):?65-772; and Berger,
R. et al. (2008) “Phase I Safety AndPharmacokinetic Study OfCT-01 I A HumanizedAntibody
Interacting With PD-I, In Patients With Advanced logic Malignancies,” Clin. Cancer
Res. 14(10):3044-3051 (see, also, United States Patents No. 8,008,449 and 8,552,154; US
Patent Publications No. 166281, 2012/0114648, 2012/0114649, 2013/0017199,
2013/0230514 and 2014/0044738; and PCT Patent Publication Nos.
2004/004771,
W0 83174, W0 2009/014708; W0 2009/073533,
2012/145549, and
However, despite all such prior advances, a need remains for ed
compositions capable of more vigorously directing the body’ s immune system to attack cancer
cells or pathogen-infected cells, especially at lower therapeutic concentrations and/or with
reduced side effects. Although the ve immune system can be a potent defense
mechanism against cancer and disease, it is often hampered by immune suppressive/evasion
mechanisms in the tumor microenvironment, such as the expression of PD-l and .
Furthermore, co-inhibitory molecules expressed by tumor cells, immune cells, and stromal
cells in the tumor milieu can dominantly attenuate T-cell responses against cancer cells. In
on, the use of TLA-4 antibodies induces well-identified side effects ed to as
“immune-related adverse events” (irAEs). IrAEs include colitis/diarrhea, dermatitis, hepatitis,
endocrinopathies, and atory myopathy. These unique side effects are reported to arise
due to breaking immune tolerance upon CTLA-4 blockade (Di Giacomo, A.M., et al. (2010)
“The Emerging Toxicity Profiles Of Anti-CTLA-4 Antibodies Across Clinical Indications,”
Semin Oncol. 37:499-507). ingly, therapies which overcome these limitations would
be of great benefit.
As described in detail below, the present invention addresses this need by
ing PD-l X CTLA-4 bispecifrc molecules. Such bispecifrc les are capable of
binding to PD-l and CTLA-4 molecules that are present on the surfaces of exhausted and
tolerant infiltrating lymphocytes and other cell types, and of thereby impairing the
y of such cell-surface molecules to respond to their tive ligands. As such, the PD-
1 X CTLA-4 bispecifrc molecules of the present ion act to block PD-l- and CTLA
mediated immune system inhibition, so as to promote the activation or continued tion of
the immune system. These attributes permit such bispecifrc molecules to have utility in
stimulating the immune system and particularly in the treatment of cancer and pathogen-
associated diseases and conditions. The present invention is directed to these and other goals.
SUMNIARY OF THE INVENTION
The present invention is directed to bispecifrc molecules (e.g., diabodies,
bispecifrc antibodies, trivalent binding molecules, etc.) that possess at least one e-binding
site that is immunospecifrc for an epitope of PD-l and at least one epitope-binding site that is
immunospecific for an epitope of CTLA-4 (i.e., a “PD-l X CTLA—4 bispecific molecule”). The
present invention concerns such PD-l X CTLA—4 bispecifrc molecules that possess two
epitope-binding sites that are immunospecifrc for one (or two) epitope(s) of PD-l and two
epitope-binding sites that are specifrc for one (or two) epitope(s) of . The
present invention also is directed to such PD-l X CTLA-4 ific les that additionally
comprise an immunoglobulin Fc Region. The PD-l X CTLA-4 bispecific molecules of the
present invention are capable of simultaneously binding to PD-l and to CTLA-4, particularly
as such molecules are arrayed on the surfaces of human cells. The ion is directed to
pharmaceutical compositions that contain such PD—l X CTLA-4 bispecific molecules, and to
methods involving the use of such bispecifrc molecules in the treatment of cancer and other
diseases and conditions. The present invention also pertains to methods of using such PD—l X
CTLA-4 bispecifrc molecules to stimulate an immune response.
In detail, the invention provides a bispecific molecule possessing both one or
more epitope—binding sites capable of immunospecific binding to (an) epitope(s) of PD-l and
one or more epitope-binding sites capable of immunospecific binding to (an) epitope(s) of
CTLA-4, wherein the molecule comprises:
(A) a Heavy Chain Variable Domain and a Light Chain Variable Domain of an antibody
that binds PD-l, and
(B) a Heavy Chain Variable Domain and a Light Chain Variable Domain of an antibody
that binds CTLA-4;
wherein the bispecific binding molecule is:
(i) a diabody, the diabody being a covalently bonded complex that comprises two, three,
four or five polypeptide chains; or
(ii) a trivalent binding molecule, the ent binding molecule being a covalently bonded
complex that comprises three, four, five, or more polypeptide chains.
The invention concerns the embodiment of such bispecific molecules, wherein
the ific binding molecule ts an activity that is enhanced relative to such activity
exhibited by two monospecific molecules one of which possesses the Heavy Chain Variable
Domain and the Light Chain Variable Domain of the antibody that binds PD-l and the other
of which possesses the Heavy Chain Variable Domain and the Light Chain Variable Domain
of the antibody that binds CTLA-4.
The invention ns the embodiment of all such bispecific molecules, wherein
the molecule elicits fewer immune-related e events ) when stered to a
t in need thereof ve to such iREs elicited by the administration of a monospecific
antibody that binds CTLA-4 such as ipilimumab.
The invention additionally concerns the embodiment of such bispecific molecules
in which the molecule comprises an Fc . The invention additionally concerns the
embodiment of such bispecific molecules wherein the Fc Region is a variant Fc Region that
comprises:
(A) one or more amino acid modifications that reduces the affinity of the variant Fc Region
for an FcyR; and/or
(B) one or more amino acid ations that enhances the serum half-life of the variant
Fc Region.
The invention additionally concerns the embodiment of such ific molecules
wherein the modifications that reduces the affinity of the variant Fc Region for an FcyR
comprise the substitution of L234A; L23 5A; or L234A and L23 5A, wherein the numbering is
that of the EU index as in Kabat.
The invention additionally concerns the embodiment of such bispecific molecules
wherein the modifications that that enhances the serum ife of the variant Fc Region
comprise the tution ofM252Y; M252Y and 8254T; M252Y and T256E; M252Y, 8254T
and T256E; or K288D and H43 5K, wherein the numbering is that of the EU indeX as in Kabat.
The invention onally concerns the embodiment of all such bispecific
molecules wherein the le is the diabody and comprises two epitope-binding sites
capable of immunospecific binding to an epitope ofPD-l and two epitope-binding sites e
of immunospecific binding to an epitope of CTLA-4.
The invention additionally concerns the embodiment of all such bispecific
les wherein the molecule is the trivalent binding molecule and ses two epitope-
binding sites capable ofimmunospecific binding to an epitope ofPD-l and one epitope-binding
site capable of immunospecific binding to an e of CTLA-4.
The invention additionally concerns the embodiment of all such bispecific
molecules wherein the molecule is capable of binding to PD-l and CTLA-4 molecules present
on the cell surface.
The invention additionally concerns the embodiment of all such bispecific
molecules wherein the molecule is capable of simultaneously binding to PD-l and CTLA-4.
The invention additionally concerns the embodiment of all such bispecific
molecules wherein the molecule promotes the stimulation of immune cells, and particularly
wherein the stimulation of immune cells results in:
(A) immune cell eration; and/or
(B) immune cell production and/or release of at least one cytokine; and/or
(C) immune cell production and/or release of at least one lytic molecule; and/or
(D) immune cell expression of at least one activation marker.
The invention additionally concerns the embodiment of all such bispecific
molecules wherein the immune cell is a T-lymphocyte or an NK-cell.
The invention additionally concerns the embodiment of all such bispecific
molecules wherein the epitope-binding sites capable of immunospecific binding to an epitope
of PD-l comprise:
(A) the VH Domain of PD-l mAb l (SEQ ID NO:47) and the VL Domain of PD-
1 mAb l (SEQ ID NO:48); or
(B) the VH Domain of PD-l mAb 2 (SEQ ID NO:49) and the VL Domain of PD-
1 mAb 2 (SEQ ID NO:50); or
(C) the VH Domain of PD-l mAb 3 (SEQ ID NO:51) and the VL Domain of PD-
1 mAb 3 (SEQ ID NO:52); or
(D) the VH Domain of PD-l mAb 4 (SEQ ID NO:53) and the VL Domain of PD-
1 mAb 4 (SEQ ID NO:54); or
(E) the VH Domain of PD-l mAb 5 (SEQ ID NO:55) and the VL Domain of PD-
1 mAb 5 (SEQ ID NO:56); or
(F) the VH Domain of PD-l mAb 6 (SEQ ID NO:57) and the VL Domain of PD-
1 mAb 6 (SEQ ID NO:58); or
(G) the VH Domain of PD-l mAb 6-I VH (SEQ ID NO:86) and the VL Domain of
PD-l mAb 6-SQ VL (SEQ ID NO:87); or
(H) the VH Domain of PD-l mAb 7 (SEQ ID NO:59) and the VL Domain of PD-
1 mAb 7 (SEQ ID NO:60); or
(I) the VH Domain of PD-l mAb 8 (SEQ ID NO:61) and the VL Domain of PD-
1 mAb 8 (SEQ ID NO:62).
The invention onally concerns the embodiment of all such bispecific
molecules n the epitope-binding site(s) capable of immunospecific binding to an epitope
of CTLA-4 comprise:
(A) the VH Domain of CTLA-4 mAb 1 (SEQ ID NO:76) and the VL Domain of
CTLA-4 mAb l (SEQ ID NO:77); or
(B) the VH Domain of CTLA—4 mAb 2 (SEQ ID NO:78) and the VL Domain of
CTLA-4 mAb 2 (SEQ ID ; or
(C) the VH Domain of CTLA-4 mAb 3 (SEQ ID NO:90) and the VL Domain of
CTLA-4 mAb 3 (SEQ ID NO:91).
The invention additionally concerns the embodiment of such bispecific molecules
wherein:
(A) the epitope-binding sites capable of immunospecific binding to an epitope of
PD-l comprise the VH Domain ofPD-l mAb 6-I VH (SEQ ID NO:86) and the
VL Domain of PD-l mAb 6—SQ (SEQ ID ; and
(B) the epitope-binding site(s) capable of immunospecific binding to an epitope of
CTLA-4 comprise(s) the VH Domain of CTLA-4 mAb 3 (SEQ ID NO:90) and
the VL Domain of CTLA-4 mAb 3 (SEQ ID NO:91).
The invention additionally concerns the embodiment of all such bispecific
molecules wherein the molecule comprises:
(A) two polypeptide chains having SEQ ID NO:95, and two polypeptide chain
having SEQ ID NO:96; or
(B) two polypeptide chains having SEQ ID NO:97, and two polypeptide chain
having SEQ ID NO:98; or
(C) two polypeptide chains having SEQ ID NO:99, and two polypeptide chain
having SEQ ID NO:100; or
(D) two polypeptide chains having SEQ ID NO:102, and two polypeptide chain
having SEQ ID NO:103; or
(E) two polypeptide chains having SEQ ID , and two polypeptide chain
having SEQ ID NO:100; or
(F) one polypeptide chains having SEQ ID NO:104, one polypeptide chain having
SEQ ID NO:105, one polypeptide chain having SEQ ID NO:106, and one
polypeptide chain having SEQ ID NO:107; or
(CD one polypeptide chains having SEQ ID NO:108, one polypeptide chain having
SEQ ID NO:105, one polypeptide chain having SEQ ID NO:109, and one
polypeptide chain having SEQ ID NO:107.
The invention additionally concerns the ment of such bispecific molecules
in which the molecule comprises an Albumin-Binding Domain, and especially a nized
Albumin-Binding Domain.
The invention additionally concerns a pharmaceutical ition that comprises
an ive amount of any of such ific molecules and a pharmaceutically acceptable
carrier.
The invention additionally concerns the use of such ceutical composition
or the use of any of the above-described bispecific molecules to promote stimulation of an
immune-mediated response of a subject in need thereof, and in particular, wherein such
molecule promotes the stimulation of immune cells, and in ular, stimulation of NK-cells
and/or T-lymphocytes. The invention particularly concerns the embodiments wherein such
stimulation results in immune cell proliferation, immune cell production and/or release of
cytokines (e.g., IFNy, IL-2, TNFOL, etc), immune cell production and/or release of lytic
molecules (e.g., granzyme, perforin, etc), and/or immune cell sion of activation markers
(e.g., CD69, CD25, CD107a, etc). The invention further concerns methods of treating cancer
or other diseases that involve the use or stration of any of the described PD-l X
CTLA-4 bispecific molecules to stimulate an immune mediated response. The invention
particularly concerns the embodiments in which the immune stimulatory activity of any of the
above-described PD-l X CTLA-4 bispeciflc molecules is more potent than the joint or
combined administration of a separate anti-PD—l antibody and a separate anti-CTLA-4
antibody ially, wherein such antibodies are monospeciflc for such molecules). The
invention also concerns embodiments in which immune cells, particularly NK-cells and/or T-
lymphocytes, stimulated by the above-described PD-l X CTLA-4 bispeciflc molecules exhibit
enhanced proliferation, altered tion and/or release of cytokines (e.g., IFNy, IL-2, TNFOL,
etc), altered production and/or release of lytic les, and/or d expression of
activation markers relative to that exhibited by such cells stimulated by the joint or combined
administration of a separate anti-PD-l antibody and a separate anti-CTLA-4 antibody. The
invention also concerns embodiments in which the above-described PD-l X CTLA-4 ific
molecules have a reduced incidence of irAEs. The invention additionally concerns the
embodiments in which any of the described PD-l X CTLA-4 bispecific molecules are
used in the treatment of a disease or condition ated with a ssed immune system,
especially cancer or an infection.
The invention additionally concerns such a use to treat a disease or ion
associated with a suppressed immune system, or in the treatment of such a disease or condition.
The invention particularly concerns such a use in in the treatment of a disease or condition
associated with a suppressed immune system, or wherein the disease or condition is cancer or
an infection cularly, an ion characterized by the ce of a bacterial, fungal, viral
or protozoan pathogen).
The invention particularly concerns such a use wherein:
(A) the use is in the treatment of cancer, and the cancer is characterized by the ce of a
cancer cell selected from the group ting of a cell of: an adrenal gland tumor, an
AIDS-associated cancer, an alveolar soft part sarcoma, an astrocytic tumor, bladder
cancer, bone cancer, a brain and spinal cord cancer, a metastatic brain tumor, a breast
cancer, a carotid body tumors, a al cancer, a chondrosarcoma, a chordoma, a
chromophobe renal cell carcinoma, a clear cell carcinoma, a colon cancer, a ctal
cancer, a cutaneous benign fibrous cytoma, a desmoplastic small round cell tumor,
an ependymoma, a Ewing’s tumor, an extraskeletal myxoid chondrosarcoma, a
fibrogenesis imperfecta ossium, a fibrous dysplasia of the bone, a gallbladder or bile duct
cancer, gastric cancer, a gestational trophoblastic disease, a germ cell tumor, a head and
neck cancer, hepatocellular carcinoma, an islet cell tumor, a Kaposi’s Sarcoma, a kidney
cancer, a leukemia, a lipoma/benign lipomatous tumor, a liposarcoma/malignant
lipomatous tumor, a liver cancer, a lymphoma, a lung cancer, a medulloblastoma, a
melanoma, a ioma, a multiple endocrine neoplasia, a le myeloma, a
ysplastic syndrome, a neuroblastoma, a neuroendocrine tumors, an ovarian cancer,
a pancreatic , a papillary thyroid carcinoma, a parathyroid tumor, a pediatric cancer,
a peripheral nerve sheath tumor, a hromocytoma, a pituitary tumor, a prostate
cancer, a posterior uveal melanoma, a rare hematologic disorder, a renal metastatic
cancer, a id tumor, a rhabdomyosarcoma, a sarcoma, a skin cancer, a issue
sarcoma, a squamous cell cancer, a stomach cancer, a synovial sarcoma, a testicular
cancer, a thymic carcinoma, a thymoma, a thyroid metastatic cancer, and a uterine cancer;
(B) the use is in the ent of infection, and the infection is a chronic viral, ial, fungal
and parasitic infection, terized the presence of Epstein Barr virus, Hepatitis A Virus
(HAV); Hepatitis B Virus (HBV); Hepatitis C Virus (HCV); herpes viruses (e.g. HSV-
1, HSV-2, HHV-6, CMV), Human Immunodeficiency Virus (HIV), Vesicular Stomatitis
Virus (VSV), Bacilli, Citrobacter, Cholera, Diphtheria, Enterobacter, Gonococci,
Helicobacter pylori, Klebsiella, Legionella, Meningococci, mycobacteria, Pseudomonas,
Pneumonococci, rickettsia bacteria, Salmonella, Serratia, Staphylococci, ococci,
Tetanus, Aspergillus (A. fumigatus, A. niger, etc.), Blastomyces dermatitidis, Candida (C.
albicans, C. krusei, C. glabrata, C. tropicalis, etc.), Cryptococcus neoformans, Genus
Mucorales (mucor, absidia, rhizopus), hrix schenkii, Paracoccidioides
brasiliensis, Coccidioides immitis, Histoplasma
capsulalum, Leptospirosis, Borrelia burgdorferi, helminth parasite (hookworm,
tapeworms, fiukes, flatworms (e.g. Schislosomia), Giardia Zambia, lrichinella,
Dientamoeba Fragilis, Trypcmosoma brucei, Trypcmosoma cruzz', or Leishmania
donovani.
The invention particularly concerns such use in the treatment of , wherein
the cancer is ctal cancer, hepatocellular carcinoma, glioma, kidney cancer, breast cancer,
multiple myeloma, bladder cancer, neuroblastoma; sarcoma, non-Hodgkin’s ma, non-
small cell lung cancer, ovarian cancer, pancreatic cancer, a rectal cancer, acute myeloid
leukemia (AML), chronic myelogenous leukemia (CML), acute B lymphoblastic leukemia (B-
ALL), chronic lymphocytic leukemia (CLL), hairy cell leukemia (HCL), blastic plasmacytoid
dendritic cell neoplasm (BPDCN), non-Hodgkin’s lymphomas (NHL), including mantel cell
leukemia (MCL), and small lymphocytic lymphoma (SLL), Hodgkin’s ma, systemic
mastocytosis, or Burkitt’ s lymphoma.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 provides a schematic of a entative covalently bonded diabody
having two epitope—binding sites composed of two polypeptide , each having an E—coil
or K-coil Heterodimer-Promoting Domain (alternative Heterodimer-Promoting Domains are
provided below). A cysteine residue may be present in a linker and/or in the dimer-
Promoting Domain as shown in Figure 3B. VL and VH s that recognize the same
e are shown using the same shading or fill pattern.
Figure 2 provides a schematic of a representative covalently bonded diabody
molecule having two epitope-binding sites composed of two polypeptide chains, each having
a CH2 and CH3 Domain, such that the associated chains form all or part of an Fc Region. VL
and VH Domains that recognize the same epitope are shown using the same shading or fill
pattern.
Figures 3A-3C provide schematics g representative covalently bonded
alent diabodies having four epitope-binding sites composed of two pairs of polypeptide
chains (i.e., four polypeptide chains in all). One polypeptide of each pair possesses a CH2 and
CH3 , such that the associated chains form all or part of an Fc Region. VL and VH
Domains that recognize the same epitope are shown using the same shading or fill pattern. The
two pairs of ptide chains may be same. In such ments wherein the two pairs of
polypeptide chains are the same and the VL and VH s recognize different epitopes (as
shown in Figures 3A-3B), the resulting molecule possesses four e—binding sites and is
bispeciflc and bivalent with t to each bound epitope. In such embodiments wherein the
VL and VH Domains recognize the same epitope (e.g., the same VL Domain CDRs and the
same VH Domain CDRs are used on both chains) the resulting molecule possesses four
epitope-binding sites and is monospecific and alent with respect to a single epitope.
Alternatively, the two pairs of polypeptides may be different. In such embodiments wherein
the two pairs of polypeptide chains are different and the VL and VH Domains of each pair of
polypeptides recognize ent epitopes (as shown by the different shading and ns in
Figure 3C), the resulting molecule possesses four e-binding sites and is tetraspeciflc and
monovalent with respect to each bound epitope. Figure 3A shows an Fc Region-containing
diabody which contains a peptide Heterodimer-Promoting Domain comprising a cysteine
residue. Figure 3B shows an Fc Region-containing diabody, which contains E-coil and K-coil
Heterodimer—Promoting Domains comprising a cysteine residue and a linker (with an al
cysteine residue). Figure 3C, shows an Fc-Region-Containing diabody, which contains
antibody CH1 and CL domains.
Figures 4A and 4B provide schematics of a entative ntly bonded
diabody molecule having two epitope-binding sites composed of three polypeptide chains.
Two ofthe polypeptide chains possess a CH2 and CH3 Domain, such that the associated chains
form all or part of an Fc Region. The polypeptide chains comprising the VL and VH Domain
further comprise a Heterodimer-Promoting Domain. VL and VH Domains that recognize the
same epitope are shown using the same shading or fill pattern.
Figure 5 provides the schematics of a representative covalently bonded diabody
molecule having four e-binding sites composed of five polypeptide chains. Two of the
polypeptide chains possess a CH2 and CH3 Domain, such that the associated chains form an
Fc Region that comprises all or part of an Fc Region. The polypeptide chains sing the
linked VL and VH Domains further se a Heterodimer-Promoting Domain. VL and VH
Domains that recognize the same epitope are shown using the same shading or fill n.
Figures 6A-6F provide schematics of representative Fc Region-containing
trivalent binding les having three epitope-binding sites. Figures 6A and 6B,
respectively, illustrate schematically the domains of trivalent binding molecules comprising
two diabody-type binding domains and a Fab-type binding domain having different domain
orientations in which the diabody-type binding domains are inal or inal to an Fc
Region. The molecules in Figures 6A and 6B comprise four chains. s 6C and 6D,
tively, illustrate schematically the domains of trivalent binding molecules comprising
two diabody-type g domains inal to an Fc Region, and a linked Fab-type binding
domain, or an scFv—type binding domain. The ent binding molecules in Figures 6E and
6F, respectively illustrate schematically the domains of trivalent binding molecules comprising
two diabody—type binding domains C-terminal to an Fc Region, and a Fab-type binding domain
in which the light chain and heavy chain are linked via a polypeptide spacer, or an scFv—type
g domain. The trivalent binding molecules in Figures 6C-6F comprise three chains. VL
and VH Domains that recognize the same epitope are shown using the same shading or fill
pattern.
Figure 7 illustrates the principles of the present ion by showing that an
exemplary bispecific molecule (a PD-1 X LAG-3 bispecific molecule, designated as DART A)
is able to stimulate cytokine production to levels higher than those observed upon the joint or
combined administration of the parental anti-PD-l and anti-LAG—3 antibodies. Shown are
IFNy secretion profiles of PBMCs from a representative donor, stimulated with SEB (0.5
ng/mL) and treated with the exemplary bispecific molecule (PD-1 X LAG-3 bispecific
molecule DART A) or with the anti-PD-1 and anti-LAG—3 antibodies alone or in combination.
Figures 8A-8D show the results of ELISA studies measuring the binding of
serially diluted binding molecules to human CTLA-4 and human PD-1. Figures 8A-8B show
the g curves of CTLA-4 mAb 3 G4P, DART D, TRIDENT A or DART B to soluble
hCTLAAvi-His (1 ug/mL) (Figure 8A) or hPD—l-His (1 ug/mL) (Figure 8B) that had been
coated onto t plates. Goat anti-human-Fc-HRP (1 : 10,000) was ed as the
ary ion molecule to detect binding. Figures 8C-8D show the results of a study on
the effect of altering orientations and binding domains on binding. PD-1 X CTLA-4 bispecific
molecules comprising the CTLA-4 binding domains of CTLA-4 mAb 1 (e.g., DART B) and
CTLA-4 mAb 3 (e.g., DART C and DART D) were incubated in the presence of soluble human
PD-l (Figure 8C) or soluble human CTLA—4-Avi-His (Figure 8D), that had been coated onto
support plates. Goat anti-human-Fcy-HRP was employed as the secondary detection le
to detect binding using PICO chemiluminescent substrate.
Figures 9A-9E show the results of an evaluation of the ability of DART D,
TRIDENT A, PD-l mAb 6 G4P, and CTLA-4 mAb 3 G4P and a control trident (having two
binding sites for RSV and one binding site for CTLA-4) to block binding ligand binding to PD-
1 and CTLA-l, alone and in combination. Blockade of PD-Ll binding to PD-l was evaluated
in the ce of equal amounts of an irrelevant antigen (Figure 9A) and in the presence of
equal amounts of CTLA—4 (Figure 9B), and blockade of B7-l binding to CTLA-4 was
evaluated evaluated in the presence of equal amounts of an irrelevant antigen (Figure 9C) and
in the ce of equal amounts of PD-l (Figure 9D) and in the presence of four fold more
PD-l (Figure 9E) using an ELISA assay.
Figures 10A-10B show the s of an evaluation of the ability of DART B,
DART D, TRIDENT A, the anti-CTLA-4 antibodies CTLA-4 mAb l, CTLA-4 mAb 3 G4P,
and an hIgG control antibody to bind to CHO cells expressing cynomolgus monkey CTLA-4
(Figure 10A) or human CTLA-4 (Figure 10B). Binding was detected using an anti-human Fc
ary dy.
s 11A-11B show the results of an tion of the ability of DART C,
DART D, DART E, TRIDENT A, the anti-CTLA-4 antibodies CTLA-4 mAb l, CTLA-4 mAb
3 GlAA, and the anti-PD-l antibody PD-l mAb 6 G4P to bind to Jurkat cells (which express
huCTLA-4 but not PD-l on their surface). Binding of the DART and TRIDENT molecules to
human CTLA-4 was detected using anti-human FC secondary Ab (FACS). Figure 11A shows
the results for DART C, DART D, DART E, CTLA-4 mAb l, CTLA-4 mAb 3 GlAA, and
PD-l mAb 6 G4P. Figure 11B shows the results for CTLA-4 mAb l, CTLA-4 mAb 3 GlAA,
PD—l mAb 6 G4P and TRIDENT A.
Figures 12A-12B show the results of an evaluation of the ability of DART D,
TRIDENT A and the anti-CTLA-4 antibodies CTLA-4 mAb l, CTLA-4 mAb 3 GlAA to block
the CTLA-4 s B7-l and B7-2 in a ased assay. His-tagged derivatives of B7-l and
B7-2 were incubated in the presence of the Jurkat cells and artificial antigen presenting cells
(Promega). Binding of His-B7-l and -2 was ed using an anti-His antibody. The
results of this tion are shown in Figure 12A (His-B7-l) and Figure 12B (His-B7-2).
Figure 13 shows the results of an evaluation of the ability of DART C, DART D,
TRIDENT A, CTLA-4 mAb 3 GlAA and PD-l mAb 6 G4P to reverse CTLA-4 immune
checkpoint inhibitory signal as demonstrated in a IL-2/Luc-Jurkat-CTLA-4 reporter assay by
increased luciferase expression. uc-Jurkat-CTLA-4 cells were incubated in the presence
of the listed binding molecules (R:S= l : 0.3) for 30 min at 37 °C, after which time artificial
antigen presenting Raji cells were added and the incubation ued for 6 hours. Reversal
of CTLA-4 immune oint inhibitory signal was determined by the luciferase assay.
Figure 14 shows the results of an evaluation of the y ofDART D, TRIDENT
A, PD-l mAb 6 G4P, and CTLA-4 mAb 3 GlAA to bind NSO cells that express PD-l but not
CTLA-4. Binding molecules were incubated in the presence of the cells and the mean
fluorescence index of the cells was measured.
s ISA-15B show the results of an evaluation of the ability of DART D,
TRIDENT A, PD-l mAb 6 G4P, and CTLA-4 mAb 3 GlAA to block binding between PD-l
and its ligands PD-Ll and PD-L2 in a cell based assay. PD—Ll-PE or PD-L2-PE was incubated
in the presence of such binding molecules and their ability to bind to NSO-PD-l cells was
evaluated using FACS. Figure 15A (PD-Ll); Figure 15B (PD-L2).
Figure 16 shows the results of an evaluation ofthe ability ofDART D, TRIDENT
A, CTLA-4 mAb 3 GlAA, and PD-l mAb 6 G4P to block immune inhibition resulting from a
PD-l / PD-Ll interaction. Binding les were ted in the presence of PD-L1+ CHO
and Jurkat effector cells, and the ability of the binding molecules to block immune inhibition
(by blocking the PD-l / PD-Ll interaction) was assessed by following the extent of CD3-
mediated activation (as demonstrated by sed luciferase expression in the NFAT-luc/PD-
l Jurkat assay; Promega).
Figure 17 shows the results of an evaluation ofthe ability ofDART D, TRIDENT
A, and a negative control antibody to co—ligate PD-l and CTLA-4 in an enzyme-fragment
complementation assay by DiscoverX. Aliquots of the UZOS CTLA-4(l-l95)—PK PD-l(l-
A cell line #9 were plated in quadruplicate at 5,000 cells / well in DiscoverX CPS plating
media on 384-well plates. Cells were allowed to attach for 4 hours at 37 oC/ 5% C02. 11 point,
1:3 dilution series of each of the binding les were then added to the PD-l — CTLA-4
cells and the DART D and TRIDENT A samples were added to the PD-l — LAG-3 cells. The
plates were incubated overnight (16 hrs) at 37 °C / 5% C02. PathHunter detection reagent was
added to the wells, which were then incubated for 1 hour at room temperature in the dark, and
the plate was then read on an Envision luminometer.
Figure 18 shows the results of an evaluation ofthe ability ofDART D; TRIDENT
A; CTLA-4 mAb 3 GlAA; PD-l mAb 6 G4P and the combinations of CTLA—4 mAb 3
G1AA/PD-1 mAb 6 G4P (Ab Combo 1) to enhance the response of a Mixed Lymphocyte
Reaction. Monocyte-derived dendritic cells were ted by treating CD14+ monocytes with
GM—CSF (provided at day 1 of the incubation period) and IL-4 (provided at day 7 of the
tion period). At day 8 of the tion period, a MLR was set up by incubating the
CD4+ T cells with the monocyte-derived dendritic cells ded at day 8 of the incubation
period) and the anti-CTLA-4 and anti-PD-l binding molecules (provided at day 8 of the
incubation perod). The release of IFN—y is plotted in Figure 18. Both the bispecific DART D
and TRIDENT A molecules were found to enhance the MLR response to the same extent or
slightly better than the combination of individual parental antibodies. The presented data
comprises seven series (each relating to a different binding molecule: hIgG4 control; PD-l
mAb 6 G4P; CTLA-4 mAb 3 GlAA; a combination of CTLA-4 mAb 3 GlAA/PD-l mAb 6
G4P (Ab Combo 1); DART D; TRIDENT A; and an hIgGl control; respectively from left to
right); each series is ed of six s (each relating to a different concentration of the
provided molecule: 0.016; 0.08; 0.4; 2; 10 or 50 nM; respectively from left to right).
Figures 19A-19D show the effect of administration of DART D; T A;
CTLA-4 mAb 3 GlAA; PD-l mAb 6 G4P and the combination of CTLA-4 mAb l/PD-l mAb
1 (Ab Combo 1) on T-cell responses using a Staphylococcus aureus toxin type B (SEB)
re-stimulation assay. Figures 19A-19B show cence-activated cell sorting (FACS) dot
plots of the sion of PD-l vs. CTLA—l by such PBMCs in the absence (Figure 19A) or
presence (Figure 19B) of SEB stimulation. Figure 19C shows the effect of the SEB
stimulation on IFN—y secretion. PBMCs were stimulated with Staphylococcus aureus
toxin type B (SEB) at 0.5 ng/ml for 48 hours. Cells were then harvested; washed and re-
plated in 96 well plates with antibodies at various concentrations with fresh SEB for an
additional 48 hours. The supernatant was then harvested and analyzed by flow cytometry
ELISA for IFN—y tion. Both the bispecific DART and the TRIDENT protein showed an
increase in IFN—y response that recapitulated the response observed with the combination of
the individual parental mAbs. Similar results were seen in a SEB Stimulation assay in which
the PBMCs were cultured with a high concentration (500 ng/mL) of SEB for 72 hours.
Presented are six series; each relating to a different binding molecule. Each series is composed
of seven columns; which relate to the result obtained with 25 nM; 6.25 nM; 1.56 nM; 0.39 nM;
0.09 nM; 0.02 nM or 0.006 nM binding molecule (respectively; from left to right). Figure 19D
shows the release of IL-2 for a representative donor. PBMCs were stimulated with 0.5 ng/ml
SEB for 48 hours, harvested, washed and re—plated in 96-well plates with fresh SEB and either
DART D, TRIDENT A, CTLA-4 mAb 3 GlAA, PD-l mAb 6 G4P or the combination of
CTLA-4 mAb 3 GlAA / PD-l mAb 6 G4P (Ab Combo 1) for an additional 48 hours, and the
released 1L-2 was measured. Presented are seven series, each relating to a different binding
le or condition. Each series is composed of three columns, which relate to the result
obtained with 0.5 nM, 5 nM or 50 nM binding molecule ctively, from left to right). When
antibodies were used in combination, each antibody was added at the indicated concentration
so that the total concentration of antibody added is doubled.
Figures 20A-20B show the activity of a PD-l x CTLA-4 bispeciflc molecule in
a PBMC implanted NOG murine model of Graft Versus Host e (GVHD). CD3+ T cell
counts were performed via FACS on study day (Figure 20A) on mice that had ed DART
D at a dose of 50 mg/kg or 500 mg/kg (Figure 20A). Survival was monitored over the course
of the study and is plotted as percent survival in Figure 20B.
Figures 21A-21C show serum concentration-time profiles for cynomolgus
monkeys (coded using a acter alphanumeric code) that had received DART D at 50
mg/kg on days 1, 8 and 15 of the study (Figure 21A), DART D at 75 mg/kg on days 1, 8 and
of the study (Figure 21B) or Trident A at 5 mg/kg on day 1 e 21C).
Figures 22A-22B show the effect of administration of DART D on absolute
lymphocyte count (ALC) in treated cynomolgus monkeys. Figure 22A shows the ALC in
thousands of cells/ul (th/ul). Figure 22B shows the percent change in the ALC normalized to
Day 1 (D1).
Figures 23A-23B show CD4+ T cell proliferation and PD-l occupancy on T cells
in lgus monkeys that had received DART D administered at 50 mg/kg (Figure 23A)
or DART D stered at 75 mg/kg (Figure 23B).
s 24A-24B show the effect of DART D administration on CD4+ T cell
proliferation in cynomolgus monkeys that had received DART D administered at 50 mg/kg
(Figure 24A) or DART D administered at 75 mg/kg (Figure 24B).
DETAILED DESCRIPTION OF THE INVENTION
The t invention is directed to bispecific molecules (e.g, diabodies,
bispeciflc antibodies, trivalent binding molecules, etc.) that possess at least one epitope-binding
site that is immunospecific for an epitope of PD-l and at least one epitope-binding site that is
specific for an epitope of CTLA-4 (i.e., a “PD-l X CTLA-4 bispecific molecule”). The
t invention concerns such PD-l X CTLA-4 bispeciflc molecules that possess two
epitope-binding sites that are immunospeciflc for one (or two) epitope(s) of PD—l and two
epitope-binding sites that are immunospecific for one (or two) epitope(s) of CTLA-4. The
present ion also is directed to such PD-l X CTLA-4 bispecific molecules that additionally
comprise an immunoglobulin Fc Region. The PD-l X CTLA-4 bispeciflc molecules of the
present invention are e of simultaneously binding to PD-l and to CTLA-4, particularly
as such molecules are arrayed on the surfaces of human cells. The invention is directed to
pharmaceutical compositions that contain such PD-l X CTLA-4 bispecific molecules, and to
methods involving the use of such bispecific molecules in the treatment of cancer and other
diseases and conditions. The present invention also pertains to methods of using such PD-l X
CTLA-4 bispeciflc molecules to stimulate an immune response.
T-cell tion requires two distinct signals (Viglietta, V. et a]. (2007)
“Modulating Co-Stimulation,” Neurotherapeutics 4:666-675, Korman, A]. et a]. (2007)
“Checkpoint Blockade in Cancer Immunothempy,” Adv. Immunol. 90:297-339), The first
signal is provided by a T-Cell Receptor (TCR) molecule, expressed on the surface of a T—cell,
that has recognized a peptide n that has become associated with a human leukocyte
antigen (HLA) sed on the surface of an n-Presenting Cell (APC). The second
signal is provided by the interaction of cognate pairs of co-stimulatory ligands: B7-l and B7-2
expressed on APCs and their corresponding ors: CD28 and CTLA-4 expressed on T-
cells.
The binding of B7-l and B7-2 molecules to CD28 stimulates T-cell eration
and additionally induces increased expression of CTLA-4. CTLA-4 is a negative-regulator
that competes with B7-l and B7-2 for g to CD28. Thus, the process responds to disease
in two phases: the initial phase involves stimulating T-cell proliferation; the subsequent phase
“winds down” the immune response and returns the subject to a ent immune state.
Antibodies that bind CD28 can mimic the binding of B7-l or B7-2 and thus induce or enhance
T-cell effector function and the generation of tumor eradicating immunity; such antibodies are
co-stimulatory. Conversely, antibodies that block CTLA-4 from binding to B7-1 and B7-2 can
prevent s from returning to a quiescent state; such T-cells thus maintain a sustained
proliferation that can lead to autoimmunity and the development of immune-related adverse
events" (irAEs) (Wang, L. et al. (March 7, 2011) , A Novel Mouse Ig amily
Ligand That vely Regulates T-Cell Responses,” J. Exp. Med. 10.1084/jem,20100619:1-
16; Lepenies, B. et al. (2008) “The Role Of Negative Costimulators During Parasitic
Infections,” Endocrine, Metabolic & Immune Disorders - Drug Targets 8:279—288). Of
particular importance is g between the B71 (CD80) and B72 (CD86) ligands of the
Antigen-Presenting Cell and the CD28 and CTLA—4 ors of the CD4+ T lymphocyte
(Sharpe, AH. et al. (2002) “The B7—CD28 Superfamily,” Nature Rev. Immunol. 126,
Dong, C. et al. (2003) “Immune Regulation by Novel Costimulatory Molecules,” Immunolog.
Res. 28(1):39-48, Lindley, P.S. et al. (2009) “The Clinical Utility OfInhibiting CD28-Mediated
ulation,” Immunol. Rev. 229:307-321). Binding ofB71 or ofB72 to CD28 stimulates
T-cell activation, g of B71 or B7.2 to CTLA—4 ts such activation (Dong, C. et al.
(2003) “Immune Regulation by Novel Costimulatory Molecules,” log. Res. 28(1):39-
48; Lindley, PS. et al. (2009) “The Clinical Utility Of Inhibiting CD28-Mediated
Costimulation,” Immunol. Rev. 229:307-321, Greenwald, R]. et al. (2005) “Ihe B7 Family
Revisited,” Ann. Rev, Immunol. 23:515-548). CD28 is constitutively expressed on the surface
of T—cells (Gross, J., et al. (1992) “Identification And Distribution Of The Costimulatory
Receptor CD28 In The Mouse,” J. Immunol. 149:380—388), whereas CTLA-4 expression is
rapidly upregulated following T-cell activation (Linsley, P. et al. (1996) “Intracellular
Traficking OfCTLA4 AndFocal Localization Towards Sites OfTCR Engagement,” Immunity
4:535—543). Since CTLA-4 is the higher affinity receptor (Sharpe, AH. et al. (2002) “The B7-
CD28 amily,” Nature Rev. Immunol. 2:116-126) binding f1rst initiates T-cell
proliferation (via CD28) and then inhibits it (via nascent expression of ), thereby
dampening the effect when proliferation is no longer needed.
In el with the above-described interactions, a second set of receptors and
binding ligands function to inhibit the immune system, thereby g as a brake to slow the
CD28/B7-1/B7mediated enhancement of the immune response. This auxiliary response
involves the binding of the programmed cell death-1 protein (PD-1) receptor, expressed on the
surface of T—cells, to corresponding ligands: PD-Ll, expressed on Antigen—Presenting Cells
(APCs) and PD-L2, expressed on epithelial cells (Chen L. et al. (2013) “Molecular
Mechanisms Of T-Cell Co-Stimulation And Co-Inhibition,” Nature Reviews Immunology
l3(4):227-242). In contrast to agonist antibodies that bind to CD28 to directly stimulate T-cell
responses, antibodies that bind to either PD-l or PD-Ll antagonize or block PD-l/PD—Ll
engagement and thus maintain T-cell activation by preventing the ry of a ve signal
to the T-cell. As such, dies that bind to either PD-l or PD-Ll augment or maintain T-
cell proliferation, cytotoxicity, and/or cytokine secretion. Taken together agonist antibodies,
such as anti-CD28, target positive signal pathways and are therefore co-stimulators, while
antagonistic antibodies, such as anti—CTLA—4 and anti-PD—l, target negative signal pathways
and are called checkpoint inhibitors.
As provided above, CTLA-4 and PD-l ent the canonical checkpoint
inhibitors which exert distinct inhibitory effects on T-cell tion. The PD-l X CTLA-4
bispeciflc molecules of the present invention are capable of binding to PD-l and CTLA-4 cell-
surface molecules that are present on the surfaces of lymphocytes, and of thereby impairing
the ability of such cell-surface molecules to respond to their respective receptors. Without
being bound by by any theory or mechanism, the inventors believe that PD-l binding can
e T-cell inhibition (e.g, at tumor sites and/or as a result of ion) and that CTLA-l
binding can stimulate polyclonal activation and stimulation. As such, the PD-l X CTLA-4
bispeciflc molecules of the present invention are able to attenuate PD-1 and CTLA—4-mediated
immune system inhibition, and promote continued immune system tion. It has been
demonstrated herein that bispecific molecules which target two immunomodulatory pathways
are more potent than the combination of separate antibodies. The instant invention also
provides PD-l X CTLA-4 bispecific molecules having PD-l :CTLA-4 binding ratios of l : 1, 1:2,
2:2 and 2:1 which allow for full blockade of both PD-l and CTLA-4 as well as blockade that
is biased toward CTLA-4 when co—eXpressed with PD-l. Accordingly, the PD-l X CTLA-4
iflc molecules of the present invention provide unexpected superiority as compared to
the combination of separate anti-PD-l and anti-CTLA-4 antibodies. Additionally, the PD-l X
CTLA-4 bispeciflc molecules of the t invention may provide immune stimulation with
reduced risk of irAEs.
1. Antibodies and Their Binding Domains
The antibodies of the t invention are immunoglobulin molecules capable of
specific binding to a target, such as a carbohydrate, polynucleotide, lipid, polypeptide, eta,
h at least one antigen recognition site, located in the Variable Domain of the
globulin molecule. As used , the terms “antibody” and “antibodies” refer to
monoclonal dies, multispecific antibodies, human antibodies, humanized antibodies,
synthetic antibodies, chimeric antibodies, polyclonal antibodies, camelized antibodies, single-
chain Fvs (scFv), single-chain antibodies, Fab fragments, F(ab’) fragments, disulfrde-linked
bispecific Fvs (dev), intrabodies, and epitope-binding nts of any of the above. In
particular, the term “antibody” includes immunoglobulin les and immunologically
active fragments of immunoglobulin molecules, i.e., les that contain an epitope-binding
site. Immunoglobulin molecules can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY),
class (e.g., IgGi, Ing, IgG3, IgG4, IgAi and IgAz) or subclass. As used herein, an Fc Region
is said to be of a particular IgG isotype, class or subclass if its amino acid sequence is most
homologous to that isotype relative to other IgG isotypes. In addition to their known uses in
diagnostics, antibodies have been shown to be useful as therapeutic agents. Antibodies are
capable of specifrcally g to a ptide or n or a non-protein molecule
due to the presence on such molecule of a particular domain or moiety or conformation (an
“epitope”). An epitope-containing molecule may have immunogenic activity, such that it
elicits an antibody production response in an animal, such molecules are termed “antigens”.
The last few decades have seen a revival of interest in the therapeutic potential of antibodies,
and antibodies have become one of the leading classes of biotechnology-derived drugs (Chan,
C.E. etal. (2009) “The Use OfAntiboa’ies In The Treatment OfInfectious Diseases,” Singapore
Med. J. 50(7):663-666). Over 200 dy-based drugs have been approved for use or are
under development.
The term “monoclonal antibody” refers to a homogeneous antibody population
wherein the monoclonal antibody is comprised of amino acids (naturally occurring and non-
naturally occurring) that are involved in the selective binding of an n. Monoclonal
dies are highly specific, being directed against a single epitope (or antigenic site). The
term “monoclonal antibody” encompasses not only intact monoclonal antibodies and full-
length monoclonal antibodies, but also fragments thereof (such as Fab, Fab', F(ab’)2 Fv), single-
chain (scFv), s thereof, fusion proteins comprising an antibody n, humanized
monoclonal antibodies, chimeric monoclonal dies, and any other modified configuration
of the immunoglobulin molecule that comprises an antigen recognition site of the required
specificity and the ability to bind to an antigen. It is not intended to be limited as regards to
the source of the antibody or the manner in which it is made (e.g., by hybridoma, phage
selection, recombinant expression, enic animals, etc.) The term includes whole
immunoglobulins as well as the fragments etc. described above under the definition of
“antibody. 77 s of making onal antibodies are known in the art. One method
which may be employed is the method of Kohler, G. et al. (1975) “Continuous Cultures Of
Fused Cells Secreting Antibody Of Predefined Specificity,” Nature 256:495-497 or a
modification thereof. Typically, monoclonal antibodies are developed in mice, rats or rabbits.
The antibodies are produced by immunizing an animal with an immunogenic amount of cells,
cell extracts, or protein preparations that contain the desired epitope. The immunogen can be,
but is not d to, primary cells, cultured cell lines, cancerous cells, proteins, peptides,
nucleic acids, or tissue. Cells used for zation may be cultured for a period oftime (e.g.,
at least 24 hours) prior to their use as an immunogen Cells may be used as immunogens by
themselves or in combination with a non-denaturing adjuvant, such as Ribi (see, e.g., Jennings,
V.M. (1995) “Review ofSelectedAdjuvants Used in Antibody Production,” ILAR J. 37(3): 1 19-
125). In general, cells should be kept intact and preferably viable when used as immunogens.
Intact cells may allow ns to be better detected than ruptured cells by the immunized
animal. Use of ring or harsh adjuvants, e.g., Freud's adjuvant, may rupture cells and
therefore is discouraged. The immunogen may be administered multiple times at periodic
intervals such as, bi weekly, or weekly, or may be administered in such a way as to maintain
viability in the animal (e.g., in a tissue recombinant). Alternatively, existing monoclonal
antibodies and any other equivalent antibodies that are immunospecific for a desired
pathogenic epitope can be sequenced and ed recombinantly by any means known in the
art. In one embodiment, such an antibody is sequenced and the polynucleotide sequence is
then cloned into a vector for expression or propagation. The sequence encoding the antibody
of st may be maintained in a vector in a host cell and the host cell can then be expanded
and frozen for future use. The polynucleotide ce of such antibodies may be used for
genetic manipulation to te the monospecific or multispecific (e.g., bispecific, trispecific
and tetraspecific) molecules of the invention as well as an affinity optimized, a chimeric
antibody, a humanized antibody, and/or a caninized antibody, to e the y, or other
characteristics of the dy. The l principle in humanizing an antibody involves
retaining the basic sequence of the antigen-binding portion of the antibody, while swapping the
non-human remainder of the antibody with human antibody ces.
l antibodies (such as IgG antibodies) are composed of two Light Chains
complexed with two Heavy Chains. Each Light Chain contains a Variable Domain (VL) and
a Constant Domain (CL). Each Heavy Chain contains a Variable Domain (VH), three Constant
Domains (CH1, CH2 and CH3), and a Hinge Region located between the CH1 and CH2
Domains. The basic structural unit of naturally occurring immunoglobulins (e.g., IgG) is thus
a tetramer having two light chains and two heavy chains, usually expressed as a glycoprotein
of about 150,000 Da. The amino-terminal (“N-terminal”) portion of each chain includes a
Variable Domain of about 100 to 110 or more amino acids primarily responsible for antigen
recognition. The carboxy-terminal (“C-terminal”) portion of each chain defines a constant
region, with light chains having a single Constant Domain and heavy chains usually having
three Constant Domains and a Hinge . Thus, the structure of the light chains of an IgG
molecule is n-VL-CL-c and the structure of the IgG heavy chains is n-VH-CHl-H-CHZ-CH3-
c (where H is the Hinge Region, and n and c represent, tively, the N—terminus and the C-
terminus of the polypeptide). The Variable Domains of an IgG molecule consist of the
mentarity determining regions (CDR), which contain the residues in contact with
e, and non-CDR segments, referred to as framework segments (FR), which in general
maintain the structure and determine the positioning of the CDR loops so as to permit such
contacting (although certain framework residues may also contact antigen). Thus, the VL and
VH s have the structure CDRl-FR2-CDR2-FR3-CDR3-FR4-c. Polypeptides
that are (or may serve as) the first, second and third CDR of an antibody Light Chain are herein
respectively designated CDRLl Domain, CDRLZ Domain, and CDRL3 Domain. Similarly,
polypeptides that are (or may serve as) the first, second and third CDR of an antibody heavy
chain are herein respectively designated CDRHI Domain, CDRHZ Domain, and CDRH3
Domain. Thus, the terms CDRLl Domain, CDRL2 , CDRL3 Domain, CDRHl ,
CDRHZ Domain, and CDRH3 Domain are directed to polypeptides that when incorporated into
a n cause that protein to be able to bind to a specific epitope regardless of whether such
protein is an antibody having light and heavy chains or a diabody or a single-chain binding
molecule (e.g., an scFv, a BiTe, etc), or is another type of n. Accordingly, as used herein,
the term “epitope-binding fragment” means a fragment of an antibody capable of
immunospecifically binding to an epitope, and the term “epitope-binding site” refers to a
portion of a molecule comprising an epitope-binding fragment. An epitope-binding nt
may contain 1, 2, 3, 4, 5 or all 6 of the CDR Domains of such antibody and, although e
of immunospecifically binding to such epitope, may exhibit an immunospecificity, affinity or
selectivity toward such epitope that differs from that of such antibody. Preferably, however,
an epitope-binding fragment will contain all 6 of the CDR Domains of such antibody, An
epitope-binding fragment of an antibody may be a single polypeptide chain (e.g., an scFv), or
may comprise two or more polypeptide , each having an amino terminus and a carboxy
terminus (e.g, a diabody, a Fab fragment, an Fabz nt, etc). Unless specifically noted,
the order of domains of the protein molecules described herein is in the N—terminal to C-
Terminal ion.
The invention particularly encompasses PD—l X CTLA-4 bispeciflc binding
molecules comprising one, two, or more than two single-chain Variable Domain fragments
”) of an anti-PD-l antibody and one, two, or more than two single-chain Variable
Domain fragments of an anti-CTLA-4 antibody. Single-chain Variable Domain fragments are
made by linking Light and Heavy chain Variable Domains using a short linking peptide.
Linkers can be modified to provide additional functions, such as to permit the attachment of
drugs or attachment to solid supports. The single-chain ts can be produced either
recombinantly or synthetically. For synthetic production of scFv, an automated synthesizer
can be used. For recombinant production of scFV, a suitable plasmid containing polynucleotide
that encodes the scFV can be introduced into a suitable host cell, either eukaryotic, such as
yeast, plant, insect or mammalian cells, or prokaryotic, such as E. coli. Polynucleotides
ng the scFV of interest can be made by routine manipulations such as ligation of
polynucleotides. The resultant scFV can be isolated using standard protein ation
techniques known in the art.
The invention also particularly encompasses PD-l X CTLA-4 iflc
molecules comprising humanized anti-PD-l and anti—CTLA-4 dies. The term
“humanized” antibody refers to a chimeric molecule, generally ed using recombinant
techniques, having an antigen—binding site of an immunoglobulin from a man species
and a remaining immunoglobulin structure of the molecule that is based upon the structure and
/or sequence of a human immunoglobulin. The polynucleotide sequence of the variable
domains of such dies may be used for genetic manipulation to generate such derivatives
and to improve the ty, or other characteristics of such antibodies. The general principle
in humanizing an antibody involves retaining the basic ce of the antigen-binding portion
of the antibody, while swapping the non-human remainder of the dy with human
antibody sequences. There are four general steps to humanize a onal antibody. These
are: (l) determining the nucleotide and predicted amino acid sequence of the starting antibody
light and heavy variable domains; (2) designing the humanized antibody or caninized antibody,
i.e., deciding which antibody framework region to use during the humanizing or canonizing
s, (3) the actual humanizing or caninizing methodologies/techniques; and (4) the
transfection and expression of the zed antibody. See, for example, US. Patents Nos.
4,816,567, 5,807,715; 5,866,692; and 6,331,415.
The antigen-binding site may se either a complete Variable Domain fused
onto Constant Domains or only the complementarity determining regions (CDRs) of such
Variable Domain grafted to riate framework s. Antigen-binding sites may be
wild-type or modified by one or more amino acid substitutions. This eliminates the constant
region as an immunogen in human individuals, but the possibility of an immune response to
the foreign variable domain remains (LoBuglio, A.F. et al. (1989) “Mouse/Human Chimeric
Monoclonal Antibody In Man: Kinetics And Immune Response,” Proc. Natl. Acad. Sci.
(USA) 86:4220-4224). Another approach focuses not only on providing human-derived
constant regions, but modifying the variable domains as well so as to reshape them as closely
as le to human form. It is known that the valiable domains ofboth heavy and light chains
contain three complementarity determining regions (CDRs) which vary in response to the
antigens in question and determine binding capability, flanked by four framework regions
(FRs) which are relatively conserved in a given species and which putatively provide a
scaffolding for the CDRs. When man antibodies are prepared with t to a particular
n, the variable s can be “reshaped” or “humanized” by grafting CDRs derived
from non-human antibody on the FRs present in the human antibody to be modified.
Application of this approach to various antibodies has been ed by Sato, K. et al. (1993)
Cancer Res 53:851-856. Riechmann, L. et al. (1988) “Reshaping Human Antibodies for
Therapy,” Nature 332:323-327, Verhoeyen, M. et al. (1988) “Reshaping Human Antibodies:
GraftingAn Antilysozyme Activity,” Science 239: 1534-1536, Kettleborough, C. A. et al. (1991)
“Humanization Of A Mouse Monoclonal Antibody By CDR-Grafting: The Importance Of
Framework Residues On Loop Conformation,” Protein Engineering 4:773—3783; Maeda, H. et
al. (1991) “Construction Of Reshaped Human Antibodies With HIV-Neutralizing ty,”
Human Antibodies oma 2:124—134; Gorman, S. D. et al. (1991) “Reshaping A
Therapeutic CD4 Antibody,” Proc, Natl. Acad. Sci. (USA) 88:4181-4185, Tempest, PR. et
al. (1991) “ReshapingA Human MonoclonalAntibody To InhibitHuman Respiratory Syncytial
Virus Infection in vivo,” Bio/Technology 9:266-271, Co, M. S. et al. (1991) “Humanized
Antibodies For Antiviral Therapy,” Proc. Natl. Acad. Sci. (USA) 9-2873; Carter, P. et
al. (1992) “Humanization OfAn Anti-p185her2 Antibody For Human Cancer Therapy,” Proc.
Natl. Acad. Sci. (USA) 5-4289, and Co, MS. etal. (1992) “Chimeric AndHumanized
Antibodies With Specificity For The CD33 Antigen,” J. Immunol. 148:1149-1154. In some
embodiments, humanized antibodies preserve all CDR sequences (for example, a humanized
mouse antibody which contains all six CDRs from the mouse antibodies). In other
embodiments, humanized antibodies have one or more CDRs (one, two, three, four, five, or
six) which differ in sequence ve to the original antibody.
A number of“humanized” dy molecules comprising an antigen-binding site
derived from a non-human immunoglobulin have been described, including ic
antibodies having rodent or modified rodent Variable Domain and their associated
complementarity determining regions (CDRs) fused to human constant domains (see, for
example, Winter et al. (1991) “Man-made Antibodies,” Nature 349:293—299, Lobuglio et al.
(1989) “Mouse/Human Chimeric Monoclonal Antibody In Man: Kinetics And Immune
Response,” Proc. Natl. Acad. Sci. (USA) 86:4220-4224 , Shaw et al. (1987)
“Characterization OfA Mouse/Human Chimeric Monoclonal Antibody (17-1A) T0 A Colon
Cancer Associated Antigen,” J. Immunol, 138:4534-4538, and Brown et al. (1987)
“Tumor-Specific cally Engineered /Human Chimeric Monoclonal Antibody,”
Cancer Res. 47:3577-3583). Other references describe rodent CDRs grafted into a human
supporting framework region (FR) prior to fusion with an appropriate human antibody
Constant Domain (see, for example, Riechmann, L. et al. (1988) “Reshaping Human
Antibodiesfor Therapy,” Nature 332:323-327, Verhoeyen, M. et al. (1988) pingHuman
Antibodies: Grafting An Antilysozyme Activity,” Science 239:1534-1536; and Jones et al.
(1986) “Replacing The Complementarity-Determining Regions In A Human Antibody With
Those From A Mouse,” Nature 321:522-525). Another reference describes rodent CDRs
supported by inantly ed rodent framework regions. See, for example, European
Patent Publication No. 519,596. These “humanized” molecules are designed to minimize
unwanted immunological response towards rodent anti-human antibody molecules, which
limits the duration and effectiveness of therapeutic applications of those moieties in human
recipients. Other methods of humanizing antibodies that may also be utilized are disclosed by
Daugherty et al. (1991) “Polymerase Chain Reaction Facilitates The Cloning, CDR-Grafting,
And Rapid Expression Of A Murine onal Antibody Directed Against The CD18
ent OfLeukocyte Integrins,” Nucl. Acids Res. 19:2471-2476 and in US. Patents Nos.
377, 6,054,297, 5,997,867, and 5,866,692.
II. Fcy Receptors (FcyRs)
The CH2 and CH3 s of the two heavy chains interact to form the Fc
Region, which is a domain that is recognized by cellular Fc Receptors, including but not
limited to Fc gamma Receptors (FcyRs). As used herein, the term “Fc Region” is used to
define a C-terminal region of an IgG heavy chain. The amino acid sequence of the CH2-CH3
Domain of an exemplary human IgG1 is (SEQ ID NO:1):
231 240 250 260 270 280
APELLGGPSV FLFPPKPKDT RM SRTBfiVT CVVVDVSHED PEVKFNWYVD
290 300 310 320 330
GVEVHNAKTK NSTY RVVSVLTVLH KEYK ALPA
340 350 360 370 380
PIEKTISKAK GQPREPQVYT LPPSREEMTK NQVSLTCLVK GFYPSDIAVE
390 400 410 420 430
WESNGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE
440 447
ALHNHYTQKS LSLSPGE
as numbered by the EU index as set forth in Kabat, wherein X is a lysine (K) or is absent.
The amino acid sequence of the CH2-CH3 Domain of an ary human IgG2
is (SEQ ID NO:2):
231 240 250 260 270 280
GPSV FLFPPKPKDT RM SRTBfiVT CVVVDVSHED PEVQFNWYVD
290 300 310 320 330
GVEVHNAKTK PRfifiQhNSTF RVVSVLTVVH QDWLNGKEYK CKVSNKGLPA
340 350 360 370 380
PIEKTISKTK GQPREPQVYT LPPSREEMTK NQVSLTCLVK GFYPSDISVE
390 400 410 420 430
PENN YKTTPPMLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE
440 447
ALHNHYTQKS LSLSPGE
as numbered by the EU index as set forth in Kabat, wherein X is a lysine (K) or is absent.
The amino acid sequence of the CH2—CH3 Domain of an exemplary human IgG3
is (SEQ ID NO:3):
231 240 250 260 270 280
APELLGGPSV FLFPPKPKDT LMISRTPEVT SHED PEVQFKWYVD
290 300 310 320 330
GVEVHNAKTK PRfifiQYNSTF RVVSVLTVLH QDWLNGKEYK CKVSNKALPA
340 350 360 370 380
PIEKTISKTK GQPREPQVYT LPPSREEMTK NQVSLTCLVK GEYPSD AVfi
390 400 410 420 430
WESSGQPENN YNTTPPMLDS DGSFFLYSKL TVDKSRWQQG NIFSCSVMHE
440 447
ALHNRFTQKS LSLSPG§
as numbered by the EU index as set forth in Kabat, wherein X is a lysine (K) or is absent.
The amino acid sequence of the CH2—CH3 Domain of an exemplary human IgG4
is (SEQ ID NO:4):
231 240 250 260 270 280
APEFLGGPSV FLFPPKPKDT LMISRTPEVT SQED PEVQFNWYVD
290 300 310 320 330
GVEVHNAKTK PRfiflQFNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS
340 350 360 370 380
S fiKTISKAK GQPREPQVYT LBPSQfifiMTK NQVSLTCLVK GEYPSD AVfi
390 400 410 420 430
WESNGQPENN YKTTPPVLDS DGSFFLYSRL WQEG NVFSCSVMHE
440 447
ALHNHYTQKS LSLSLGE
as numbered by the EU index as set forth in Kabat, wherein X is a lysine (K) or is absent.
Throughout the t specification, the numbering of the residues in the
constant region of an IgG heavy chain is that of the EU index as in Kabat et al., SEQUENCES OF
NS OF IMMUNOLOGICAL INTEREST, 5th Ed. Public Health Service, NHl, MD (1991)
t”), expressly incorporated herein by references. The term “EU index as in Kabat” refers
to the numbering of the human IgG1 EU antibody. Amino acids from the Variable Domains
of the mature heavy and light chains of immunoglobulins are designated by the position of an
amino acid in the chain. Kabat described numerous amino acid sequences for antibodies,
identified an amino acid consensus sequence for each subgroup, and assigned a e number
to each amino acid, and the CDRs are fied as defined by Kabat (it will be understood that
CDRHl as defined by Chothia, C. & Lesk, A. M. ((1987) “Canonical structures for the
hypervariable regions of immunoglobulins,” J. Mol. Biol. 196:901-917) begins five residues
earlier). Kabat’s numbering scheme is ible to antibodies not included in his
dium by aligning the antibody in question with one ofthe consensus sequences in Kabat
by reference to conserved amino acids. This method for ing residue numbers has become
standard in the field and readily identifies amino acids at equivalent positions in different
antibodies, including chimeric or humanized variants. For example, an amino acid at position
50 of a human antibody light chain occupies the equivalent position to an amino acid at position
50 of a mouse antibody light chain.
Polymorphisms have been observed at a number of ent positions within
antibody constant regions (e. g., Fc positions, including but not limited to positions 270, 272,
312, 315, 356, and 358 as numbered by the EU index as set forth in Kabat), and thus slight
ences between the presented sequence and sequences in the prior art can exist.
Polymorphic forms of human immunoglobulins have been haracterized. At present, 18
Gm allotypes are known: G1m (1, 2, 3, 17) or G1m (a, X, f, z), G2m (23) or G2m (n), G3m (5,
6,10,11,13,14,15,16,21, 24, 26, 27, 28) or G3m (b1, c3, b3, b0, b3, b4, 5, t, g], c5, u, v, g5)
(Lefranc, et al. , “The Human IgG Subclasses: Molecular Analysis OfStructure, Function And
Regulation.” Pergamon, Oxford, pp. 43 -78 (1990); Lefranc, G. et al., 1979, Hum. Genet: 50,
199-211). It is specifically contemplated that the antibodies of the present invention may
incorporate any allotype, isoallotype, or haplotype of any globulin gene, and are not
limited to the allotype, isoallotype or ype ofthe sequences provided herein. Furthermore,
in some expression systems the C-terminal amino acid residue (bolded above) of the CH3
Domain may be post-translationally removed. Accordingly, the C-terminal residue of the CH3
Domain is an al amino acid residue in the PD-l X CTLA-4 bispecific molecules of the
ion. Specifically encompassed by the instant invention are PD-1 X CTLA-4 bispecific
molecules lacking the C-terminal residue of the CH3 Domain. Also specifically encompassed
by the t invention are such constructs comprising the C-terminal lysine residue of the
CH3 Domain.
As stated above, the Fc Region of natural IgG antibodies is capable of binding to
cellular Fc gamma Receptors (FcyRs). Such binding results in the transduction of activating
or inhibitory signals to the immune system. The ability of such binding to result in
diametrically opposing functions reflects structural differences among the different FcyRs, and
in particular reflects whether the bound FcyR possesses an immunoreceptor tyrosine-based
activation motif (ITAM) or an immunoreceptor tyrosine-based inhibitory motif (ITIM). The
tment of different cytoplasmic enzymes to these structures dictates the outcome of the
FcyR—mediated cellular responses. ontaining FcyRs include FcyRI, FcyRIIA,
FcyRIIIA, and activate the immune system when bound to an Fc Region. FcyRIIB is the only
tly known l ITIM-containing FcyR, it acts to dampen or inhibit the immune system
when bound to an Fc . Human neutrophils express the A gene. FcyRIIA
clustering via immune complexes or specific antibody linking serves to aggregate ITAMs
with receptor-associated kinases which facilitate ITAM phosphorylation. ITAM
phosphorylation serves as a docking site for Syk kinase, the activation of which results in the
activation of downstream substrates (e. g., PI3K). Cellular activation leads to release of pro-
inflammatory mediators. The B gene is expressed on B lymphocytes; its extracellular
domain is 96% identical to FcyRIIA and binds IgG complexes in an indistinguishable manner.
The presence of an ITIM in the cytoplasmic domain ofFcyRIIB defines this inhibitory subclass
of FcyR. Recently the molecular basis of this inhibition was established. When co-ligated
along with an activating FcyR, the ITIM in FcyRIIB becomes phosphorylated and attracts the
SH2 domain of the ol polyphosphate 5’—phosphatase (SHIP), which hydrolyzes
oinositol messengers released as a consequence of ITAM—containing FcyR- mediated
ne kinase activation, consequently preventing the influx of intracellular Ca”. Thus cross-
g of FcyRIIB dampens the activating response to FcyR ligation and inhibits cellular
responsiveness. B-cell activation, B-cell proliferation and dy secretion is thus aborted.
III. Bispecific Antibodies, Multispecific Diabodies and DART® Diabodies
The ability of an antibody to bind an epitope of an n depends upon the
presence and amino acid ce of the antibody’s VL and VH Domains. Interaction of an
antibody’s Light Chain and Heavy Chain and, in particular, interaction of its VL and VH
Domains forms one of the two e-binding sites of a natural dy, such as an IgG.
Natural antibodies are capable of binding to only one epitope species (116., they are
monospeciflc), although they can bind multiple copies of that species (i.e., exhibiting bivalency
or multivalency).
The binding domains of an antibody, and of the PD-l X CTLA-4 bispecific
molecules of the t invention, bind to epitopes in an “immunospecific” . As used
herein, an antibody, diabody or other epitope-binding molecule is said to
“immunospecifically” bind a region of r molecule (i.e., an epitope) if it reacts or
ates more ntly, more rapidly, with greater duration and/or with greater affinity with
that epitope relative to alternative epitopes. For example, an antibody that immunospecifically
binds to a viral epitope is an antibody that binds this viral e with r affinity, avidity,
more readily, and/or with greater duration than it immunospecifically binds to other viral
epitopes or non-viral epitopes. It is also understood by reading this definition that, for example,
an antibody (or moiety or epitope) that immunospecifically binds to a first target may or may
not specifically or preferentially bind to a second target. As such, “immunospecific g”
does not necessarily e (although it can include) exclusive binding. Generally, but not
necessarily, reference to binding means “immunospecific” binding. Two molecules are said to
be capable of g to one another in a “physiospecific” manner, if such binding exhibits the
specificity with which receptors bind to their respective ligands.
One aspect of the present invention reflects the recognition that the functionality
of antibodies can be ed by generating multispecific antibody—based molecules that can
simultaneously bind to one or more epitope(s) of PD-l and also one or more epitope(s) of
CTLA-4. For molecules having more than one epitope-binding site specific for an
epitope of PD-l, such epitopes may be identical to one another, overlapping, or distinct from
one another; binding to one such epitope may compete with or not compete with g to
another of such epitopes. Likewise, for molecules having more than one epitope—binding site
immunospecific for an epitope of CTLA-4, such epitopes may be cal to one another,
overlapping, or distinct from one another; binding to one such epitope may compete with or
not compete with binding to the second of such epitopes. It is expressly contemplated that such
characteristics may be independently varied to yield PD—l X CTLA-4 bispecific molecules that,
for example, possess:
(1) the ability to bind to two identical epitopes of PD-l and to:
(a) two cal epitopes of CTLA-4, or
(b) two overlapping epitopes of CTLA-4, or
(c) two distinct epitopes of CTLA—4;
(2) the ability to bind to two overlapping epitopes of PD-l and to:
(a) two cal epitopes of CTLA-4, or
(b) two overlapping epitopes of CTLA-4; or
(c) two distinct es of CTLA-4,
(3) the ability to bind to two distinct epitopes of PD-l and to:
(a) two identical epitopes of CTLA-4; or
(b) two overlapping epitopes of CTLA-4, or
(c) two distinct epitopes of CTLA-4.
In order to provide les having greater capability than natural antibodies, a
wide variety of recombinant bispecific antibody s have been developed (see, e. g., PCT
Publication Nos.
either to fuse a further epitope-binding fragment (e.g., an scFv, VL, VH, etc.) to, or within the
dy core (IgA, IgD, IgE, IgG or IgM), or to fuse multiple epitope-binding fragments (e.g.,
two Fab nts or . Alternative formats use linker peptides to fuse an e-binding
fragment (e.g, an scFv, VL, VH, etc.) to a dimerization domain such as the CH2-CH3 Domain
or alternative polypeptides (
2007/046893). PCT Publications Nos.
2010/136172 disclose a trispecific antibody in which the CL and CH1 Domains are switched
from their respective natural positions and the VL and VH Domains have been diversified (WO
2008/027236,
Publications Nos. WO 63427 and
Domain to contain a fusion protein adduct comprising a binding domain. PCT ations
Nos. WO 28797, W02010028796 and
antibodies whose Fc Regions have been replaced with additional VL and VH Domains, so as
to form ent binding molecules. PCT Publications Nos. WO 2003/025018 and
W02003012069 se recombinant diabodies whose individual chains contain scFv
Domains. PCT Publications No.
are synthesized as a single polypeptide chain and then subjected to proteolysis to yield
heterodimeric structures. PCT Publications Nos.
2012/162583,
additional binding domains or functional groups to an dy or an antibody portion (e.g.,
adding a diabody to the antibody’s light chain, or adding additional VL and VH Domains to
the antibody’s light and heavy chains, or adding a heterologous fusion protein or chaining
multiple Fab Domains to one another).
The art has additionally noted the lity to produce diabodies that differ from
such natural antibodies in being capable of binding two or more ent epitope species (i. e.,
ting bispeciflcity or peciflcity in addition to bivalency or multivalency) (see, e.g.,
Holliger et al. (1993) odies Small Bivalent AndBispecific Antibody Fragments,” Proc.
Natl. Acad. Sci. (USA) 90:6444-6448, US 2004/0058400 (Hollinger et al.), US
2004/0220388 /WO 02/02781 (Mertens et al.), Alt et al. (1999) FEBS Lett. 454(1-2):90-94,
Lu, D. et al. (2005) “A Fully Human Recombinant IgG-Like Bispecific Antibody T0 Both The
Epidermal Growth Factor Receptor And The Insulin-Like Growth Factor Receptor For
EnhancedAntitumor ty,” J. Biol. Chem. 280(20):]9665-19672; WO 02/02781 (Mertens
et al.), Olafsen, T. et al (2004) “Covalent Disulfide-Linked Anti-CEA Diabody Allows Site-
Specific Conjugation And Radiolabeling For Tumor Targeting Applications,” Protein Eng.
Des. Sel. 17(1):21-27, Wu, A. et al. (2001) merization OfA Chimeric Anti-CD20 Single
Chain Fv-Fv Fusion Protein Is Mediated Through Variable Domain Exchange,” Protein
Engineering 14(2):1025-1033, Asano et al. (2004) “A Diabody For Cancer Immunotherapy
And Its Functional Enhancement By Fusion Of Human Fc Domain,” Abstract 3P-683, J.
Biochem. 76(8):992; Takemura, S. et al. (2000) “Construction Of A y (Small
Recombinant Bispecific Antibody) Using A Refolding System,” Protein Eng. 13(8):583-588,
Baeuerle, PA. et al. (2009) cific T-Cell Engaging Antibodies For Cancer Therapy,”
Cancer Res. 69(12):4941-4944).
The design of a diabody is based on the antibody derivative known as a singlechain
Variable Domain fragment (scFv). Such molecules are made by linking Light and/ or
Heavy Chain Variable s using a short linking peptide. Bird et al. (1988) (“Single-
Chain Antigen-BindingProteins,” Science 242:423-426) describes example of linking peptides
which bridge imately 3.5 nm between the carboxy terminus of one Variable Domain
and the amino terminus of the other Variable Domain. Linkers of other sequences have been
designed and used (Bird et al. (1988) e-Chain Antigen-Binding Proteins,” Science
242:423-426). Linkers can in turn be modified for additional functions, such as attachment of
drugs or attachment to solid supports. The -chain variants can be produced either
recombinantly or tically. For synthetic production of scFv, an automated synthesizer
can be used. For inant production of scFv, a suitable plasmid containing polynucleotide
that s the scFv can be introduced into a suitable host cell, either eukaryotic, such as
yeast, plant, insect or mammalian cells, or prokaryotic, such as E. coli. Polynucleotides
encoding the scFv of interest can be made by routine manipulations such as ligation of
polynucleotides. The resultant scFv can be isolated using standard protein purification
techniques known in the art.
The provision of bispecific binding molecules (e.g., non-monospecific diabodies)
es a significant advantage over antibodies, including but not limited to, a “trans” binding
capability sufficient to co-ligate and/or co-localize different cells that s different epitopes
and/or a “cis” binding capability sufficient to co—ligate and/or co-localize different molecules
expressed by the same cell. Bispecific binding molecules (e.g., non-monospecific diabodies)
thus have wide-ranging applications including therapy and immunodiagnosis. Bispecificity
allows for great flexibility in the design and engineering of the diabody in various applications,
providing enhanced avidity to multimeric antigens, the cross-linking of differing antigens, and
directed targeting to specific cell types g on the presence of both target antigens. Due to
their increased valency, low dissociation rates and rapid clearance from the circulation (for
diabodies of small size, at or below ~50 kDa), diabody molecules known in the art have also
shown particular use in the field of tumor imaging (Fitzgerald et al. (1997) “Improved Tumour
Targeting By Disulpliide Stabilized Diabodies Expressed In Pichia pastoris, ” Protein Eng.
: 1221).
The ability to produce ific diabodies has led to their use (in “trans”) to co-
ligate two cells together, for example, by co-ligating receptors that are present on the surface
of different cells (e.g., linking cytotoxic T-cells to tumor cells) (Staerz et al. (1985)
d dies Can Target Sites For Attack By T Cells,” Nature 314:628-631, and
Holliger et al. (1996) “Specific Killing OfLymphoma Cells By xic T-Cells MediatedBy
A ific Diabody, ” Protein Eng. 9:299-305, Marvin et al. (2005) “Recombinant
Approaches To IgG-Like Bispecifzc Antibodies,” Acta Pharmacol. Sin. 26:649-65 8).
Alternatively, or additionally, bispecific diabodies can be used (in “cis”) to co-ligate les,
such as ors, etc, that are present on the surface of the same cell. Co—ligation of different
cells and/or receptors is useful to modulation or functions and/or immune cell signaling.
However, the above advantages come at a salient cost. The formation of such non-
monospecific diabodies requires the successful assembly of two or more ct and different
polypeptides (i. e., such formation requires that the diabodies be formed through the
heterodimerization of different polypeptide chain species). This fact is in contrast to
monospecific ies, which are formed through the homodimerization of identical
polypeptide . Because at least two dissimilar polypeptides (i.e., two polypeptide species)
must be provided in order to form a non-monospecific diabody, and because homodimerization
of such polypeptides leads to inactive les (Takemura, S. et al. (2000) “Construction Of
A Diabody (Small Recombinant Bispecific Antibody) UsingA Refolding ,” Protein Eng.
l3(8):583-588), the production of such polypeptides must be accomplished in such a way as to
prevent covalent g between polypeptides of the same species (i.e., so as to prevent
merization) (Takemura, S. et al. (2000) “Construction Of A Diabody (Small
Recombinant Bispecific Antibody) Using A Refolding System,” Protein Eng. l3(8):583-588).
The art has therefore taught the non-covalent association of such polypeptides (see, e.g.,
Olafsen et al. (2004) “Covalent ide-Linked Anti-CEA Diabody Allows Site-Specific
Conjugation And Radiolabeling For Tumor Targeting Applications,” Prot. Engr. Des. Sel.
17:21-27, Asano et al. (2004) “A Diabody For Cancer Immunotherapy And Its onal
ement By Fusion Of Human Fc Domain,” Abstract 3P-683, J. Biochem. 76(8):992;
Takemura, S. et al. (2000) “Construction Of A Diabody (Small Recombinant Bispecific
Antibody) Using A Refolding ,” Protein Eng. l3(8):583-588, Lu, D. et al. (2005) “A
Fully Human Recombinant IgG-Like Bispecific Antibody To Both The Epidermal Growth
Factor Receptor And The Insulin-Like Growth Factor Receptor For Enhanced Antitumor
Activity,” J. Biol. Chem. 280(20):]9665-19672).
r, the art has ized that bispecific diabodies composed of non-
covalently associated polypeptides are unstable and readily dissociate into nctional
monomers (see, e.g., Lu, D. et al. (2005) “A Fully Human Recombinant IgG—Like Bispecific
Antibody To Both The Epidermal Growth Factor Receptor And The Insulin-Like Growth
Factor Receptor For EnhancedAntitumor ty,” J. Biol. Chem. ): 19665-19672).
In the face of this challenge, the art has succeeded in developing stable, covalently
bonded heterodimeric non-monospecific diabodies, termed DART® (Qual Affinity Be-
largeting Reagents) diabodies; see, e.g., United States Patent Publications No. 2013-
0295121, 2010-0174053 and 2009—0060910, European Patent Publication No. EP 2714079,
EP 2601216, EP 2376109; EP 2158221 and PCT Publications No.
2012/018687;
Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV
Envelope and Recruit Cytotoxic T Cells,” PLoS . 11(11):e1005233. doi:
. 1371/joumal.ppat. 1005233; Al Hussaini, M. et al. (2015) “Targeting CD123 In AML Using
A T-Cell DirectedDual-Afinizy Re-Targeting (DART®) Platform,” Blood pii: 2014
575704; Chichili, G.R. et al. (2015) “A CD3xCD123 Bispecific DARTFor Redirecting Host T
Cells To enous ia: Preclinical Activity And Safety In Nonhuman Primates,” Sci.
Transl. Med. 7(289):289ra82; Moore, RA. et al. (2011) “Application Of Dual Ayfmity
Retargeting Molecules To Achieve Optimal Redirected T-Cell Killing OfB-Cell Lymphoma,”
Blood 117(17):4542-4551; Veri, MC. et al. (2010) “Therapeutic Control OfB Cell tion
Via Recruitment Of chamma Receptor IIb (CD323) Inhibitory Function With A Novel
ific Antibody Scaflol ,” Arthritis Rheum. 62(7):1933-1943; Johnson, S. et al. (2010)
“Eflector Cell Recruitment With NovelFv-BasedDual-Aflinity Re-Targeting Protein Leads To
Potent Tumor sis And in vivo B—Cell Depletion,” J. Mol. Biol. 399(3):436-449). Such
diabodies comprise two or more covalently complexed polypeptides and involve engineering
one or more cysteine residues into each of the employed polypeptide species that permit
disulfide bonds to form and thereby covalently bond one or more pairs of such polypeptide
chains to one another. For e, the addition of a cysteine residue to the C—terminus of
such constructs has been shown to allow disulfide bonding between the involved polypeptide
chains, stabilizing the ing y t interfering with the diabody’s binding
characteristics.
Many variations of such molecules have been described (see, e. g., United States
Patent Publications No. 2015/0175697; 2014/0255407; 2014/0099318; 2013/0295121;
2010/0174053; 2009/0060910; 2007-0004909; European Patent ation No. EP 2714079;
EP 2601216; EP 2376109; EP 2158221; EP 1868650; and PCT Publications No. WO
2012/162068;
herein.
Alternative constructs are known in the art for applications where a tetravalent
molecule is desirable but an PC is not required including, but not limited to, tetravalent tandem
antibodies, also referred to as “TandAbs” (see, e.g. United States Patent Publications Nos.
2005-0079170, 2007-0031436, 2010-0099853, 20667 2013—0189263; European Patent
ation Nos. EP 1078004, EP 2371866, EP 2361936 and EP 1293514; PCT Publications
homo-dimerization of two identical chains each sing a VH1, VL2, VH2, and VL2
Domain.
IV. Preferred PD-l x CTLA-4 Bispecific Molecules
One embodiment of the present invention relates to PD-1 X CTLA-4 bispecific
molecules that are capable of binding to a “first epitope” and a “second epitope,” such
epitopes not being identical to one another. Such bispecific molecules comprise “VLl” /
“VH1” domains that are capable of binding to the first epitope and “VL2” / “VH2” domains
that are capable of binding to the second epitope. The notations “VLl” and “VH1” denote,
respectively, the Light Chain Variable Domain and Heavy Chain Variable Domain that bind
the “first” epitope of such bispecific molecules. Similarly, the notations “VL2” and “VH2”
denote, respectively, the Light Chain Variable Domain and Heavy Chain Variable Domain that
bind the “second” epitope of such ific molecules. It is irrelevant whether a particular
epitope is designated as the first vs. the second epitope, such notations having relevance only
with respect to the ce and orientation of domains of the ptide chains of the binding
molecules of the present ion. In one embodiment, one of such epitopes is an epitope of
human PD-l and the other of such epitopes is an e of CTLA-4. In certain ments,
a bispecific molecule comprises more than two epitope-binding sites. Such bispecific
molecules will bind at least one e of PD-1 and at least one epitope of CTLA-4 and may
further bind additional epitopes of PD-1 and/or additional epitopes of CTLA-4.
The t invention particularly relates to PD-1 X CTLA-4 bispecific molecules
(e.g, bispecific antibodies, bispecific diabodies, ent binding molecules, etc.) that s
epitope-binding fragments of antibodies that enable them to be able to coordinately bind to at
least one epitope of PD-l and at least on epitope of CTLA-4. Selection of the VL and VH
Domains of the polypeptide domains of such molecules is coordinated such that the VL
Domain and VH Domain of the same polypeptide chain are not capable of forming an epitope-
binding site capable of binding either PD-1 or CTLA-4. Such selection is additionally
coordinated so that polypeptides chains that make up such PD-l X CTLA-4 bispecific
molecules assemble to form at least one functional antigen binding site that is c for at
least one epitope of PD-1 and at least one functional n binding site that is specific for at
least one epitope of CTLA-4.
The present invention particularly relates to such PD-1 X CTLA—4 bispecific
molecules that exhibit an activity that is enhanced relative to such activity oftwo monospecific
molecules one of which possesses the Heavy Chain Variable Domain and the Light Chain
Variable Domain of the antibody that binds PD-1 and the other of which possesses the Heavy
Chain le Domain and the Light Chain Variable Domain of the antibody that binds
CTLA-4. Examples of such activity es attenuating the activity of PD-1, attenuating the
activity of CTLA-4, enhancing immune system activation, ing effector function,
enhancing anti-tumor activity. As used herein, such attenuation of activity refers to a se
of 10% or more, a decrease of 20% or more, a decrease of 50% or more, a decrease of 80% or
more, or a decrease of 90% or more in a PD-l and/or CTLA-4 inhibitory activity, or the
complete elimination of such PD-l and/or CTLA-4 inhibitory activity. As used herein, such
enhancement of activity refers to an enhancement of 10% or more, an enhancement of 20% or
more, an enhancement of 50% or more, an enhancement of 80% or more, or an enhancement
of 90% or more in an immune system-activating activity mediated by or affected by the
expression or ce of PD-l and/or CTLA-4, relative to the activity ted by two
monospecific molecules one of which possesses the Heavy Chain Variable Domain and the
Light Chain Variable Domain ofthe antibody that binds PD-1 and the other of which possesses
the Heavy Chain Variable Domain and the Light Chain Variable Domain of the antibody that
binds CTLA-4. Examples of immune system-activating activity include, but are not limited to
immune cell (e. g., hocyte, NK-cell) eration, immune cell production and/or
release of cytokines, immune cell production and/or release of lytic molecules (e.g., me,
perforin, etc), and/or immune cell expression of activation markers. Cytokines which are
released upon activation of the immune system are known in the art and include, but are not
limited to: IFNy, IL—2, and TNFOL, (see, e.g., Janeway, CA. ei al. 2011) IMMUNOBIOLOGY” 8th
ed. Garland e Publishing, NY; Banyer, J.L. (2000) “Cytokines in innate and adaptive
immunity,” Rev Immunogenet. 2359-3 73). Activation s expressed by immune cells are
known in the art and include, but are not limited to, CD69, CD25, and CD107a (see, e.g.,
Janeway, C.A. el al. (2011) IMMUNOBIOLOGY” 8th ed. Garland Science Publishing, NY,
Shipkova, M. and Wieland, E. (2012) “Surface markers oflymphocyie activation and markers
ofcellproliferation,” Clin Chim Acta 413: 1338-1349).
A. PD-l x CTLA-4 Bispecific Antibodies
The instant invention asses bispeciflc antibodies capable of
simultaneously binding to PD-1 and CTLA-4. In some embodiments, the bispeciflc antibody
capable of simultaneously binding to PD-l and CTLA-4 is produced using any of the s
described in PCT Publications No.
2007/146968,
2012/009544, WO 03652,
reference in its entirety.
B. PD-l x CTLA-4 Bispecific Diabodies Lacking Fc Regions
One embodiment of the present invention relates to bispecific ies that
comprise, and most preferably are composed of, a first polypeptide chain and a second
polypeptide chain, whose sequences permit the polypeptide chains to covalently bind to each
other to form a covalently associated diabody that is capable of simultaneously binding to PD-
1 and to CTLA-4.
The first polypeptide chain of such an embodiment of bispecific diabodies
comprises, in the N—terminal to C-terminal ion, an N—terminus, the VL Domain of a
monoclonal antibody capable of binding to either PD-l or CTLA-4 (i.e., either VLPD-l or
VLan-4), a first intervening spacer e (Linker l), a VH Domain of a monoclonal
antibody capable of binding to either CTLA—4 (if such first polypeptide chain ns VLPD-
1) or PD-l (if such first polypeptide chain contains VLCTLA-4), a second intervening spacer
peptide (Linker 2) optionally containing a cysteine residue, a Heterodimer—Promoting Domain
and a C-terminus (Figure 1).
The second polypeptide chain of this embodiment of ific diabodies
comprises, in the N—terminal to C-terminal direction, an N—terminus, a VL Domain of a
monoclonal antibody capable of binding to either PD-l or CTLA-4 (i.e., either VLPD-l or
VLCTLA-4, and being the VL Domain not selected for inclusion in the first polypeptide chain of
the diabody), an intervening spacer peptide (Linker l), a VH Domain of a monoclonal antibody
capable of binding to either CTLA-4 (if such second polypeptide chain contains VLPD-l) or to
PD-l (if such second polypeptide chain contains -4), a second intervening spacer
peptide (Linker 2) ally containing a cysteine residue, a Heterodimer-Promoting Domain,
and a C-terminus (Figure 1),
The VL Domain of the first polypeptide chain interacts with the VH Domain of
the second polypeptide chain to form a first functional antigen-binding site that is specific for
a first antigen (i.e., either PD-l or CTLA-4). se, the VL Domain of the second
polypeptide chain interacts with the VH Domain of the first polypeptide chain in order to form
a second functional n—binding site that is specific for a second antigen (i.e., either CTLA-
4 or PD-l). Thus, the selection of the VL and VH Domains of the first and second polypeptide
chains is coordinated, such that the two polypeptide chains ofthe diabody collectively comprise
VL and VH Domains capable ofbinding to both an epitope ofPD-l and to an epitope of CTLA-
4 (i.e., they collectively comprise VLPD.1/VHPD-1 and -4/VHCTLA-4).
Most preferably, the length of the intervening linker peptide (Linker 1, which
separates such VL and VH Domains) is selected to ntially or completely prevent the VL
and VH Domains ofthe polypeptide chain from binding to one r (for example consisting
of from O, l, 2, 3, 4, 5, 6, 7, 8 or 9 intervening linker amino acid residues). Thus the VL and
VH s ofthe first polypeptide chain are substantially or completely incapable of binding
to one another. Likewise, the VL and VH s of the second polypeptide chain are
substantially or completely incapable of binding to one r. A preferred intervening spacer
peptide (Linker 1) has the sequence (SEQ ID NO:5): GGGSGGGG.
The length and composition of the second intervening spacer peptide (Linker 2)
is selected based on the choice of one or more ptide domains that promote such
dimerization (i.e., a “Heterodimer-Promoting Domain”). Typically, the second intervening
spacer peptide (Linker 2) will comprise 3—20 amino acid es. In particular, where the
employed Heterodimer-Promoting Domain(s) do/does not comprise a cysteine e a
cysteine-containing second intervening spacer peptide (Linker 2) is ed. A cysteine-
containing second intervening spacer peptide (Linker 2) will contain 1, 2, 3 or more cysteines.
A preferred cysteine—containing spacer peptide (Linker 2) has the sequence is SEQ ID NO:6:
GGCGGG. Alternatively, Linker 2 does not comprise a cysteine (e.g., GGG, GGGS (SEQ ID
NO:7), LGGGSG (SEQ ID NO:8), GGGSGGGSGGG (SEQ ID NO:9), ASTKG (SEQ ID
NO:10), LEPKSS (SEQ ID NO:11), APSSS (SEQ ID NO:12), etc.) and a Cysteine-
Containing Heterodimer-Promoting , as described below is used. Optionally, both a
cysteine-containing Linker 2 and a cysteine-containing Heterodimer-Promoting Domain are
used.
The Heterodimer-Promoting Domains may be C (SEQ ID NO:13) or
VEPKSC (SEQ ID NO:14) or AEPKSC (SEQ ID NO:15) on one polypeptide chain and
GFNRGEC (SEQ ID NO:16) or FNRGEC (SEQ ID NO:17) on the other polypeptide chain
(USZOO7/OOO4909).
] In a preferred embodiment, the Heterodimer—Promoting Domains will comprise
tandemly repeated coil domains of opposing charge for example, “E-coil” l domains
(SEQ ID NO:18: EVAALEK—EVAALEK—EVAALEK—EVAALEK), whose glutamate residues
will form a negative charge at pH 7, and “K-coil” s (SEQ ID NO:19: EVAALEE—
EVAAT .541 —§VAAT .E'i—EVAALEE), whose lysine residues will form a positive charge at pH 7.
The presence of such charged domains promotes association between the first and second
polypeptides, and thus fosters heterodimer formation. Heterodimer-Promoting s that
se modifications of the above-described E-coil and K-coil sequences so as to include
one or more cysteine residues may be utilized. The presence of such cysteine residues permits
the coil present on one polypeptide chain to become covalently bonded to a complementary
coil present on another polypeptide chain, thereby covalently bonding the polypeptide chains
to one another and increasing the stability of the diabody. es of such particularly
preferred are Heterodimer—Promoting Domains include a Modified E-Coil having the amino
acid ce EVAAQEK—EVAALEK—§VAAL§K—§VAAL§K (SEQ ID NO:20), and a
modified K-coil having the amino acid sequence EVAAggE—EVAALEE—§VAAL§E—
EVAALEE (SEQ ID NO:21).
As disclosed in WO 2012/018687, in order to e the in vivo
pharmacokinetic properties of diabodies, a diabody may be modified to contain a polypeptide
portion of a serum—binding protein at one or more of the termini of the y. Most
preferably, such polypeptide portion of a serum-binding protein will be installed at the C-
us of the diabody. Albumin is the most nt protein in plasma and has a half-life
of 19 days in humans. Albumin possesses several small molecule binding sites that permit it
to non-covalently bind to other proteins and thereby extend their serum half-lives. The
Albumin-Binding Domain 3 (ABD3) of protein G of Streptococcus strain G148 consists of 46
amino acid residues forming a stable three-helix bundle and has broad albumin-binding
specificity sson, M.U. er al. (2002) “Structure, Specificity, AndMode OfInteraction For
Bacterial Albumin-BindingModules,” J. Biol. Chem. 277(10):8114-8120. Thus, a particularly
preferred polypeptide portion of a serum-binding protein for improving the in vivo
pharmacokinetic properties of a diabody is the Albumin-Binding Domain (ABD) from
streptococcal protein G, and more preferably, the Albumin-Binding Domain 3 (ABD3) of
protein G of Streptococcus strain G148 (SEQ ID NO:22): LAEAKVLANR ELDKYGVSDY
NAKS LIDE ILAALP.
As disclosed in WO 2012/162068 (herein incorporated by reference),
“deimmunized” variants of SEQ ID NO:22 have the ability to attenuate or eliminate MHC
class II binding. Based on ational mutation results, the following combinations of
substitutions are considered to be preferred substitutions for forming such a deimmunized
ABD: 66D/7OS +71A; 66S/7OS +71A; 66S/7OS +79A; 64A/65A/71A; 64A/65A/71A+66S;
64A/65A/71A+66D; 64A/65A/71A+66E; 64A/65A/79A+66S; 64A/65A/79A+66D,
64A/65A/79A+66E. Variant ABDs having the modifications L64A, I65A and D79A or the
modifications N668, T708 and D79A. Variant deimmunized ABD having the amino acid
sequence:
LAEAKVLANR ELDKYGVSDY YKNLIQ66NAK§70 éuEGVKALIDE ILAALP (SEQ
ID NO:23),
or the amino acid sequence:
LAEAKVLANR ELDKYGVSDY §65NNAKT VEGVKALI§79E ILAALP (SEQ
or the amino acid sequence:
LAEAKVLANR ELDKYGVSDY YKNLI§66NAK§70 VEGVKAL é79l12 TIAALB (SEQ
ID NO:25),
are particularly preferred as such deimmunized ABD exhibit substantially wild-type binding
while providing attenuated MHC class II binding. Thus, the first polypeptide chain of such a
diabody having an ABD contains a third linker r 3) ably positioned C—terminally
to the E-coil (or K-coil) Domain of such polypeptide chain so as to intervene between the E-
coil (or K-coil) Domain and the ABD (which is preferably a deimmunized ABD). A preferred
sequence for such Linker 3 is SEQ ID NO:7: GGGS.
C. PD-l x CTLA-4 ific Diabodies ning Fc Regions
One embodiment of the t invention relates to bispeciflc diabodies capable
of simultaneously g to PD-l and CTLA-4 that comprise an Fc Region. The addition of
an IgG CH2-CH3 Domain to one or both of the diabody polypeptide chains, such that the
complexing of the diabody chains results in the formation of an Fc Region, increases the
biological half-life and/or alters the valency of the diabody. Incorporating an IgG CH2-CH3
Domains onto both of the diabody polypeptides will permit a ain bispecific ion-
containing diabody to form (Figure 2).
Alternatively, incorporating an IgG 3 Domains onto only one of the
diabody polypeptides will permit a more x four-chain bispecific Fc Region-containing
diabody to form (Figures 3A-3C). Figure 3C shows a representative four-chain diabody
sing the Constant Light (CL) Domain and the Constant Heavy CH1 Domain, however
fragments of such domains as well as other polypeptides may alternatively be employed (see,
e.g., Figures 3A and 3B, United States Patent Publications No. 2013-0295121; 2010-0174053
and 2009-0060910; European Patent Publication No. EP 2714079; EP 2601216; EP 2376109;
EP 2158221 and PCT Publications No.
2010/080538). Thus, for example, in lieu of the CH1 Domain, one may employ a peptide
having the amino acid ce GVEPKSC (SEQ ID NO:13) VEPKSC (SEQ ID NO:14),
or AEPKSC (SEQ ID , derived from the Hinge Region of a human IgG, and in lieu of
the CL Domain, one may employ the C-terminal 6 amino acids ofthe human kappa light chain,
GFNRGEC (SEQ ID NO:16) or FNRGEC (SEQ ID NO:17). A representative peptide
containing four-chain diabody is shown in Figure 3A. Alternatively, or in addition, one may
employ a peptide sing tandem coil domains of opposing charge such as the “E-coil”
helical s (SEQ ID NO:18: EVAALEK—§VAAL§K—§VAAL§K—§VAAL§K or SEQ
ID NO:19: EK—EVAALEK—EVAALEK—EVAALEK); and the “K-coil” domains (SEQ
ID NO:20: EVAATET.—§VAAT.§E—§VAAL§?—§VAAT.§E or SEQ ID NO:21: EVAAggE—
EVAALEE—EVAALEE—EVAALEE). A representative coil domain-containing four-chain
diabody is shown in Figure 3B.
The ific Fc Region-containing molecules of the present invention may
include additional intervening spacer peptides rs), generally such Linkers will be
incorporated between a peptide Heterodimer-Promoting Domain (e.g., an E-coil or K-coil) and
CH2-CH3 Domains and/or between CH2-CH3 Domains and a Variable Domain (i.e., VH or
VL). Typically, the additional Linkers will comprise 3-20 amino acid residues. Linkers that
may be ed in the bispecific Fc Region-containing diabody molecules of the present
invention include: GGGS (SEQ ID NO:7), LGGGSG (SEQ ID NO:8), GGGSGGGSGGG (SEQ
ID NO:9), ASTKG (SEQ ID NO:10), DKTHTCPPCP (SEQ ID NO:26),
EPKSCDKTHTCPPCP (SEQ ID NO:27), LEPKSS (SEQ ID NO:11), APSSS (SEQ ID
NO:28), and APSSSPME (SEQ ID NO:29), LEPKSADKTHTCPPC SEQ ID NO:30), GGC,
and GGG. SEQ ID NO:11 may be used in lieu of GGG or GGC for ease of cloning. Additionally,
the amino acids GGG, or SEQ ID NO:11 may be immediately followed by SEQ ID NO:26 to
form the alternate linkers: GGGDKTHTCPPCP (SEQ ID NO:31); and LEPKSSDKTHTCPPCP
(SEQ ID NO:32). Bispecific Fc Region-containing molecules of the present invention may
incorporate an IgG Hinge Region in addition to or in place of a linker. Exemplary Hinge
Regions e: EPKSCDKTHTCPPCP (SEQ ID NO:33) from IgGl, ERKCCVECPPCP
(SEQ ID NO:34) from IgG2, ESKYGPPCPSCP (SEQ ID NO:35) from IgG4, and
ESKYGPPCPECP (SEQ ID NO:36) an IgG4 hinge variant comprising a stabilizing 8228P
tution (as numbered by the EU index as set forth in Kabat) to reduce strand exchange.
] As provided in Figure 3A-3C, bispecifrc Fc Region-containing diabodies of the
ion may comprise four different chains. The first and third polypeptide chains of such a
diabody contain three domains: (i) a VLl-containing Domain, (ii) a VH2-containing Domain,
(iii) Heterodimer-Promoting Domain and (iv) a Domain containing a CH2—CH3 sequence. The
second and fourth polypeptide chains contain: (i) a VL2—containing Domain, (ii) a VH1-
containing Domain and (iii) a dimer-Promoting Domain, where the dimer-
Promoting Domains promote the dimerization of the first/third ptide chains with the
second/fourth polypeptide chains. The VL and/or VH Domains of the third and fourth
polypeptide chains, and VL and/or VH Domains ofthe first and second polypeptide chains may
be the same or different so as to permit tetravalent binding that is either monospeciflc,
bispecifrc or tetraspecifrc. The notations “VL3” and “VH3” denote, tively, the Light
Chain le Domain and Variable Heavy Chain Domain that bind a “third” epitope of such
diabody. Similarly, the notations “VL4” and “VH4” denote, respectively, the Light Chain
Variable Domain and Variable Heavy Chain Domain that bind a “fourth” epitope of such
diabody. The general ure of the ptide chains of a representative four-chain
bispecifrc Fc Region-containing diabodies of invention is provided in Table 1:
\Hz-VLZ-VH l-HPD-COOH
\Hz-VL l -VH2-HPD—CH2-CH3-COOH
1fic. .
\Hz-VL l -VH2-HPD-CH2-CH3-COOH
NHz-VLZ-VHI-HPD-COOH
\Hz-VLZ-VHI-HPD-COOH
KHz-VL l -VH2—HPD—CH2-CH3-COOH
Tetraspecific. 7
\Hz-VL3-VH4-HPD-CH2-CH3-COOH
\Hz—VL4-VH3-HPD-COOH
HPD = Heterodimer—Promoting Domain
In a specific embodiment, ies of the present invention are bispecific,
tetravalent (i.e., possess four epitope—binding sites), Fc-containing diabodies that are composed
of four total polypeptide chains (Figures 3A-3C). The bispecific, tetravalent, Fc-containing
diabodies of the invention comprise two epitope-binding sites immunospecific for PD-l (which
may be capable of binding to the same epitope of PD-l or to different epitopes of PD-l), and
two epitope-binding sites immunospecific for CTLA-4 (which may be capable of binding to
the same epitope of CTLA-4 or to different es of CTLA-4).
In a further embodiment, the ific Fc Region—containing ies may
comprise three polypeptide chains. The first polypeptide of such a diabody ns three
domains: (i) a VLl—containing Domain, (ii) a VH2-containing Domain and (iii) a Domain
containing a CH2-CH3 sequence. The second polypeptide of such a y ns: (i) a
VL2-containing Domain, (ii) a VHl-containing Domain and (iii) a Domain that promotes
heterodimerization and covalent bonding with the diabody’s first polypeptide chain. The third
polypeptide of such a diabody comprises a CH2—CH3 sequence. Thus, the first and second
polypeptide chains of such a diabody associate together to form a VLl/VHl binding site that
is capable of binding to the first epitope (i.e., either PD-l or CTLA-4), as well as a 2
binding site that is e of binding to the second epitope (i.e., either CTLA-4 or PD-l). The
first and second ptides are bonded to one another through a disulfide bond involving
cysteine residues in their respective Third Domains. Notably, the first and third polypeptide
chains complex with one another to form an Fc Region that is stabilized via a disulfide bond.
Such bispecific diabodies have enhanced potency. Figures 4A and 4B illustrate the structures
of such diabodies, Such Fc-Region-containing bispecific diabodies may have either of two
orientations (Table 2):
Table 2
NH2-CH2-CH3—COOH
First
NHz-VL l -VH2-HPD-CH2—CH3-COOH
Orientation
NHz-VLZ—VHl-HPD-COOH
NHz-CHZ-CH3-COOH
Second
NHz-CHZ-CH3-VLl-VH2—HPD-COOH
Orientation
NH2-VL2-VH1-HPD-COOH
HPD = Heterodimer—Promoting Domain
In a specific embodiment, diabodies of the present invention are bispecific,
bivalent (i.e., possess two epitope-binding sites), Fc-containing diabodies that are composed of
three total polypeptide chains (Figures 4A-4B). The bispecific, bivalent Fc-containing
diabodies of the invention comprise one epitope-binding site immunospecific for PD-l, and
one epitope—binding site specific for CTLA-4.
In a further ment, the bispecific Fc Region-containing diabodies may
comprise a total of five polypeptide chains. In a particular embodiment, two of the five
ptide chains have the same amino acid sequence. The first polypeptide chain of such a
diabody contains: (i) a VH1-containing domain, (ii) a CHl-containing domain, and (iii) a
Domain containing a CH2—CH3 sequence. The first polypeptide chain may be the heavy chain
of an antibody that contains a VH1 and a heavy chain constant region. The second and fifth
polypeptide chains of such a y contain: (i) a VLl-containing domain, and (ii) a CL-
containing domain. The second and/or fifth polypeptide chains of such a y may be light
chains of an antibody that contains a VLl complementary to the VH1 of the first/third
polypeptide chain. The first, second and/or fifth polypeptide chains may be isolated from a
lly occurring antibody. atively, they may be constructed recombinantly. The third
polypeptide chain of such a y contains: (i) a VH1-containing domain, (ii) a CH1-
containing domain, (iii) a Domain containing a CH2-CH3 sequence, (iv) a ntaining
Domain, (v) a VH3-containing Domain and (vi) a Heterodimer-Promoting , where the
Heterodimer-Promoting Domains promote the dimerization of the third chain with the fourth
chain. The fourth ptide of such diabodies contains: (i) a VL3-containing Domain, (ii) a
VH2-containing Domain and (iii) a Domain that es heterodimerization and covalent
bonding with the diabody’s third polypeptide chain.
Thus, the first and second, and the third and fifth, polypeptide chains of such
diabodies associate together to form two VLl/VHl binding sites e of binding a first
epitope. The third and fourth polypeptide chains of such diabodies associate together to form
a VL2/VH2 binding site that is capable of binding to a second epitope, as well as a VL3/VH3
binding site that is e of binding to a third e. The first and third polypeptides are
bonded to one another through a disulfide bond involving cysteine residues in their tive
constant regions. Notably, the first and third polypeptide chains complex with one another to
form an Fc Region. Such bispecific diabodies have enhanced potency. Figure 5 illustrates the
structure of such diabodies. It will be understood that the VLl/VHl, VLZ/VHZ, and VL3/VH3
Domains may be the same or different so as to permit binding that is monospecific, bispecific
or trispecific. However, as provided , these domains are preferably selected so as to bind
PD-l and CTLA-4.
The VL and VH Domains of the ptide chains are selected so as to form
VL/VH binding sites specific for a desired epitope. The VL/VH binding sites formed by the
association of the polypeptide chains may be the same or different so as to permit tetravalent
binding that is monospecific, bispecific, trispecific or tetraspecific. In particular, the VL and
VH Domains may be ed such that a bispecific diabody may comprise two binding sites
for a first epitope and two binding sites for a second epitope, or three binding sites for a first
epitope and one binding site for a second epitope, or two g sites for a first epitope, one
binding site for a second epitope and one g site for a third epitope (as depicted in Figure
). The general structure of the polypeptide chains of representative five-chain Fc Region-
containing diabodies of invention is provided in Table 3:
Table 3
l\H2-VL1-CL COOH
1\’H2 VHl-CHI CH2 CH3 COOH
BiSPecific (2x2) kHz-VH1-CH1-CH2-CH3-VL2-VH2-HPD-COOH
NHz-VLl—CL-COOH
NH2-VL2-VH2-HPD-COOH
I\;H2 VL1 CL COOH
NHz-VLZ-VHl-HPD—COOH
NH2-VL3-VH2-HPD—COOH
HPD = Heterodimer—Promoting Domain
In a c embodiment, diabodies of the present invention are bispecific,
tetravalent (i.e., possess four epitope-binding sites), Fc-containing diabodies that are ed
of five total polypeptide chains having two e-binding sites immunospecific for PD-l
(which may be capable of binding to the same epitope of PD-l or to different epitopes of PD-
1), and two epitope-binding sites specific for CTLA—4 (which may be capable of binding to the
same epitope of CTLA-4 or to ent epitopes of CTLA-4). In another embodiment, the
ific, tetravalent, Fc-containing diabodies of the invention comprise three e-binding
sites immunospecific for PD-l (which may be capable of binding to the same epitope of PD-l
or to two or three different epitopes of PD—l), and one epitope-binding site specific for CTLA-
4. In another embodiment, the bispecific, tetravalent, Fc-containing diabodies of the invention
comprise one epitope-binding sites immunospecific for PD-l, and three epitope-binding sites
specific for CTLA-4 (which may be capable of binding to the same epitope of CTLA-4 or to
two or three different es of CTLA-4).
D. PD-l x CTLA-4 Bispecific Trivalent g Molecules Containing Fc
] A further embodiment of the present invention relates to bispecific trivalent
binding molecules comprising an Fc Region capable of simultaneously binding to an epitope
of PD-l and an epitope present on CTLA-4. Such bispecific trivalent binding molecules
comprise three epitope-binding sites, two ofwhich are Diabody-Type Binding Domains, which
provide binding Site A and binding Site B, and one of which is a Fab-Type Binding Domain
(or an scFv-Type Binding Domain), which es binding Site C (see, e.g., Figures 6A-6F,
and PCT Application No: PCT/USIS/33081, and PCT/US 1 5/33076). Such bispeciflc trivalent
molecules thus comprise “VLl” / “VH1” domains that are capable of binding to the first
epitope and “VL2” / “VH2” domains that are capable of binding to the second epitope and
“VL3” and “VH3” domains that are capable of binding to the “third” epitope of such trivalent
molecule. A “Diabody-Type Binding Domain” is the type of epitope-binding site present in a
diabody, and especially, a DART® y, as described above. Each of a ype Binding
Domain” and an “scFv-Type Binding Domain” are e—binding sites that are formed by the
interaction of the VL Domain of an immunoglobulin light chain and a menting VH
Domain of an globulin heavy chain. Fab-Type Binding Domains differ from Diabody-
Type g Domains in that the two polypeptide chains that form a Fab-Type Binding
Domain comprise only a single epitope-binding site, whereas the two polypeptide chains that
form a y-Type Binding Domain comprise at least two epitope-binding sites. rly,
scFv-Type Binding s also differ from Diabody-Type Binding Domains in that they
comprise only a single epitope-binding site. Thus, as used herein Fab-Type, and scFv-Type
Binding Domains are distinct from Diabody-Type Binding Domains.
Typically, the trivalent binding molecules of the present invention will se
four different polypeptide chains (see s 6A-6B), however, the molecules may comprise
fewer or greater numbers ofpolypeptide chains, for example by fusing such polypeptide chains
to one another (e.g, via a peptide bond) or by dividing such ptide chains to form
additional polypeptide chains, or by associating fewer or additional polypeptide chains via
disulfide bonds. Figures 6C-6F illustrate this aspect of the present invention by schematically
depicting such molecules having three polypeptide chains. As ed in Figures 6A-6F, the
ent binding molecules of the present invention may have alternative orientations in which
the Diabody—Type Binding Domains are N—terminal (Figures 6A, 6C and 6D) or C-terminal
(Figures 6B, 6E and 6F) to an Fc Region.
In certain embodiments, the first polypeptide chain of such trivalent binding
molecules of the present invention contains: (i) a VLl-containing Domain, (ii) a VH2-
containing Domain, (iii) a Heterodimer-Promoting Domain, and (iv) a Domain containing a
CH2-CH3 sequence. The VLl and VL2 Domains are located N—terminal or C-terminal to the
CH2—CH3-containing domain as presented in Table 4 (also see, Figures 6A and 6B). The
second polypeptide chain of such embodiments contains: (i) a VL2-containing Domain, (ii) a
VHl—containing Domain, and (iii) a Heterodimer-Promoting Domain. The third polypeptide
chain of such embodiments contains: (i) a VH3-containing Domain, (ii) a CH1-containing
Domain and (iii) a Domain containing a CH2-CH3 sequence. The third polypeptide chain may
be the heavy chain of an antibody that contains a VH3 and a heavy chain constant region, or a
polypeptide that contains such s. The fourth polypeptide of such embodiments
contains: (i) a VL3-containing Domain and (ii) a taining Domain. The fourth
polypeptide chains may be a light chain of an antibody that contains a VL3 complementary to
the VH3 of the third polypeptide chain, or a polypeptide that contains such domains. The third
or fourth polypeptide chains may be isolated from naturally occurring antibodies.
Alternatively, they may be ucted recombinantly, synthetically or by other means.
The Light Chain Variable Domain of the first and second polypeptide chains
are separated from the Heavy Chain Variable Domains of such polypeptide chains by an
intervening spacer peptide having a length that is too short to permit their VL1/VH2 (or their
VL2/VH1) domains to associate together to form epitope-binding site capable of binding to
either the first or second e. A preferred intervening spacer peptide (Linker 1) for this
purpose has the sequence (SEQ ID NO:5): GGGSGGGG. Other Domains of the trivalent
g molecules may be separated by one or more intervening spacer es (Linkers),
optionally comprising a cysteine e. In particular, as provided above, such Linkers will
typically be incorporated between Variable Domains (i.e., VH or VL) and peptide
Heterodimer-Promoting Domains (e.g., an E-coil or K-coil) and between such e
Heterodimer-Promoting Domains (e.g., an E-coil or K-coil) and CH2-CH3 Domains.
ary linkers useful for the tion of ent binding molecules are provided above
and are also provided in PCT Application Nos: PCT/US15/33081; and PCT/US15/33076.
Thus, the first and second polypeptide chains of such trivalent binding molecules associate
together to form a VL1/VH1 binding site capable of binding a first epitope, as well as a
2 binding site that is capable of g to a second epitope. The third and fourth
polypeptide chains of such trivalent binding molecules associate together to form a VL3/VH3
binding site that is capable of binding to a third epitope.
As described above, the trivalent binding molecules of the present invention
may comprise three polypeptides. ent g molecules comprising three polypeptide
chains may be obtained by linking the domains of the fourth polypeptide N-terminal to the
ntaining Domain of the third polypeptide (e.g., using an intervening spacer peptide
(Linker 4)). Alternatively, a third polypeptide chain of a trivalent binding molecule of the
invention
containing the following s is utilized: (i) a ntaining Domain, (ii) a VH3-
containing Domain, and (iii) a Domain containing a 3 sequence, wherein the VL3 and
VH3 are spaced apart from one another by an intervening spacer peptide that is sufficiently
long (at least 9 or more amino acid residues) so as to allow the association of these domains to
form an epitope-binding site. One preferred intervening spacer peptide for this purpose has the
ce: GGGGSGGGGSGGGGS (SEQ ID NO:37).
It will be understood that the VLl/VHl, VL2/VH2, and VL3/VH3 Domains of
such trivalent binding molecules may be different so as to permit binding that is bispeciflc or
trispecific. However, as ed herein, these domains are selected so as to provide a trivalent
binding molecule capable of binding PD-l and .
In particular, the VL and VH Domains may be selected such that a trivalent
binding molecule comprises two binding sites for PD-l (which may be capable of binding to
the same epitope of PD-l or to different epitopes of PD-l) and one binding sites for a CTLA-
4, or one g site for PD-l and two binding sites for CTLA-4 (which may be capable of
binding to the same epitope of CTLA-4 or to different epitopes of ), or one binding
site for PD-l, one binding site for CTLA-4 and one binding site for a third antigen that is not
PD-l or CTLA-4. The general structure of the polypeptide chains of representative trivalent
binding molecules of invention is provided in Figures 6A-6F and in Table 4:
21101 Chain NHz-VLZ-VHl-HPD-COOH
Four Chain
1st Chain l\‘H2-VL1-VH2-HPD-CH2-CH3-COOH
Orientation 3r01 Chain NH2-VH3-CH1-CH2-CH3-COOH
2ncl Chain NHz-VL3-CL-COOH
211d Chain 2-VHl-HPD-COOH
Four Chain
1st Chain NHz-CHZ-CH3-VL1-VH2-HPD-COOH
Orientation 3rcl Chain NHz—VH3-CH1-CH2-CH3-COOH
2““1 Chain 3-CL—COOH
th-VLZ-VHl-HPD-COOH
Three Chain
lst NHz-VLI-VH2-HPD-CH2-CH3-COOH
onematlon
NHz-VL3-VH3-HPD-CH2-CH3-COOH
2nd h ’ NHZ VL— 2-VH l-I‘IPD-COOH
Three Chain
2nd NH2-CH2-CH3-VL1-VH2-HPD-COOH
O'“en a 1°“tt.
3-VH3-HPD-CH2-CH3-COOH
HPD = Heterodimer—Promoting Domain
One embodiment of the present invention relates to bispecific trivalent g
molecules that se two e-binding sites for PD-l and one epitope-binding site for
CTLA-4.
The two epitope-binding sites for PD-l may bind the same epitope or different
epitopes. Another embodiment of the present invention relates to bispecific trivalent g
molecules that comprise, one epitope-binding site for PD-l and two epitope-binding sites for
CTLA-4. The two epitope-binding sites for CTLA-4 may bind the same epitope or different
epitopes of CTLA-4. As provided above, such bispecific trivalent binding molecules may
comprise three, four, five, or more polypeptide chains.
V. nt Domains and Fe Regions
Provided herein are antibody Constant Domains useful in the generation of the
PD-l X CTLA-4 bispecific molecules (e.g, antibodies, diabodies, trivalent binding les,
etc.) of the invention.
A preferred CL Domain is a human IgG CL Kappa Domain. The amino acid
sequence of an exemplary human CL Kappa Domain is (SEQ ID NO:38):
RTVAAPSVFI FPPSDEQLKS GTASVVCLLN NFYPREAKVQ WKVDNALQSG
NSQfiSVTfiQD SKDSTYSLSS TLTLSKADYE CEVT HQGLSSPVTK
SFNQGEC
Alternatively, an ary CL Domain is a human IgG CL Lambda Domain.
The amino acid sequence of an exemplary human CL Lambda Domain is (SEQ ID NO:39):
SVTL FPPSSEELQA NKATLVCLIS DFYPGAVTVA WKADSSPVKA
GVETTPSKQS NNKYAASSYL SLTPEQWKSH QSYSCQVTHE GSTVEKTVAP
As provided herein, the PD-l X CTLA-4 bispecific molecules of the invention
may comprise an Fc Region. The PC Region of such molecules of the invention may be of any
isotype (e.g., IgG], IgG2, IgG3, or IgG4). The PD-l X CTLA-4 bispecific molecules of the
invention may further comprise a CH1 Domain and/or a Hinge Region. When present, the
CH1 Domain and/or Hinge Region may be of any isotype (e.g., IgGl, IgG2, IgG3, or IgG4),
and is preferably of the same isotype as the desired Fc Region.
] An exemplary CH1 Domain is a human IgG1 CH Domain. The amino acid
sequence of an ary human IgG1 CH1 Domain is (SEQ ID NO:40):
ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV
HTFPAVLQSS GLYSLSSVVT GTQT YICNVNHKPS NTKVDKRV
An exemplary CH1 Domain is a human IgG2 CH Domain. The amino acid
sequence of an exemplary human IgG2 CH1 Domain is (SEQ ID :
ASTKGPSVFP LAPCSRSTSE STAALGCLVK DYFPEPVTVS TSGV
LQSS GLYSLSSVVT VPSSNFGTQT YTCNVDHKPS NTKVDKTV
An exemplary CH1 Domain is a human IgG4 CH1 Domain. The amino acid
sequence of an exemplary human IgG4 CH1 Domain is (SEQ ID NO:42):
ASTKGPSVFP LAPCSRSTSE STAALGCLVK DYFPE?VTVS TSGV
HTFPAVLQSS GLYSLSSVVT VPSSSLGTKT YTCNVDHKPS NTKVDKRV
One exemplary Hinge Region is a human IgG1 Hinge Region. The amino acid
sequence of an exemplary human IgG1 Hinge Region is (SEQ ID NO:33):
EPKSCDKTHTCPPCP.
Another exemplary Hinge Region is a human IgG2 Hinge Region. The amino acid
sequence of an exemplary human IgG2 Hinge Region is (SEQ ID NO:34): ERKCCVECPPCP .
Another exemplary Hinge Region is a human IgG4 Hinge Region. The amino
acid sequence of an exemplary human IgG4 Hinge Region is (SEQ ID NO:35):
ESKYGPPCPSCP. As described herein, an IgG4 Hinge Region may comprise a stabilizing
on such as the $228P substitution. The amino acid sequence of an exemplary stabilized
IgG4 Hinge Region is (SEQ ID NO:36): ESKYGPPCPPCP .
The Fc Region ofthe Fc Region-containing molecules (e.g., antibodies, diabodies,
ent molecules, etc.) of the present invention may be either a complete Fc Region (e.g., a
te IgG Fc Region) or only a fragment of an Fc Region. Optionally, the Fc Region of
the Fc Region-containing molecules of the present ion lacks the C-terminal lysine amino
acid residue.
In traditional immune function, the interaction of antibody-antigen complexes
with cells of the immune system results in a wide array of responses, ranging from effector
functions such as antibody dependent cytotoxicity, mast cell degranulation, and phagocytosis
to immunomodulatory signals such as ting lymphocyte proliferation and dy
secretion. All of these interactions are ted through the binding of the Fc Region of
antibodies or immune complexes to specialized cell surface receptors on hematopoietic cells.
The diversity of cellular responses triggered by antibodies and immune complexes results from
the structural geneity of the three Fc receptors: FcyRI (CD64), FcyRII (CD32), and
FcyRIII (CD16). FcyRI (CD64), A (CD32A) and FcyRIII (CD16) are activating (i.e.,
immune system enhancing) receptors, FcyRIIB (CD32B) is an inhibiting (i.e., immune system
dampening) or. In addition, interaction with the neonatal Fc Receptor (FcRn) mediates
the recycling ofIgG molecules from the endosome to the cell surface and release into the blood.
The amino acid sequence of exemplary wild-type IgGl (SEQ ID NO:1), IgG2 (SEQ ID
NO:2), IgG3 (SEQ ID NO:3), and IgG4 (SEQ ID NO:4) are presented above.
Modification of the Fc Region may lead to an d phenotype, for example
altered serum half—life, d ity, altered tibility to cellular enzymes or altered
effector function. It may therefore be desirable to modify an Fc Region—containing PD—l X
CTLA-4 bispecific molecule of the t invention with respect to or function, for
e, so as to enhance the effectiveness of such molecule in ng cancer. Reduction or
elimination of effector function is desirable in certain cases, for example in the case of
antibodies whose mechanism of action involves blocking or antagonism, but not killing of the
cells bearing a target antigen. Increased effector function is generally desirable when directed
to undesirable cells, such as tumor and foreign cells, where the FcyRs are expressed at low
levels, for example, tumor—specific B cells with low levels of FcyRIIB (e.g., non—Hodgkin’s
lymphoma, CLL, and Burkitt’s lymphoma). Molecules of the invention possessing such
conferred or altered effector on activity are useful for the treatment and/or prevention of
a disease, disorder or infection in which an enhanced efficacy of effector function activity is
desired.
Accordingly, in certain embodiments, the Fc Region of the Fc Region-containing
les of the present invention may be an engineered variant Fc Region. Although the Fc
Region of the bispecific Fc Region-containing molecules of the t invention may possess
the ability to bind to one or more Fc receptors (e.g, FcyR(s)), more preferably such variant PC
Region have altered binding to chRIA (CD64), chRIIA (CD32A), FcvRIIB (CD32B),
FcyRIIIA (CD16a) or IB (CD16b) ive to the g exhibited by a wild-type Fc
Region), e.g., will have enhanced binding to an activating receptor and/or will have
substantially reduced or no ability to bind to inhibitory receptor(s). Thus, the Fc Region of the
Fc Region-containing molecules of the present invention may include some or all of the CH2
Domain and/or some or all of the CH3 Domain of a complete Fc Region, or may comprise a
variant CH2 and/or a variant CH3 ce (that may include, for example, one or more
insertions and/or one or more deletions with respect to the CH2 or CH3 domains of a complete
Fc Region). Such Fc Regions may comprise non—Fc polypeptide portions, or may se
portions of non-naturally te Fc Regions, or may comprise non-naturally occurring
orientations of CH2 and/or CH3 Domains (such as, for example, two CH2 domains or two CH3
domains, or in the N—terminal to C-terminal direction, a CH3 Domain linked to a CH2 Domain,
etc.).
Fc Region modifications identified as ng effector function are known in the
art, including modifications that increase binding to activating ors (e.g., FcyRIIA
(CD16A) and reduce binding to inhibitory receptors (e.g., FcyRIIB (CD32B) (see, e.g.,
Stavenhagen, J.B. et al. (2007) “Fc Optimization 0f Therapeutic Antibodies Enhances Their
Ability To Kill Tumor Cells In Vitro Ana’ Controls Tumor Expansion In Vivo Via Low-Afinity
Activating chamma Receptors,” Cancer Res. 57(18):8882-8890). Table 5 lists exemplary
single, , triple, quadruple and quintuple substitutions (relative to the amino acid
sequence of SEQ ID NO:1) of exemplary modification that increase binding to activating
ors and/or reduce binding to tory receptors.
Table 5
F243L and R292P
mm and P396L
R292P and P396L
mm and P396L ———
Table 5
Variations of Preferred Activatin- Fc Re'ions
mm,mm andmm
F243L, R292P and WM
F243L, R292P and V3051
F243L, R292P and P396L
F243L, mm and P396L
V284M R292L and K370N
L234F, F243L, R292P and Y300L
L234F, F243L, R292P and Y300L
L23 51, F243L, R292P and Y300L
L23 5Q, F243L, R292P and WM
P247L, D270E, Y300L and N421K
R255L, D270E, R2926 and P396L
R255L, D270E, Y300L and P396L
D270E, G316D, P396L and R416G —
L235V, F243L, R292P, Y300L and P396L F243L, R292P, V3051, Y300L and P396L
L235P, F243L, R292P, WM and P396L—
Exemplary variants of human IgG1 Fc Regions with reduced binding to CD32B
and/or sed binding to CD16A contain F243L, R292P, Y300L, V3051 or P296L
tutions. These amino acid substitutions may be present in a human IgG1 Fc Region in
any combination. In one embodiment, the human IgG1 Fc Region variant ns a F243L,
R292P and Y300L substitution. In another embodiment, the human IgG1 Fc Region variant
contains a F243L, R292P, Y300L, V3051 and P296L tution.
] In certain embodiments, it is preferred for the Fc Regions of PD-l X CTLA-4
bispeciflc molecules of the present invention to exhibit decreased (or substantially no) binding
to FcyRIA (CD64), FcyRIIA (CD32A), FcyRIIB (CD32B), IA (CD16a) or FcyRIIIB
(CD16b) (relative to the binding exhibited by the wild-type IgGl Fc Region (SEQ ID NO:1).
In a specific embodiment, the PD—l X CTLA-4 iflc molecules of the present invention
comprise an IgG Fc Region that exhibits reduced ADCC effector function. In a preferred
embodiment the CH2-CH3 Domains of such PD-l X CTLA-4 bispeciflc molecules include any
1, 2, 3, or 4 of the substitutions: L234A, L235A, D265A, N297Q, and N297G. In another
embodiment, the 3 Domains contain an N297Q substitution, an N297G substitution,
L234A and L235A substitutions or a D265A substitution, as these mutations abolish FcR
binding. Alternatively, a CH2-CH3 Domain of a naturally occurring Fc region that inherently
ts decreased (or substantially no) binding to FcyRIIIA (CD16a) and/or reduced effector
function ive to the binding and or function exhibited by the wild-type IgGl Fc
Region (SEQ ID NO:1)) is utilized. In a specific embodiment, the PD-l X CTLA—4 bispecific
molecules of the present invention se an IgG2 Fc Region (SEQ ID NO:2) or an IgG4
Fc Region (SEQ ID:NO:4). When an IgG4 Fc Region is utilized, the instant invention also
encompasses the introduction of a stabilizing mutation, such as the Hinge Region $228P
substitution described above (see, e.g., SEQ ID NO:36). Since the N297G, N297Q, L234A,
L235A and D265A substitutions abolish effector function, in circumstances in which effector
function is desired, these substitutions would preferably not be employed.
A preferred IgGl sequence for the CH2 and CH3 Domains of the Fc Region-
containing molecules of the present invention having reduced or abolished effector function
will comprise the substitutions L235A (SEQ ID NO:43):
APEA_AGGPSV FLFPPKPKUT TM SRTBHV'I' CVVV)VSHH) NWYV.)
GVEVHNA<TK PRfifiQYNSTY VLH QDWLWGKEYK CKVSNKALPA
PIEKTISKAK GQBRiPQVYT LPPSREEMTK CLVK IAVE
WESNGQPENN YKTT?PVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE
AL-INHYTQKS LSLSPG§
wherein, X is a lysine (K) or is absent.
The serum half—life of proteins comprising Fc Regions may be increased by
increasing the binding affinity of the Fc Region for FcRn. The term “half-life” as used herein
means a pharmacokinetic property of a le that is a measure of the mean survival time
ofthe molecules following their administration. Half-life can be expressed as the time required
to eliminate fifty percent (50%) of a known quantity of the molecule from the subject’s body
(e.g., human patient or other ) or a specific compartment f, for example, as
ed in serum, i.e., circulating half-life, or in other tissues. In general, an increase in half-
life results in an increase in mean residence time (MRT) in circulation for the molecule
stered.
In some embodiments, the PD-l X CTLA-4 bispecific molecules of the present
invention comprise a variant Fc Region, wherein the variant Fc Region comprises at least one
amino acid modification relative to a wild-type Fc Region, such that the le has an
increased half-life (relative to a molecule comprising a wild-type Fc Region). In some
embodiments, the PD-l X CTLA-4 bispecific molecules of the present ion comprise a
variant IgG Fc Region, wherein the variant Fc Region comprises a half-live extending amino
acid substitution at one or more positions selected from the group consisting of 238, 250, 252,
254,256,257, 256,265, 272, 8, 303, 305, 307, 308,309, 311, 312, 317, 340, 356, 360,
362, 376, 378, 380, 382, 413, 424, 428, 433, 434, 435, and 436. Numerous mutations capable
of increasing the half-life of an Fc Region-containing molecule are known in the art and
include, for e M252Y, S254T, T256E, and combinations thereof. For example, see the
mutations bed in US. Patents No. 6,277,375, 7,083,784, 7,217,797, 8,088,376, US.
Publication Nos. 2002/0147311; 2007/0148164; and International Publication Nos. WO
98/23289,
reference in their ties. PD-l X CTLA-4 bispeciflc molecules with enhanced half-life also
include those possessing t Fc Regions comprising tutions at two or more of PC
Region residues 250, 252, 254, 256, 257, 288, 307, 308, 309, 311, 378, 428, 433, 434, 435 and
436. In particular, two or more substitutions selected from: T250Q, M252Y, S254T, T256E,
K288D, T307Q, V308P, A378V, M428L, N434A, H435K, and Y436I.
In a specific embodiment, a PD-l X CTLA—4 bispeciflc molecule possesses a
t IgG Fc Region comprising substitutions of:
(A) M252Y, $254T and T256E,
(B) M252Y and S254T,
(C) M252Y and T256E,
(D) T250Q and M428L,
(E) T307Q and N434A,
(F) A378v and N434A,
(G) N434A and Y43 61,
(H) V308P and N434A, or
(I) K288D and H43 5K.
In a preferred embodiment PD-l X CTLA-4 bispecific molecules possess a variant
IgG Fc Region comprising any 1, 2, or 3 of the substitutions: M252Y, S254T and T256E. The
invention further encompasses PD-l X CTLA-4 bispecific molecules possessing variant Fc
Regions comprising:
(A) one or more mutations which alter effector function and/or chR, and
(B) one or more mutations which extend serum half-life.
A preferred IgGl sequence for the CH2 and CH3 Domains of the Fc Region-
containing les of the present ion having increased serum ife will comprise
the substitutions M252Y, $254T and T256E (SEQ ID NO:80):
ABEA_AGGJ:’SV b'Lh'PBKk’KJT LY__TREPJL'V'1' cvvv )VSHH ) BHVKENWYV.)
GVEVHNA<TK PRfifiQYNSTY QVVSVLTVLH QDWLWGKEYK CKVSNKALPA
PIEKTISKAK GQBRiPQVYT LPPSREEMTK NQVSLTCLVK GFYPSDIAVE
WESNGQPENN YKTT?PVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE
ALHNHYTQKS LSLSPG§
wherein, X is a lysine (K) or is absent.
As will be noted, the CH2-CH3 Domains of SEQ ID NO:80 includes
substitutions at positions 234 and 235 with alanine, and thus form an Fc Region exhibit
decreased (or substantially no) binding to FcyRIA (CD64), A (CD32A), FcyRIIB
(CD32B), FcyRIIIA (CDl6a) or FcyRIIIB (CDl6b) ive to the binding exhibited by the
wild-type Fc Region (SEQ ID NO:1). The invention also encompasses such IgGl CH2—CH3
Domains, which comprise the ype alanine residues, alternative and/or additional
substitutions which modify or function and/or FyR binding activity of the Fc region.
A preferred IgG4 sequence for the CH2 and CH3 Domains of the Fc Region-
ning molecules of the present invention having increased serum half—life will comprise
the tutions M252Y, $254T and T256E (SEQ ID NO:81):
APEFLGGPSV FLF?PKPKDT LYITREPEVT CVVVDVSQED PZVQFNWYVDJ.
GVEViNA<TK PQfifiQFNSTY QVVSVLTVLH QDWLNGKEYK C(VSNKGLPS
SIEKTISKAK GQPREPQVYT LPPSQEEMTK NQVSLTCLVK GFYPSDIAVE
WESNGQPENN Y<TTPPVLDS DGSFFLYSRL TVDKSRWQEG VMHE
ALHNHYTQKS LSLSLG§
wherein, X is a lysine (K) or is absent.
For certain antibodies, diabodies and trivalent binding molecules whose Fc
Region-containing first and third polypeptide chains are not identical, it is desirable to reduce
or t homodimerization from occurring between the CH2-CH3 Domains of two first
polypeptide chains or between the CH2-CH3 Domains of two third polypeptide chains. The
CH2 and/or CH3 Domains of such polypeptide chains need not be identical in sequence, and
advantageously are modified to foster complexing between the two polypeptide chains. For
example, an amino acid substitution (preferably a substitution with an amino acid comprising
a bulky side group g a “knob”, e.g., tryptophan) can be introduced into the CH2 or CH3
Domain such that steric interference will t interaction with a similarly mutated domain
and will obligate the mutated domain to pair with a domain into which a complementary, or
accommodating mutation has been engineered, i. e., “the hole” (e. g., a substitution with
e). Such sets of ons can be engineered into any pair of polypeptides comprising
3 Domains that forms an Fc Region to foster heterodimerization. Methods of protein
engineering to favor heterodimerization over homodimerization are well known in the art, in
particular with respect to the ering of immunoglobulin-like molecules, and are
encompassed herein (see e.g., y et al. (1996) “‘Knobs—Into-Holes’ Engineering Of
Antibody CH3 Domains For Heavy Chain Heterodimerization, ” Protein Engr. 9:617-621,
Atwell et al. (1997) ”Stable Heterodimers From Remodeling Yhe Domain ace Of A
Homodimer Using/1 Phage Display Library, ” J. Mol. Biol. 270: 26—3 5, and Xie et al. (2005)
“A New Format OfBispecijic Antibody: Highly Eflicient Heterodimerization, Expression And
Tumor Cell Lysis, ” J. Immunol. Methods 296:95-101, each of which is hereby incorporated
herein by nce in its ty),
A preferred knob is created by modifying an IgG Fc Region to contain the
modification T366W. A preferred hole is d by modifying an IgG Fc Region to contain
the modification T366S, L368A and Y407V. To aid in purifying the hole-bearing third
polypeptide chain homodimer from the final bispecific heterodimeric Fc Region-containing
molecule, the protein A binding site of the hole-bearing CH2 and CH3 Domains of the third
polypeptide chain is preferably mutated by amino acid substitution at position 435 (H435R).
Thus, the hole-bearing third ptide chain homodimer will not bind to protein A, whereas
the bispecific heterodimer will retain its ability to bind protein A via the protein A binding site
on the first polypeptide chain. In an alternative embodiment, the hole-bearing third polypeptide
chain may incorporate amino acid substitutions at positions 434 and 435 (N434A/N43 5K).
A preferred IgGl amino acid sequence for the CH2 and CH3 Domains of the first
ptide chain of an Fc Region-containing molecule of the present invention will have the
“knob-bearing” sequence (SEQ ID NO:44):
APEééGGPSV FLFP?KPKDT EM SRTPfiVT CVVVDVSiED PEVKFWWYVD
GVEVHNAXTK PREEQYNSTY RVVSVLTVLH KEYK CKVSN<ALPA
PIEKTISKAK GQPREPQVYT LPPSREEWTK NQVSTKCWVK GTYPSDIAVE
WLSNGQBLNN VLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE
ALHNHYTQKS LSLS?G§
wherein X is a lysine (K) or is .
A preferred IgGl amino acid sequence for the CH2 and CH3 Domains of the
second polypeptide chain of an Fc Region-containing molecule of the present invention having
two polypeptide chains (or the third polypeptide chain of an Fc Region-containing le
having three, four, or five polypeptide chains) will have the “hole-bearing” sequence (SEQ
AEEééGGPSV ELHPPKEKJT LMHSRTPEVT CVVV)VSHH) BHVKENWYVJ
GVEVHNA<TK PRfifiQYNSTY QVVSVLTVLH QDWLWGKEYK ALPA
PIEKTISKAK GQBRiPQVYT LPPSREEMTK NQVSL§C§VK IAVE
WESNGQPENN YKTT?PVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE
ALHNBYTQKS LSLSPG§
wherein X is a lysine (K) or is absent.
As will be noted, the CH2-CH3 Domains of SEQ ID NO:44, and SEQ ID NO:45
include substitutions at positions 234 and 235 with alanine, and thus form an Fc Region exhibit
decreased (or substantially no) binding to FcyRIA (CD64), A (CD32A), FcyRIIB
(CD32B), FcyRIIIA (CDl6a) or FcyRIIIB (CDl6b) (relative to the binding ted by the
wild-type Fc Region (SEQ ID NO:1). The invention also encompasses such IgGl CH2—CH3
s, which se the wild-type alanine residues, alternative and/or additional
substitutions which modify effector function and/or FyR binding activity of the Fc region. The
invention also encompasses such CH2-CH3 Domains, which further comprise one or more
half—live extending amino acid substitutions. In particular, as provided above, the invention
encompasses such hole-bearing and such knob-bearing CH2-CH3 Domains which further
comprise the M252Y/S254T/T256E.
A red IgGl amino acid ce, for the CH2 and CH3 Domains further
comprising M252Y/S254T/T256E, of the first polypeptide chain of an Fc -containing
le of the present invention will have the “knob-bearing” sequence (SEQ ID NO:82):
APEééGGPSV FLFP?KPKDT LI IREPfiVT CVVVDVSiED PEVKFWWYVD
GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNXALPA
PIEKTISKAK GQPREPQVYT TPPSREEWTK NQVSVECTVK GTYPSDIAVE
WESNGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE
ALHNHYTQKS §
wherein X is a lysine (K) or is absent.
A preferred IgGl amino acid sequence, for the CH2 and CH3 Domains further
comprising M252Y/S254T/T256E, of the second polypeptide chain of an Fc Region-
containing le of the present invention having two polypeptide chains (or the third
polypeptide chain of an Fc Region-containing molecule having three, four, or five polypeptide
chains) will have the “hole-bearing” sequence (SEQ ID NO:83):
APEééGGPSV FLFP?KPKDT PX TREPfiVT CVVVDVSIED PEVKFWWYVD
GVEVHNAKTK PREEQYNSTY RVVSVLTVLH KEYK ALPA
PIEKTISKAK GQPQEPQVYT WPPSRFHWTK NQVSL§C§VK GFYPSD"AV?
WESNGQPENN YKTTPPVLDS DGSFFLZSKL TVDKSRWQQG NVFSCSVMHE
ALHNEYTQKS LSLS?G§
wherein X is a lysine (K) or is absent.
] A preferred IgG4 amino acid sequence for the CH2 and CH3 Domains,
comprising M252Y/SZS4T/T256E, of the first polypeptide chain of an F0 Region-containing
molecule of the present invention will have the “knob-bearing” sequence (SEQ ID NO:84):
APEFLGGPSV FL??PKPKDT LYITREPEVT CVVVDVSQED PEVQFVWYVD
GVEViNA<TK BQfifiQFNSTY QVVSVLTVLH QDWLNGKEYK CKVSN<GLPS
SIEKTISKAK GQPREPQVYT LPPSQEEMTK NQVSLECLVK GHYPS) AVE
WESNGQPENN Y<TTPPVLDS YSRL TVDKSRWQEG NVFSCSVMHE
ALHNHYTQKS LSLSLG§
wherein X is a lysine (K) or is .
A preferred IgG4 amino acid sequence, for the CH2 and CH3 Domains
comprising M252Y/SZS4T/T256E, of the second polypeptide chain of an Fc Regioncontaining
molecule of the t invention having two polypeptide chains (or the third
polypeptide chain of an Fc Region-containing molecule having three, four, or five polypeptide
chains) will have the “hole-bearing” sequence (SEQ ID NO:85):
APEFLGGPSV FLFPPKPKDT PEVT CVVV)VSQH) PHVQENWYVJ
GVEVHNA<TK PRfifiQFNSTY QVVSVLTVLH KEYK CKVSNKGLPS
SIEKTISKAK GQPREPQVYT LPPSQEEMTK NQVSL§CA¥K GFYPSDIAVE
WESNGQPENN YKTTPPVLDS YSRL TVDKSRWQEG NVFSCSVMHE
ALINBYTQKS LSLSLG§
wherein X is a lysine (K) or is absent.
As will be noted, the CH2-CH3 Domains of SEQ ID NO:84, and SEQ ID NO:85
e the M252Y/8254T/T256E tutions, and thus form an IgG4 Fc Region exhibiting
sed serum half-life. The invention also encompasses IgG4 CH2-CH3 Domains, which
comprise the wild-type ZS4/T256 residues.
It is red that the first polypeptide chain will have a “knob-bearing” CH2-
CH3 sequence, such as that of SEQ ID NO:44. However, as will be recognized, a “hole-
bearing” CH2-CH3 Domain (e.g., SEQ ID NO:45) could be employed in the first polypeptide
chain, in which case, a “knob-bearing” CH2-CH3 Domain (e.g., SEQ ID NO:44) would be
employed in the second polypeptide chain of an Fc Region-containing molecule of the present
invention having two polypeptide chains (or in the third ptide chain of an Fc Region-
ning molecule having three, four, or five polypeptide chains).
In other embodiments, the invention encompasses PD-l X CTLA—4 bispecific
molecules sing CH2 and/or CH3 Domains that have been engineered to favor
heterodimerization over homodimerization using mutations known in the art, such as those
disclosed in PCT Publication No.
VI. Anti-PD-l Binding lities
Antibodies that are immunospecific for PD-l are known (see, e.g., United States
Patent Applications No. 62/198,867; 62/239,559; 62/255,140 United States s No.
8,008,449, 8,552,154, PCT Patent ations
2013/014668). Preferred PD-l binding capabilities useful in the generation of the PD-l X
CTLA-4 bispecific molecules of the present invention are e of binding to a continuous
or discontinuous (e.g., conformational) portion (epitope) of human PD-l (CD279) and will
preferably also t the ability to bind to PD-l molecules of one or more non-human species,
in particular, primate species (and especially a primate species, such as cynomolgus monkey).
Additional desired antibodies may be made by isolating antibody-secreting hybridomas elicited
using PD-l or a peptide fragment thereof. A entative human PD-l polypeptide (NCBI
Sequence 009.2; ing a 20 amino acid residue signal sequence, shown underlined)
and the 268 amino acid residue mature protein) has the amino acid sequence (SEQ ID NO:46):
MQIPQAPWPV VWAVLQLGWR PGWFLDSPDR PWNPPTFSPA_LWVVT?GDNA
TFTCSFSNTS ESFVLNWYRM SPSNQTD<LA AFPEDRSQPG QDCRFRVTQL
PNGRDFHMSV VRARRNDSGT YWCGATSWAP KAQIKFSTRA FTRVTFRRAF
VPTAiPSPSP RPAGQFQTLV LLGS LVTLVWVLAV "CSRAAQGT"
GARRTGQPLK EDPSAVPVES VJYGELDEQW PBVP CVPEQTLYAT
MGTS SPARRGSADG PQSAQPLRPE DGHCSWPL
Preferred anti-PD-l binding molecules (e.g., antibodies) useful in the generation
of the PD-l X CTLA—4 bispecific molecules of the instant invention possess the VL and/or VH
Domains of the anti-human PD-l monoclonal antibody “PD-1 mAb 1” (nivolumab, CAS Reg.
No.:9464l4—94-4, also known as 5C4, BMS—936558, ONO—4538, MDX-llO6, and ed
as OPDIVO® by Bristol-Myers Squibb), “PD-1 mAb 2” (pembrolizumab, (formerly known
as lizumab), CAS Reg. No.:13748534, also known as MK-3475, SCH-900475, and
marketed as KEYTRUDA® by Merck); “PD-1 mAb 3” (EH12.2H7; Dana ), “PD-1
mAb 4” (pidilizumab, CAS Reg. No: 1036730-42—3 also known as CT-Oll, CureTech,), or
any of the anti-PD-l antibodies in Table 6; and more preferably possess 1, 2 or all 3 of the
CDRLS of the VL Region and/or 1, 2 or all 3 of the CDRHS of the VH Domain of such anti-PD-
1 monoclonal antibodies. onal anti-PD-l antibodies possessing unique binding
characteristics useful in the methods and compositions of the instant inventions have recently
been identified (see, United States Patent Application Nos. 62/198,867; 62/239,559;
62/255,140). Particularly, preferred are PDbinding molecules which possess a humanized
VH and/or VL Domain of the anti-PD-l antibody “PD-1 mAb 5” (hPD—l mAb 2,
MacroGenics); “PD-1 mAb 6” (hPD-1 mAb 7, MacroGenics); “PD-1 mAb 7” (hPD-1 mAb
9, MacroGenics); or “PD-1 mAb 8” (hPD-1 mAb 15, MacroGenics); and more ably
possess 1, 2 or all 3 of the CDRLS of the VL Region and/or 1, 2 or all 3 of the CDRHs of the
VH Domain of such humanized D-l monoclonal antibodies.
A. PD-l mAb 1
] The amino acid sequence of the VH Domain of PD-l mAb 1 (SEQ ID NO:47) is
shown below (CDRH residues are shown underlined).
QVQLVESGGG SLRL 0C ASG"TFS NSGMHWVRQA PGKGLEWVAZ
IWYDGSKRYY ADSVKGRFTI SRDNSKNTLF LQMNSLRAED TAVYYCATEE
EWGQGTLVT vss
The amino acid sequence of the VL Domain of PD-1 mAb 1 (SEQ ID NO:48) is
shown below (CDRL residues are shown underlined).
EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD
ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ SSNWPRTFGQ
GTKVEIK
B. PD-l mAb 2
The amino acid ce of the VH Domain of PD-1 mAb 2 (SEQ ID NO:49) is
shown below (CDRH es are shown underlined).
QVQLVQSGVE VKKPGASVKV SC<ASGYTFT NYYMYWVRQA PGQGLEWMGQ
INPSNGGTNF NEKFKNRVTL TTDSSTTTAY MELKSLQFDD TAVYYCARED
YRFDMGFDYW GQGTTVTVSS
The amino acid sequence of the VL Domain of PD-1 mAb 2 (SEQ ID NO:50)
is shown below (CDRL residues are shown underlined).
EIVLTQSPAT LSLSPGERAT KGVS TSGYSYLHWY QQKPGQAPRL
LIYLASYLES GVPARFSGSG SGTDFTLTIS SLEPEDFAVY YCQHSRDLPL
TFGGGTKVEIK
C. PD-1 mAb 3
The amino acid sequence of the VH Domain of PD-1 mAb 3 (SEQ ID NO:51) is
shown below (CDRH residues are shown ined).
QVQLQQSGAE LAKPGASVQM SCKASGYSFT SSWIHWVKQR PGQGLEWIGY
IYPSTGFTEY NQKFKDKATL TADKSSSTAY MQLSSLTSED SAVYYCARWR
AMDY WGQGTSVTVSS
The amino acid sequence of the VL Domain of PD-1 mAb 3 (SEQ ID NO:52) is
shown below (CDRL residues are shown underlined).
DIVLTQSPAS LTVSLGQRAT ISCRASQSVS MHWY QQKPGQPPKL
NLES GIPARFSGSG SGTDFTLNIH PVEEEDTATY YCQHSWEIPY
TFGGGTKLEI K
D. PD-1 mAb 4
The amino acid sequence of the VH Domain of PD-1 mAb 4 (SEQ ID NO:53) is
shown below (CDRH residues are shown underlined).
SGSE LKKPGASVKI SCKASGYTFT NYGMNWVRQA PGQGLQWMGW
INTDSGESTY AEEFKGRFVF NTAY LQITSLTAED TGMYFCVRVG
YDALDYWGQG TLVTVSS
The amino acid sequence of the VL Domain of PD-1 mAb 4 (SEQ ID NO:54) is
shown below (CDRL residues are shown underlined).
EIVLTQSPSS LSASVGDRVT ITCSARSSVS YMHWFQQKPG KAPKLWIYRT
SNLASGVPSR FSGSGSGTSY CLTINSLQPE DFATYYCQQR SSFPLTFGGG
TKLEIK
E. PD-1 mAb 5
The amino acid sequence of the VH Domain of PD-1 mAb 5 (SEQ ID NO:55) is
shown below (CDRH es are shown underlined).
EVQLVESGGG LVQPGGSLRL SCAASGFVFS SFGMHWVRQA PGKGLEWVAY
SISY ADTVKGRFTI SRDNAKNTLY LQMNSLRTED TALYYCASLS
DYFDYWGQGT TVTVSS
The amino acid sequence of the VL Domain of PD-l mAb 5 (SEQ ID NO:56) is
shown below (CDRL residues are shown underlined).
DWMTQSPLS LPVTLGQPAS IISCRSSQSLV HSTGNTYLHW YLQKPGQSPQ
SNRF §GVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCSQTTHVP
VEFGQGTKLE IK
F. PD-l mAb 6
The amino acid sequence of the VH Domain of PD-l mAb 6 (SEQ ID NO:57) is
shown below (CDRH residues are shown underlined).
QVQLVQSGAE VKKPGASVKV SCXASGYSFT SYWMNWVRQA PGQGLEWXlGZ
IHPSDSETWL DQKFKDRVTI TVDKSTSTAY MELSSLRSED TAVYYCAREE
YGTSPFAYWG QGTLVTVSS
n X1 is I or A
The amino acid sequence of the VL Domain of PD-l mAb 6 (SEQ ID NO:58) is
shown below (CDRL residues are shown ined).
EIVLTQSPAT LSLSPGERAT LSCRAXLESVD MNWF QQKPGQPPKL
L:HAASNX2GS GVPSRFSGSG SGTDFTLTIS SLEPEDFAVY EVPY
EFGGGTKVEI K
wherein: X1 is N or S and X2 is Q or R; or
X1 is N and X2 is Q; or
X1 is S and X2 is Q; or
X1 is S and X2 is R
In particular embodiments the amino acid sequence of PD-l mAb 6 comprises:
(a) SEQ ID NO:57; wherein X1 is I; and SEQ ID NO:58; wherein X1 is
N and X2 is Q; or
(b) SEQ ID NO:57; wherein X1 is I; and SEQ ID NO:58; wherein X1 is S
and X2 is Q.
An exemplary anti-PD—l VH Domain designated “PD-1 mAb 6-I VH” ses
SEQ ID NO:57 wherein X1 is I and has the amino acid sequence (SEQ ID NO:86):
QVQLVQSGAE VKKPGASVKV SC<ASGYSFT SYWMNWVRQA PGQGLEWIGV
IHPSDSETWL DQKFKDRVTI TVDKSTSTAY MELSSLRSED TAVYYCAREH
YGTSPFAYWG QGTLVTVSS
An exemplary anti-PD-l VL Domain designated “PD-1 mAb 6-SQ VL”
comprises SEQ ID NO:58 wherein X1 is S and X2 is Q and has the amino acid sequence (SEQ
ID NO:87):
EIVLTQSPAT LSLSPGERAT LSCRASESVD NYGMSFMNWF PPKL
LIHAASNQGS GVPSRFSGSG SGTDFTLT S SLJPEDEAVY ECQQSKEVPY
TFGGGTKVEI K
An exemplary anti-PD-l antibody that ses a PD—l mAb 6-I VH domain and
a PD-l mAb 6-SQ VL domain is designated as “PD-1 mAb 6-ISQ.”
G. PD-l mAb 7
The amino acid sequence of the VH Domain of PD-l mAb 7 (SEQ ID NO:59) is
shown below (CDRH residues are shown ined).
EVQLVESGGG LXlRPGGSLKL SCAASGFTFS SYLVX¢WVRQA PGKGLEWXgAE
ISGGGGNTYY SDSVKGRFTI SRDNAKNSLY LQMNSX4RAED TATYYCARXE
FDGAWFAYWG QGTLVTVSS
wherein: X1 is V or A; X2 is S or G; X3 is V or T; X4 is L or A; or
X1 is V, X2 is S, X3 is V, and X4 is L; or
X1 is A, X2 is G, X3 is T, and X4 is A
The amino acid sequence of the VL Domain of PD-l mAb 7 (SEQ ID NO:60) is
shown below (CDRL residues are shown underlined).
SPSS LSASVGDRVT ITCRASENIY XIYLAWYQQKP GKAPKLLIY§£
GVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQH HYAVPWTFGQ
GTKLEIK
wherein: X1 is S or N and X2 is N or D; or X1 is S and X2 is N; or
X1 isN and X2 isD
In particular embodiments PD-l mAb 7 comprises:
(a) SEQ ID NO:59, wherein X1 is V, X2 is S, X3 is V, and X4 is L; and
SEQ ID NO:60, wherein X1 is S and X2 is N; or
(b) SEQ ID NO:59, wherein X1 is A, X2 is G, X3 is T, and X4 is A; and
SEQ ID NO:60, wherein X1 is N and X2 is D.
H. PD-l mAb 8
The amino acid sequence of the VH Domain of PD-l mAb 8 (SEQ ID NO:61) is
shown below (CDRH residues are shown underlined).
EVQLVESGGG LVRPGGSLRL SCAASGFTFS SYLISWVRQA PGKGLEWVAé
DTYY ADSVKGRFTI SRDNAKNSLY LQMNSLRAED TATYYCARBE
TYAMDYWGQG TLVTVSS
The amino acid sequence of the VL Domain of PD-l mAb 8 (SEQ ID NO:62) is
shown below (CDRL residues are shown ined).
DIQMTQSPSS LSASVG)RVT TCRASENIY NYLAWYQQKP GKAPKLLIYE
AKTLAAGVPS SGTD SLQP EDFATYYCQE HYAVPWTFGQ
GTKLEIK
1. Additional Anti-PD-l Antibodies
Additional anti-PD-l antibodies which may be utilized to generate the PD-l X
CTLA—4 bispecific molecules of the instant invention are ed in Table 6.
Table 6: Additional Anti-PD-l Antibodies
PD-l Antibodies Reference / Source
PDl-l7; PDl-28; ; PD1-35; and PDl-F2 US Patents No. 7,488,802;
7,521,051; and 8,088,905; PCT
Patent Publication WO
2004/056875
l7D8; 2D3; 4H1; 5C4; 4A1 l; 7D3; and 5F4 US Patents No. 8,008,449;
8,779,105; and 9,084,776; PCT
Patent Publication WO
2006/121168
hPD-l.08A; hPD-1.09A; 109A, KO9A, 409A; US Patents No. 8,354,509;
h409Al l; 6; h409Al7; Codon optimized 8,900,587; and 5,952,136; PCT
109A; and Codon optimized 409A Patent Publication WO
2008/156712
1E3; 1E8, and 1H3 US Patent ation
2014/004473 8; PCT Patent
Publication
9A2; 10B11; 6E9; APE1922; APE1923; APE1924;
APE1950; APE1963; and APE2058 2014/179664
GAl; GA2; GBl, GB6; GHl; A2; C7; H7; SH-A4; US Patent ation
SH-A9; RG1H10; RG1H11; RG2H7; RGZHIO; 2014/0356363; PCT Patent
RG3E12, RG4A6; RG5D9; RG1H10-H2AIS; Publication wo 2014/194302
RG1H10-H2AZS; RG1H10-3C; RG1H10-16C;
RG1H10-17C; RG1H10-19C; RG1H10-21C; and
RGlH10-23C2
Table 6: Additional Anti-PD-l Antibodies
PD-l Antibodies nce / Source
H1M7789N; H1M7799N; H1M78OON' US Patent Publication
H2M7780N; H2M7788N; H2M7790N; 2015/0203579; PCT Patent
1N; H2M7794N; H2M7795N; Publication WO 12800
H2M7796N; H2M7798N; H4H9019P;
H4xH9034P2;H4xH9035P2;H4xH9037P2
H4XH9045P2; H4XH9O48P2; H4H9057P2;
H4H9068P2; H4XH91 19P2; 20P2;
H4Xh9128p2; H4Xh9135p2; H4Xh9l45p2;
H4Xh8992 o; H4Xh8999 o; and H4Xh9008 .;
PD-l mAb 1; PD-l mAb 2; hPD-l mAb 2; PD-l US Patent Applications No.
mAb 3; PD-l mAb 4; PD-l mAb 5; PD-1 mAb 6; 62/198,867 and 62/239,559
PD—l mAb 7; hPD—l mAb 7; PD-l mAb 8; PD-l
mAb 9; hPD-l mAb 9; PD-l mAb 10; PD-l mAb
11; PD-l mAb 12; PD-l mAb 13; PD-l mAb 14;
PD—l mAb 15; and hPD-l mAb 15
J. Exemplary anti-PD-l Antibody
An exemplary anti-PD-l antibody designated “PD-1 mAb 6 G4P” comprises: a
heavy chain having the VH Domain of PD-l mAb 61 (SEQ ID NO:86), an IgG4 CH1 Domain
(SEQ ID NO:42); a stabilized IgG 4 Hinge (SEQ ID NO:36); and IgG4 CH2-CH3 Domains
lacking the C-terminal lysine (SEQ ID NO:4); and a light chain having the VL Domain ofPD-
1 mAb 6SQ (SEQ ID NO:87) and a kappa CL (SEQ ID NO:38),
The amino acid sequence of the complete heavy chain of PD-l mAb 6 G4P (SEQ
ID NO:88) is shown below.
QVQLVQSGAE VKKPGASVKV SCKASGYSFT SYWMNWVRQA WIGV
IHPSDSETWL DQKFKDRVTI TVDKSTSTAY MELSSLRSED TAVYYCAREH
AYWG QGTLVTVSSA STKGPSVFPL APCSRSTSES TAALGCLVKD
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTKTY
TCNVDHKPSN TKVDKRVESK BCPA RflELGGPSVF LEPPKPKDTL
MISRTPEVTC VVVDVSQEDP EVQFNWYVDG VEVHNAKTKP REEQFNSTYR
VVSVLTVLiQ KVSNKGLBSS fiKTTS {AKG Q?REPQVYTL
PPSQEEMT<N LVKG EYPSDIAVLW LSNGQRflNNY KTTPPVLDSD
GSFFTYSRTT QEGN MHEA WHNHYTQKSL LSLG
The amino acid sequence of the complete light chain of PD-l mAb 6 G4P (SEQ
ID NO:89) is shown below.
EIVLTQSPAT LSLSPGERAT ESVD NYGMSFMNWF QQKPGQ?PKL
LIHAASNQGS GVPSRFSGSG SGTDFTLT S SLfiP fiDhAVY ECQQSKEVPY
TFGGGTKVEI KRTVAABSVE iFPBSDEQLK SGTASVVCLL NNFYPREAKV
QWKVDNALQS GNSQ?SVT?Q YSLS STLTLSKADY EKHKVYACEV
THQGLSSPVT KSFNRGEC
VII. Anti-CTLA-4 Binding Capabilities
Antibodies that are immunospecific for CTLA-4 are known (see, e.g., United
States Patents No. 6,984,720, 6,682,736; 7,034,121, 7,109,003, 7,132,281; 7,411,057,
7,605,238; 7,807,797; 7,824,679; 8,017,114; 8,143,379; 8,318,916; 895; 8,784,815; and
8,883,984; US Patent Publications 2009/0123477; 2009/0252741; and 105914; PCT
Patent Publications No. WO 00/37504; WO 01/14424; WO 01/54732;
2006/066568; and
useful in the generation of the PD-l X CTLA-4 bispecific molecules of the present invention
are capable ofbinding to a continuous or discontinuous (e.g., conformational) n (epitope)
of human CTLA-4 and will preferably also t the ability to bind to CTLA-4 les of
one or more non-human species, in particular, primate species (and especially a primate
species, such as cynomolgus monkey), Additional desired antibodies may be made by isolating
antibody-secreting hybridomas elicited using CTLA-4 or a peptide fragment thereof. A
representative human CTLA-4 polypeptide (NCBI Sequence NP_005205.2; including a 35
amino acid residue signal sequence (shown underlined) and the 188 amino acid residues of the
mature protein) has the amino acid sequence (SEQ ID NO:75):
MACLGFQRHK AQLNLATRTW PCTLLFFLLF IPVFCKAMHV AQPAVVLASS
RGHASFVCLY ASPGKATLVR VTVLRQADSQ VTEVCAATYM MGNELTFLDD
SICTGTSSGN QVNLTIQGLR AMDTGLY CK PPYY LGIGNGTQIY
VIDPEPCPDS DFLLWILAAV SSGLFFYSFL LTAVSLSKML KKRSPLTTGV
YVKMPPTfiPfi CfiKQEQPYEi PHW
Preferred anti-CTLA-4 binding les (e.g., antibodies) useful in the
generation of the PD-l X CTLA-4 bispecific molecules of the t invention possess the VL
and/or VH Domains of the anti-human CTLA-4 monoclonal dy “CTLA-4 mAb 1”
mumab, CAS Reg. No: 9, also known as MDXOIO, and ed as
YERVOY® by Bristol-Myers Squibb); “CTLA-4 mAb 2” (tremelimumab, CAS Reg. No.:
745013-59—6, also known as CP-675206); “CTLA-4 mAb 3” (4B6 as provided in Table 7) or
any of the other anti—CTLA—4 antibodies in Table 7; and more preferably possess 1, 2 or all 3
of the CDRLS of the VL Region and/or 1, 2 or all 3 of the CDRHs of the VH Domain of such
anti-CTLA-4 monoclonal antibodies.
A. CTLA-4 mAb 1
The amino acid sequence of the VH Domain of CTLA-4 mAb 1 (SEQ ID
NO:76) is shown below (CDRH residues are shown underlined).
QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYTMHWVRQA PGKGLEWVTF
ISYDGNNKYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAIYYCARTG
WLGPFDYWGQ GTLVTVSS
The amino acid sequence of the VL Domain of CTLA-4 mAb 1 (SEQ ID NO:77)
is shown below (CDRL residues are shown underlined).
EIVLTQSPGT LSLSPGERAT LSCRASQSVG SSYLAWYQQK PGQAPRLLIY
GAFSRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ WTFG
B. CTLA-4 mAb 2
The amino acid sequence of the VH Domain of CTLA-4 mAb 2 (SEQ ID NO:78)
is shown below (CDRH residues are shown underlined).
QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYGMHWVRQA PGKGLEWVAV
NKYY ADSVKGRFTI SRDNSKNTLY RAED ARDP
RGATLYYYYY GMDVWGQGTT VTVSS
The amino acid sequence of the VL Domain of CTLA-4 mAb 2 (SEQ ID NO:79)
is shown below (CDRL residues are shown ined).
DIQMTQSPSS LSASVGDRVT ITCRASQSIN SYLDWYQQKP LIYA
ASSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YYSTPFTFGP
GTKVEIK
C. CTLA-4 mAb 3
The amino acid sequence of the VH Domain of CTLA-4 mAb 3 (SEQ ID NO:90)
is shown below (CDRH residues are shown underlined).
SGGG VVQPGRSLRL SCAASGFTFS VRQA PGKGLEWVTF
ISYDGSNKHY ADSVKGRFTV SRDNSKNTLY LQMNSLRAED TAIYYCARTG
WLGPFDYWGQ GTLVTVSS
The amino acid sequence of the VL Domain of CTLA-4 mAb 3 (SEQ ID NO:91)
is shown below (CDRL residues are shown underlined).
EIVLTQSPGT LSLSPGERAT LSCRASQSVS SSFLAWYQQK PGQAPRLLIY
GASSRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYGSSPWTFG
QGTKVEIK
D. Additional Anti-CTLA-4 Antibodies
Additional anti-CTLA-4 antibodies which may be utilized to generate the PD-1 X
CTLA-4 bispecific molecules of the instant invention are provided in Table 7.
Table 7: Additional Anti-CTLA-4 dies
CTLA-4 Antibodies Reference / Source
mAb 26 US Patent No. 7,034,121; PCT Patent
Publication WO 01/54732
10D1, 1E2; and 4B6 US Patents No. 6,984,720; 238,
8,017,114; 8,318,916, and 8,784,815, PCT
Patent Publication W0 01/14424
2.13, 3.1.1, 4.1.1; 4.8.1, 4.91, 4102, US Patents No. 6,682,736, 7,109,003,
4.13.1,4.14.3,6.1.1,11.2.1,11.6.1,11.7.1, 7,132,281; 7,411,057, 7,807,797; 7,824,679,
12.241, 1231, 1231.1, 129.1, and 12.911 8,143,379; 8,491,895, and 8,883,984, PCT
Patent Publication WO 00/3 7504
3B10; 8H5; 8H5-1B1, 3B10-4F7; 3; US Patent Publication 2014/0105914, PCT
2C7-1G10; 3B10-6E3, and 1 Patent Publication
3.7F10A2; 4.3F6B5, 4.4A7F4, 4.6C1E3, US Patent Publication 2009/0123477, PCT
4.7A8H8; 4.7E11F1; 4.8H10H5; TGN2122; Patent Publication
and TGN2422
L3D10, L1B11, K4G4, KMlO, and YL2 US Patent Publication 2009/0252741, PCT
Patent Publication
E. Exemplary anti-CTLA-4 dies
An ary anti-CTLA-4 antibody designated “CTLA-4 mAb 3 GlAA”
comprises a heavy chain having the VH Domain ofCTLA-4 mAb 3 (SEQ ID NO:90), an IgGl
CH1 Domain (SEQ ID NO:40), an IgGl Hinge (SEQ ID , and IgG1 CH2-CH3
Domains the substitutions L234A/L235A (SEQ ID NO:43).
The amino acid ce of the complete heavy chain of CTLA-4 mAb 3 GlAA
(SEQ ID NO:92) is shown below.
SGGG VVQPGRSLRL SCAASGFTFS SYTMHWVRQA PGKGLEWVTF
ISYDGSNKHY ADSVKGRFTV SRDNSKNTLY LQMNSLRAED TAIYYCARTG
WLGPFDYWGQ GTLVTVSSAS FPLA PSSKSTSGGT AALGCLVKDY
FPEPVTVSWN GV-T FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI
CNVNHKPSWT KVDKRVEPKS CDKTHTCPPC PAPEAAGGPS VFLFPPKPKD
TLW SRTPfiV TCVVVDVS E WWYV DGVEVHNAKT KPREEQYNST
YRVVSVLTVL HQDWLNGKEY KC<VSNKALP AP EKT SKA KGQPREPQVY
TLPPSREEWT KNQVSLTCLV D AV fiWflSNGQPEN NYKTTPPVLD
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK
An alternative exemplary anti-CTLA—4 antibody designated “CTLA-4 mAb 3
G4P” comprises a heavy chain having the VH Domain of CTLA-4 mAb 3 (SEQ ID NO:90),
an IgG4 CH1 Domain (SEQ ID NO:42), a stabilized IgG4 Hinge (SEQ ID NO:36), and IgG4
CH2—CH3 Domains g the C-terminal lysine (SEQ ID NO:4). The amino acid sequence
of the complete heavy chain of CTLA-4 mAb 3 G4P is shown below (SEQ ID NO:93).
QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYTMHWVRQA PG<GLEWVTF
ISYDGSNKHY ADSVKGRFTV NTLY LQMNSLRAED TAIYYCARTG
WLGBEJYWGQ GTLVTVSSAS TKGPSVFPLA SEST AALGCLVKDY
FPL‘LJ N SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTKTYT
CNVDflXPSNT KVDKRVESKY GPBCPPCBAP SVEL EBBKPKDTLM
IS?T?EVTCV EDPE VQFNWYVDGV EVHNAKTKPR TYRV
VSVLTVLHQD WLWGKEYKCK VSNKGLPSSI EKTISKAKGQ PEEPQVYULP
PSQEEWTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TT?PVLDSDG
SFFLYSRLTV DKSRWQEGNV FSCSVMHEAL {NHYTQKSLS LSLG
The amino acid sequence of the te light chain of CTLA-4 mAb 3 GlAA
and CTLA-4 mAb 3 G4P (SEQ ID NO:94) is shown below.
EIVLTQSPGT WSLSPGERAT LSCRASQSVS SSFLAWYQQK PGQAPQLLIY
GASSRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYGSSPWTFG
QGTKVEIKRT VAAPSVTIFP ?SDEQLKSGT ASVVCLLNNF YPREA<VQWK
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACQVUHQ.L
GLSSPVTKSF NRGEC
The exemplary anti-CTLA-4 antibodies, CTLA-4 mAb 3 GlAA and CTLA-4
mAb 3 G4P, both comprise a light chain having the VL Domain of CTLA-4 mAb 3 (SEQ ID
NO:91) and a kappa CL (SEQ ID NO:38).
VIII. Exemplary PD-l x CTLA-4 Bispecific Molecules
A. Exemplary Four Chain Fc Region-Containing Diabodies Having E/K-
Coils
Three exemplary PD-l X CTLA-4 bispecific, four-chain, Fc Region—containing
ies, comprising E/K—coil Heterodimer-Promoting Domains were generated (designated
“DART B,” “DART C,” and “DART D”). The structure of these Fc Region-containing
ies is detailed below. These ary PD-l X CTLA-4 diabodies are intended to
illustrate, but in no way limit, the scope of the invention.
1. DART B
DART B is a bispecific, four—chain, Fc Region-containing diabody having two
binding sites specific for PD-l, two binding sites specific for CTLA-4, a variant IgG4 Fc
Region engineered for extended ife, and E/K-coil Heterodimer—Promoting Domains. The
first and third polypeptide chains of DART B comprise, in the N—terminal to C-terminal
direction: an N—terminus, a VL Domain of a monoclonal antibody capable ofbinding to CTLA-
4 (VLCTLA-4 CTLA-4 mAb l VL) (SEQ ID NO:77); an intervening linker peptide (Linker 1:
GGGSGGGG (SEQ ID NO:5)); a VH Domain of a monoclonal antibody capable of binding to
PD-l (VHPD-l PD-l mAb 6—1 VH) (SEQ ID NO:86); a cysteine-containing intervening linker
peptide (Linker 2: GGCGGG (SEQ ID ; a cysteine—containing Heterodimer-Promoting
(E4mfl) Dommn (HVAACEK—HVAALHK-HVAALHK—HVAALHK (SEQ ID ; a
stabilized IgG4 hinge region (SEQ ID NO:36); a variant of an IgG4 CH2-CH3 Domain
comprising substitutions M252Y/8254T/T256E and lacking the C-terminal residue (SEQ ID
NO:81); and a C-terminus.
] The amino acid ce of the first and third polypeptide chains of DART B is
(SEQ ID NO:95):
EIVLTQSPGT LSLSPGERAT LSCRASQSVG YQQK PGQAPRLLIY
GAFSRATGIP DRFSGSGSGT UFTTTTSRTF PEDFAVYYCQ QYGSSPWTFG
IKGG GSGGGGQVQL VQSGAEVK<P SGYSFTSYWM
NWVRQAPGQG LEWiGViHPS JSETWLDQKF KDRVTITVDK
SWRSEDTAVY YCAREHYGTS PFAYWGQGTL VTVSSGGCGG
AALEKEVAAL HKfiVAALfiKfi SKYGPBCPRC BABLELGGBS
(Ill—ZIKJl—J DY TREPflV TCVVVUVSQ? NWYV DGVEVHNAKT
RVVSVLTVL HQDWLNG<E KC<VSNKGLP ISKA KGQPREPQVY
LPPSQEEWT KNQVSVTCVV KGTYPSDIAV QPEN NYKTT??VLD
YSR LTVDKSRWQE GNVFSCSVMH EALHNHYTQK G
The second and fourth ptide chains ofDART B comprise, in the N—terminal
to C—terminal direction: an N—terminus, a VL Domain of a monoclonal antibody capable of
g to PD-l (VLPD-l PD-l mAb 6-SQ VL) (SEQ ID NO:87); an intervening linker peptide
(Linker 1: GGGSGGGG (SEQ ID NO:5)); a VH Domain of a monoclonal antibody capable of
binding CTLA-4 (VHCTLA-4 CTLA-4 mAb l VH) (SEQ ID NO:76); a cysteine-containing
intervening linker peptide (Linker 2: GGCGGG (SEQ ID NO:6)); a cysteine-containing
Heterodimer—Promoting (K—coil) Domain (KVAACKE—KVAALKE—KVAALKE—KVAALKE
(SEQ ID NO:21); and a C-terminus.
The amino acid sequence of the second and fourth polypeptide chains of DART
B is (SEQ ID NO:96):
EIVLTQSPAT ERAT LSCRASESVD NYGMSFMNWF QQKPGQPPKL
LIHAASNQGS GVPSRFSGSG SGTDETLTiS SLEPEDEAVY ECQQSKEVPY
TFGGGTKVEI KGGGSGGGGQ VQLVESGGGV VQPGRSLRLS CAASGFTFSS
YTMHWVRQAP VTFI KYYA FTIS TLYL
QMNSLRAEDT RTGW LG?FDYWGQG TLVTVSSGGC GGGKVAACKE
KVAALKEKVA ALKEKVAALK E
2. DART C
DART C is a bispecific, four-chain, Fc Region-containing diabody having two
binding sites specific for PD-l, two binding sites specific for CTLA-4, a variant IgG4 Fc
Region engineered for extended half-life, and E/K-coil Heterodimer—Promoting Domains. The
first and third polypeptide chains of DART C comprise, in the N—terminal to C-terminal
direction: an N—terminus, a VL Domain of a monoclonal antibody capable ofbinding to CTLA-
4 (VLCTLA-4 CTLA-4 mAb 3 VL) (SEQ ID NO:91); an intervening linker peptide (Linker 1:
GGGSGGGG (SEQ ID NO:5)); a VH Domain of a monoclonal antibody capable of binding to
PD—l (VHPD-l PD-l mAb 6-I VH) (SEQ ID N0:86); a cysteine-containing intervening linker
peptide (Linker 2: GGCGGG (SEQ ID NO:6)); a cysteine—containing Heterodimer-Promoting
l) Domain (EVAACEK—41VAAT.fitK—EVAALEK—RVAATEK (SEQ ID NO:20)); a
stabilized IgG4 hinge region (SEQ ID NO:36); a variant of an IgG4 3 Domain
comprising substitutions M252Y/SZS4T/T256E and lacking the C-terminal residue (SEQ ID
NO:81); and a inus.
The amino acid sequence of the first and third polypeptide chains of DART C is
(SEQ ID NO:97):
EIVLTQSPGT TSLSPGERAT WSCRASQSVS SSTLAWYQQK PGQAPRLLIY
GASSRATGIP DQFSGSGSGT DFTLT"SRLF YYCQ QYGSSPWTFG
QGTKVEIKGG GSGGGGQVQL VQSGAEVKKP GASVKVSCKA SGYSFTSYWM
NWVQQAPGQG TfiW GV {PS DSLTWLDQKF TVDK STSTAYMELS
SLRSEDTAVY YCAREHYGTS PFAYWGQGTL VTVSSGGCGG GEVAACEKEV
AALEKEVAAW EKfiVAALfiK? CPPC GGPS VFLFPPKPKD
TLY TRHBfiV VSQS DPEVQEWWYV DGVEVHNAKT KPREEQFNST
YRVVSVTTVT HQDWLNGKEY KCKVSNKGLP SSIEKTISKA KGQPREPQVY
TLPBSQLLWT KNQVSLTCLV KGEYPSD AV fiWfiSNGQPEN NYKTTPPVLD
SDGSFFLYSR LTVDKSRWQE GNVFSCSVMH EALHNHYTQK SLSLSLG
The second and fourth polypeptide chains ofDART C se, in the N—terminal
to inal direction: an N—terminus, a VL Domain of a monoclonal antibody capable of
binding to PD-l (VLPD-i PD-l mAb 6-SQ VL) (SEQ ID NO:87); an intervening linker peptide
(Linker 1: GGGSGGGG (SEQ ID NO:5)); a VH Domain of a monoclonal antibody capable of
binding CTLA-4 (VHCTLA-4 CTLA-4 mAb 3 VH) (SEQ ID NO:90); a cysteine-containing
intervening linker peptide (Linker 2: GGCGGG (SEQ ID N0:6)); a cysteine-containing
Heterodimer-Promoting (K-coil) Domain (KVAACKE—KVAALKE—KVAALKE—KVAALKE
(SEQ ID NO:21); and a inus.
The amino acid sequence of the second and fourth polypeptide chains of DART
C is (SEQ ID NO:98):
EIVLTQSPAT ERAT LSCRASESVD NYGMSFMNWF QQKPGQPPKL
NQGS GVPSRFSGSG SGTJETLT S SLHBKJEAVY ECQQSKEVPY
KVfi KGGGSGGGGQ VQLVESGGGV VQPGRSLRLS CAASGFTFSS
YTMHWVRQAP GKGLEWVTFI SYDGSNKHYA DSVKGRFTVS RDNSKNTLYL
QMNSLRAfiDT A YYCARTGW LGPFDYWGQG TLVTVSSGGC GGGKVAACKE
KVAALKEKVA ALKEKVAALK E
3. DART D
] DART D is a bispecific, four-chain, Fc Region-containing diabody having two
binding sites specific for PD-l, two binding sites specific for CTLA-4, a variant IgG4 Fc
Region engineered for extended ife, and E/K-coil Heterodimer—Promoting Domains. The
first and third polypeptide chains of DART D comprise, in the N—terminal to C-terminal
direction: an inus, a VL Domain of a monoclonal antibody capable of g to PD-l
(VLPD.1 PD-l mAb 6-SQ VL) (SEQ ID NO:87); an intervening linker peptide (Linker 1:
GGGSGGGG (SEQ ID NO:5)); a VH Domain of a monoclonal antibody capable of binding
CTLA-4 (VHCTLA-4 CTLA—4 mAb 3 VH) (SEQ ID N0:90); a cysteine-containing intervening
linker peptide (Linker 2: GGCGGG (SEQ ID NO:6)); a cysteine-containing Heterodimer-
Promoting (E-coil) Domain (EVAACEK— fiVAAL fiK-FVAALFK- fiVAAL fiK (SEQ ID
NO:20)); a ized IgG4 hinge region (SEQ ID NO:36); a variant of an IgG4 CH2—CH3
Domain comprising substitutions 8254T/T256E and lacking the C-terminal residue
(SEQ ID NO:81); and a C-terminus.
The amino acid sequence of the first and third polypeptide chains of DART D is
(SEQ ID NO:99):
EIVLTQSPAT LSLS?GERAT LSCRASESVD NYGMSTMNWF QQKPGQ?PKL
LIHAASNQGS GVPSRFSGSG SGTDFTLTLS SLEPEDEAVY ECQQSKEVPY
TFGGGTKV? _ KGGGSGGGGQ VQLVESGGGV VQ?GRSLRLS CAASGFTFSS
YTMHWVRQAP GKGLEWVTFI SYDGSNKHYA DSVKGRFTVS RDNSKNTLYL
QMNSLRAEDT AIYYCARTGW LGPFDYWGQG SGGC GGGEVAACEK
FVAATFIKEVA ATE3KEVAALR K fiSKYGPBCP PCBAPLELGG PPKP
KDTLYITREP EVTCVVVDVS QEDPEVQFNW YVDGVEVHNA KTKPREEQFN
STYRVVSVLT VL GK EYKCKVSNKG LPSSIEKTIS KAKGQPREPQ
VYTLPPSQEE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP TPPV
LDSDGSFFLY SRLTVDKSRW QEGNVFSCSV NHYT QKSLSLSLG
] The second and fourth polypeptide chains of DART D se, in the N-
terminal to C-terminal direction: an N-terminus, a VL Domain of a onal dy
e of binding to CTLA-4 (VLCTLA-4 CTLA-4 mAb 3 VL) ( SEQ ID NO:91); an
intervening linker peptide r 1: GGGSGGGG (SEQ ID NO:5)); a VH Domain of a
monoclonal antibody capable of binding to PD-1 (VHPD-1 PD-1 mAb 6-I VH) (SEQ ID
NO:86); a cysteine-containing intervening linker peptide (Linker 2: GGCGGG (SEQ ID
NO:6)); a cysteine -containing Heterodimer-Promoting (K-coil) Domain (KVAACKE-
KVAALKE-KVAALKE-KVAALKE (SEQ ID NO:21); and a C-terminus.
] The amino acid sequence of the second and fourth polypeptide chains of DART
D is (SEQ ID NO:100):
EIVLTQSPGT LSLSPGERAT LSCRASQSVS SSFLAWYQQK PGQAPRLLIY
GASSRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYGSSPWTFG
QGTKVEIKGG GSGGGGQVQL VQSGAEVKKP GASVKVSCKA SGYSFTSYWM
NWVRQAPGQG LEWIGVIHPS DSETWLDQKF KDRVTITVDK STSTAYMELS
SLRSEDTAVY YCAREHYGTS QGTL VTVSSGGCGG GKVAACKEKV
AALKEKVAAL KEKVAALKE
4. DART F
DART F is a bispecific, four-chain, Fc Region-containing diabody having two
binding sites specific for PD-1, two binding sites ic for CTLA-4, a variant IgG1 Fc
Region engineered to reduce/eliminate effector function and to extend half-life, and il
Heterodimer-Promoting Domains. The first and third polypeptide chains of DART F comprise,
in the inal to C-terminal direction: an N-terminus, a VL Domain of a monoclonal
antibody capable of binding to PD-1 (VLPD-1 PD-1 mAb 6-SQ VL) (SEQ ID ; an
intervening linker peptide (Linker 1: GGGSGGGG (SEQ ID NO:5)); a VH Domain of a
monoclonal antibody capable of binding CTLA-4 (VHCTLA-4 CTLA-4 mAb 3 VH) (SEQ ID
NO:90); a cysteine-containing intervening linker peptide (Linker 2: GGCGGG (SEQ ID
NO:6)); a cysteine-containing Heterodimer-Promoting (E-coil) Domain (EVAACEK-
EVAALEK-EVAALEK-EVAALEK (SEQ ID NO:20)); a linker (SEQ ID NO:30); a variant of
an IgG1 CH2-CH3 Domain comprising substitutions L235A/L235A/M252Y/S254T/T256E
and lacking the C-terminal residue (SEQ ID NO:80); and a C-terminus.
The amino acid sequence of the first and third polypeptide chains of DART F
(SEQ ID NO:101) is:
EIVLTQSPAT LSLS?GERAT LSCRASESVD NYGMSFMNWF QQKPGQPPKL
LIHAASNQGS GVPSRFSGSG SGTDFTLTTS SLEPEJEAVY ECQQSKEVPY
TFGGGTKV?’ KGGGSGGGGQ VQLVESGGGV LRLS CAASGFTFSS
YTMHWVRQAP GKGLEWVTFI SYDGSN<€YA DSVKGRFTVS RDNSKNTLYL
QMNSLRAEDT AIYYCARTGW LG?FDYWGQG TLVTVSSGGC GGGEVAACEK
EVAALEKT.L A ATMZKEVAATM AD<T {TCPPCPAPE VFLF
PPKPKDT1Y_ TREPEVTCVV VDVSHED?E KFNWYVDGVE VHNAKTKPRE
EQYNSTYRVV SVLTVLHQDW KC<V SNKALPAPIE KTISKAKGQP
REPQVYTLPP SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT
TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL
The second and fourth polypeptide chains ofDART F comprise, in the N—terminal
to C-terminal direction: an N—terrninus, a VL Domain of a monoclonal antibody capable of
binding to CTLA-4 A-4 CTLA-4 mAb 3 VL) (SEQ ID NO:91), an intervening linker
peptide (Linker 1: GG (SEQ ID NO:5)); a VH Domain of a monoclonal antibody
capable of binding to PD—l (VHPD-l PD-l mAb 6-I VH) (SEQ ID NO:86); a cysteine-
containing intervening linker peptide (Linker 2: GGCGGG (SEQ ID NO:6)); a cysteine-
containing Heterodimer-Promoting (K-coil) Domain (KVAACKE—KVAALKE—KVAALKE—
KVAALKE (SEQ ID NO:21), and a C-terminus.
The amino acid sequence of the second and fourth polypeptide chains of DART
F is the same as that ofthe econd and fourth polypeptide chains ofDART D (SEQ ID NO: 100).
B. Exemplary Four-Chain Fc Region-Containing Diabodies Having CL/CHl
s: DART E
An exemplary PD-l X CTLA-4 bispecific, four-chain, Fc Region-containing
y sing CL/CHl s designated “DART E” was generated. The structure
of this Fc Region-containing diabodies is detailed below. This exemplary PD-l X CTLA-4
diabody is intended to illustrate, but in no way limit, the scope of the invention.
DART E is a bispecific, four—chain, Fc -containing diabody having two
binding sites specific for PD-l, two binding sites specific for CTLA-4, CL/CHl Domains, and
a variant IgG4 Fc Region engineered for extended half-life. The first and third polypeptide
chains of DART E se, in the inal to inal direction: an N—terminus; a VL
Domain of a monoclonal antibody capable of binding to CTLA—4 (VLCTLA-4 CTLA-4 mAb 3
VL) (SEQ ID NO:91); an ening linker peptide (Linker 1: GGGSGGGG (SEQ ID N0:5));
a VH Domain of a monoclonal antibody capable of binding to PD-l (VHPD-l PD-l mAb 6-I
VH) (SEQ ID NO:86); an intervening linker peptide (Linker 2: LGGGSG (SEQ ID NO:8));
an IgG4 CH1 Domain (SEQ ID NO:42); a ized IgG4 hinge region (SEQ ID NO: 36); a
variant of an IgG4 CH2-CH3 Domain sing substitutions M252Y/SZS4T/T256E and
lacking the C-terminal e (SEQ ID NO:81); and a C-terminus.
The amino acid sequence of the first and third polypeptide chains of DART E is
(SEQ ID NO:102):
EIVLTQSPGT isLSPGERAT WSCRASQSVS SSTLAWYQQK PGQAPRLLIY
GASSRATG__P JRESGSGSGT DFTLTISRLE PEDFAVYYCQ QYGSSPWTFG
’KGG GSGGGGQVQL VQSGAEVKKP GASVKVSCKA SGYSFTSYWM
NWVRQAPGQG LfiW GV HES DQKF KDQVTITVDK STSTAYMELS
SLRSEDTAVY YCAREHYGTS PFAYWGQGTL VTVSSLGGGS GASTKGPSVF
PLAPCSRSTS ESTAALGCLV {DYFPEPVTV LTSG VHTFPAVLQS
SGLYSLSSVV TVPSSSLGTK TYTCNVDHKP SNTKVDKRVE SKYGPPCPPC
GGPS VELEPPKPKD TLYITQEPEV TCVVVDVSQE DPEVQFNWYV
DGVEVHNA<T KPREEQFNST YQVVSVLTVL HQDWLNGKEY {CKVSNKGLP
SSIEKTIS<A TWPPSQEEMT KNQVSWTCTV {GFYPSDIAV
EWLSNGQPLN NYKTTPPVLD SDGSFFLYSR RWQE GNVFSCSVMH
The second and fourth polypeptide chains ofDART E se, in the N—terminal
to C-terminal direction: an N—terminus; a VL Domain of a monoclonal antibody capable of
binding to PD-l (VLPD-l PD-l mAb 6-SQ VL) (SEQ ID NO:87); an intervening linker peptide
(Linker 1: GGGSGGGG (SEQ ID NO:5)); a VH Domain of a monoclonal antibody capable of
g CTLA-4 (VHCTLA-4 CTLA-4 mAb 3 VH) (SEQ ID NO:90); an intervening linker
peptide (Linker 2: LGGGSG (SEQ ID NO:8)); a Kappa CL Domain (SEQ ID NO:38); and a
C-terminus.
The amino acid sequence of the second and fourth polypeptide chains of DART
E is (SEQ ID NO:103):
EIVLTQSPAT LSLS?GERAT LSCRASESVD NYGMSFMNWF QQKPGQPPKL
NQGS GVPSRFSGSG SGTDFTLTLS SLEPEDEAVY ECQQSKEVPY
TFGGGTKVEI KGGGSGGGGQ VQLVESGGGV VQPGRSLRLS CAASGFTFSS
YTWHWVRQAP GKGLEWVTFI SYDGSN<€YA DSVKGQFTVS TLYL
QMVSLRAEDT AIYYCARTGW LG?FDYWGQG TLVTVSSLGG GSGRTVAAPS
VEHEPPSDEQ LKSGTASVVC LLWNFYPQEA {VQWKVDNAL QSGNSQESVT
EQ)SK)STYS LSSTLTLSKA DYEKHKVYAC EVTHQGLSSP VTKSFNRGEC
C. Exemplary Trivalent Binding Molecules Containing Fc s
Two exemplary PD-l X CTLA-4 bispecific, four—chain, Fc Region-containing
trivalent binding molecules were generated (designated NT A” and “TRIDENT B”).
The structure of these Fc Region-containing trivalent binding molecules is detailed below.
Also presented below is a three chain variant designated “TRIDENT C,” which may be
generated. These ary PD-l X CTLA-4 trivalent binding molecules are intended to
rate, but in no way limit, the scope of the invention.
1. TRIDENT A
TRIDENT A is a bispecific, four chain, Fc Region-containing trivalent binding
molecule having two binding sites specific for PD-l, one binding sites specific for CTLA-4, a
variant knob/hole-bearing IgG4 Fc Region ered for extended half-life, E/K—coil
Heterodimer—Promoting Domains and CL/CHl Domains. The first polypeptide chain of
T A ses, in the N—terminal to C—terminal direction: a VL Domain of a
monoclonal antibody e of binding to PD-l I PD-l mAb 6-SQ VL) (SEQ ID
NO:87); an intervening linker peptide (Linker 1: GGGSGGGG (SEQ ID NO:5)); a VH Domain
of a monoclonal antibody capable of binding to PD-l (VHPD-I PD-l mAb 6-I VH) (SEQ ID
NO:86); a cysteine-containing intervening linker peptide (Linker 2: GGCGGG (SEQ ID
; a cysteine-containing Heterodimer-Promoting (E-coil) Domain (EVAACEK—
+1VAAT. +1K—EVAATEK— 41VAAT. 41K (SEQ ID NO:20)); a ized IgG4 hinge region (SEQ ID
NO: 36); a knob-bearing IgG4 CH2-CH3 Domain comprising substitutions
V1252Y/8254T/T256E and lacking the C-terminal residue (SEQ ID NO:84); and a C-terminus.
The amino acid sequence of the first polypeptide chain of TRIDENT A is (SEQ
ID NO:104):
EIVLTQSPAT ERAT LSCRASESVD NYGMSFMNWF QQKPGQPPKL
LIHAASNQGS SGSG SGTDETLT S SLHBK)EAVY ECQQSKEVPY
TFGGGTKVZ.L KGGGSGGGGQ VQLVQSGAEV KKPGASVKVS C(ASGYSFTS
YWMNWVRQAP GQGLEWLGVL HBSDSETWLD QKEKDRVTLT VDKSTSTAYM
FLSSWRSEDT AVYYCAREiY GTS?FAYWGQ GTLVTVSSGG AACE
KFVAALF<EV AALEKFVAAL H<fiSKYGP3C PPCPABEHLG GBSVELEBPK
PKDTLYITQE PEVTCVVVDV S QEDPEVQTN WYVDGVEVHN AKTKPREEQF
NSTYQVVSVL TVLiQDWLWG KEY<CKVSWK GLPSS fiKTi S<AKGQPREP
QVYTLPPSQE EMT<NQVSLW CLV<GFYPSD :AVEWESNGQ PENNYKTTPP
VLDSDGSFFL DKSR WQEGNVFSCS VMHEALiNHY TQKSLSLSLG
The second polypeptide chain of TRIDENT A comprises, in the N—terminal to C-
terminal direction: an N—terminus, a VL Domain of a monoclonal antibody capable of binding
to PD-l (VLPD-l PD-l mAb 6-SQ VL) (SEQ ID NO:87), an intervening linker e (Linker
1: GG (SEQ ID NO:5)); a VH Domain of a monoclonal antibody capable of binding
to PD-l l PD-l mAb 6-1 VH) (SEQ ID NO:86); a cysteine-containing intervening
linker peptide (Linker 2: GGCGGG (SEQ ID ; a ne-containing Heterodimer-
Promoting (K-coil) Domain (KVAACKE—KVAALKE—KVAALKE—KVAALKE (SEQ ID
NO:21)), and a C-terminus.
] The amino acid sequence of the second polypeptide chain of TRIDENT A is
(SEQ ID NO:105):
EIVLTQSPAT LSLSPGERAT LSCRASESVD NYGMSFMNWF PPKL
LIHAASNQGS SGSG SGTDETLTiS SLLPEJEAVY ECQQSKEVPY
TFGGGTKVEI KGGGSGGGGQ VQLVQSGAEV KK?GASVKVS CKASGYSFTS
YWMNWVRQAP GQGLEWIGVI HPSDSETWLD QKFKDRVTIT TAYM
ELSSLRSZDT AVYYCAREHY GTS?FAYWGQ GTLVTVSSGG CGGGKVAACK.L
EKVAALKE<V AALKEKVAAL KB
The third polypeptide chains of TRIDENT A comprises, in the N—terrninal to C-
terminal direction: an N—terminus; a VH Domain of a monoclonal antibody capable of binding
CTLA-4 (VHCTLA-4 CTLA-4 mAb 3 VH) (SEQ ID NO:90), an IgG4 CH1 Domain (SEQ ID
NO:42), a stabilized IgG4 hinge region (SEQ ID NO: 36), a hole-bearing IgG4 CH2-CH3
Domain comprising substitutions M252Y/SZS4T/T256E and lacking the C-terminal residue
(SEQ ID NO:81); and a inus.
The amino acid sequence of the third polypeptide chain of TRIDENT A (SEQ ID
NO:106):
SGGG VVQPGRSLRL SCAASGFTFS SYTMHWVQQA PGKGLEWVTF
NKHY ADSVKGRFTV SRDNSKNTLY LQMNSLRAED TAIYYCARTG
WLGPFDYWGQ GTLVTVSSAS TKGPSVF?LA SEST AALGCLVKUY
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTKTYT
CNVDHKPSNT KVDKRVESKY GPPCPPC?AP EFLGGPSVFL DTLY
ITQEPEVTCV VVDVSQfiDPfi VQENWYVDGV EVTNA<TKPR fifiQFNSTYRV
WLNGKEYKCK VSNKGLPSSI EKTISKAKGQ PREPQVYTLP
VSLSCAV<GT YPSDIAVEWE SNGQPENNYK TTPPVLDSDG
DKSRWQEGNV FSCSVMHEAL HNRYTQKSLS LSLG
The fourth polypeptide chain of TRIDENT A comprises, in the N—terrninal to C-
terminal direction: an N—terminus; a VL Domain of a monoclonal antibody capable of binding
to CTLA-4 (VLCTLA-4 CTLA-4 mAb 3 VL) (SEQ ID NO:91); a Kappa CL Domain (SEQ ID
NO:38); and a C-terminus.
The amino acid sequence ofthe fourth polypeptide chain of TRIDENT A is (SEQ
ID NO:107):
EIVLTQSPGT LSLSPGERAT LSCRASQSVS SSFLAWYQQK LLIY
GASSRATGIP DQFSGSGSGT DFTWT"SRLE PEDFAVYYCQ QYGSSPWTFG
QGTKVEIKRT VAABSVEHEP BSDEQLKSGT ASVVCLLNNF YPREAKVQWK
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ
GLSSBVTKSE NQGLC
2. TRIDENT B
TRIDENT B is a bispecific, four-chain, Fc Region-containing trivalent binding
molecule having two binding sites specific for PD-l, one binding sites specific for CTLA—4, a
variant knob/hole-bearing IgGl Fc Region engineered to reduce/eliminate effector function
and to extend half-life, E/K—coil Heterodimer—Promoting Domains and CL/CHl Domains. The
first polypeptide chain of TRIDENT B comprises, in the N—terminal to C-terminal direction: a
VL Domain of a monoclonal antibody capable of binding to PD-l (VLPD-l PD-l mAb 6-SQ
VL) (SEQ ID NO:87); an intervening linker peptide (Linker 1: GGGSGGGG (SEQ ID NO:5));
a VH Domain of a monoclonal antibody capable of binding to PD-l l PD-l mAb 6-I
VH) (SEQ ID NO:86); a cysteine-containing intervening linker e (Linker 2: GGCGGG
(SEQ ID NO:6)); a cysteine-containing Heterodimer-Promoting (E—coil) Domain (EVAACEK—
RVAATEK—FVAATEK—FVAATRK (SEQ ID NO:20)); a linker (SEQ ID NO: 31); a knob-
g IgGl 3 Domain comprising substitutions L234A/L235A/M252Y/8254T/
T256E and lacking the C-terminal residue (SEQ ID N0:82); and a C-terminus.
The amino acid sequence of the first polypeptide chain of T B is (SEQ
ID NO:108):
SPAT LSLSPGERAT LSCRASESVD NYGMSTMNWF QQKPGQ?PKL
LIHAASNQGS GVPSRFSGSG SGTDFTLTLS SLEPEDEAVY ECQQSKEVPY
KVE: GGGQ VQLVQSGAEV KK?GASVKVS CKASGYSFTS
YWMNWVRQAP GQGLEWIGVI TWLD QKFKDQVTIT TAYM
ELSSLRSEDT AVYYCAREHY GTSPFAYWGQ GTLVTVSSGG CGGGEVAACE
EKEV AALEKEVAAW EKGGGDKTHT CPPCPAPEAA GGPSVFLFPP
KPKDTLYLTR EBEVTCVVVD VSflEDPEVKF NWYVDGVEVH NAKTKPREEQ
YNSTYRVVSV LTVTHQDWLW KVSN XALPAP EKT SKAKGQPRE
PQVYTLPPS? EEWTKNQVSL WCLVKGEYBS D AVEWfiSNG QPENNYKTTP
PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP
The second polypeptide chain of T B comprises, in the N—terminal to C-
terminal direction: an N—terminus, a VL Domain of a monoclonal antibody capable of binding
to PD-l (VLPD-l PD—l mAb 6-SQ VL) (SEQ ID NO:87), an intervening linker peptide (Linker
1: GGGSGGGG (SEQ ID NO:5)); a VH Domain of a onal antibody capable of binding
to PD-l (VHPD-l PD—l mAb 6-I VH) (SEQ ID NO:86); a cysteine-containing intervening
linker peptide (Linker 2: GGCGGG (SEQ ID NO:6)), a cysteine-containing Heterodimer-
Promoting (K-coil) Domain (KVAACKE—KVAALKE—KVAALKE—KVAALKE (SEQ ID
NO:21)), and a C-terminus.
The amino acid sequence of the second polypeptide chain of TRIDENT B is the
same as that of the second polypeptide chain of TRIDENT A (SEQ ID NO:105):
] The third polypeptide chains of T B ses, in the N—terminal to C-
terminal direction: an N—terminus, a VH Domain of a monoclonal antibody capable of binding
CTLA-4 (VHCTLA-4 CTLA-4 mAb 3 VH) (SEQ ID N0:90), an IgGl CH1 Domain (SEQ ID
NO:40), an IgGl hinge region (SEQ ID NO:33); a hole—bearing IgGl CH2-CH3 Domain
comprising substitutions L234A/L235A/M252Y/S254T/T256E and lacking the C-terminal
residue (SEQ ID NO:83); and a C—terminus.
The amino acid sequence of the third ptide chain of TRIDENT B is (SEQ
ID NO:109):
QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYTMHWVRQA PGKGLEWVTF
ISYDGSNKHY ADSVKGRFTV SQDNSKNTLY LQMNSLRAED TAIYYCARTG
WLGBEJYWGQ GTLVTVSSAS TKGPSVFPLA PSSXSTSGGT AALGCLVKDY
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI
PSNT EP<S CDKTHTCPBC PABjAAGGPS VELEBPKPKD
mar-<HLYITREPEV TCVVVDVSEE D?EVKFVWYV DGVEVHNAKT KPREEQYNST
RVVSVLTVL HQDWLNGKEY KCKVSN<ALP AP fiKT SKA PQVY
EMT KNQVSLSCAV KGEYBS) AV HWHSNGQPEN PVLD
DGSFFLVSK LTVDKSRWQQ GNVFSCSVMH EALHNRYTQK GK
The fourth polypeptide chain of TRIDE\IT B comprises, in the N—terminal to C-
terminal direction: an N—terminus; a VL Domain of a monoclonal antibody capable of binding
to CTLA-4 (VLCTLA.4 CTLA-4 mAb 3 VL) (SEQ ID NO:91), a Kappa CL Domain (SEQ ID
NO:38); and a C-terminus.
The amino acid ce of the fourth polypeptide chain of TRIDENT B is the
same as that of the second polypeptide chain of TRIDENT A (SEQ ID NO:107).
3. TRIDENT C
As provided herein, trivalent binding les sing three polypeptide
chain may be generated by combining (e.g., fusing encoding polynucleotides, etc.) the binding
domains of two te polypeptide chains into one chain. One bispecific, chain, Fc
Region-containing trivalent binding molecule that may be generated has two binding sites
specific for PD-l, one binding sites specific for CTLA-4, a variant knob/hole-bearing IgG4 Fc
Region engineered for extended half-life, and E/K-coil Heterodimer-Promoting Domains
(“TRIDENT C”). The first and second polypeptide chains of TRIDENT C may be identical to
those of TRIDENT A provided above.
Where the first and second chains are identical to those of TRIDENT A, the third
polypeptide chain of TRIDENT C may comprise, in the N-terminal to C-terminal direction: an
N—terminus; a VL Domain of a monoclonal antibody capable of g to CTLA—4 (VLCTLA-4
CTLA-4 mAb 3 VL) (SEQ ID , an intervening spacer peptide (GGGGSGGGGSGGGGS
(SEQ ID NO:37)); a VH Domain of a onal antibody capable of binding CTLA-4
(VHCTLA-4 CTLA-4 mAb 3 VH) (SEQ ID N0:90), a stabilized IgG4 hinge region (SEQ ID
NO: 36); a hole-bearing IgG4 CH2-CH3 Domain comprising substitutions
M252Y/8254T/T256E and lacking the C-terminal e (SEQ ID NO:85), and a C-terminus.
Thus, the amino acid sequence of the third polypeptide chain of TRIDENT C is
(SEQ ID NO:110):
EIVLTQSPGT LSLSPGERAT LSCRASQSVS SSFLAWYQQK LLIY
GASSRATGIP GSGT DFTLTISRLE PEDFAVYYCQ QYGSSPWTFG
QGTKVEIKGG GGSGGGGSGG GGSQVQLV:.L GGGVVQPGRS LQLSCAASGF
TFSSYTMHWV RQAPGKGLEW VTFISYDGSN KAYADSVKGR FTVSRDNSKN
TLYLQWNSLR AEDTAIYYCA RTGWLGPFDY WGQGTLVTVS SESKYGPPCP
PCPAPLELGG PSVELEPBKP KDTLYLTREP LVTCVVVDVS QfiDBfiVQENW
YVDGVEVHNA KTKPREEQFN STYRVVSVLT VLHQDWLWGK EYKCKVSNKG
LESS EKT S KA<GQPREPQ VYTLPPSQEE SLSC AVKGFYPSD:
AVEWESNGQP ENWYKTTPPV LDSDGSFFLV KSRW QEGNVFSCSV
MHEALHNRYT QKSLSLSLG
IX. Methods of Production
The PD-1 X CTLA-4 bispecifrc molecules of the present invention are most
preferably produced through the recombinant expression of nucleic acid molecules that encode
such polypeptides, as is well-known in the art.
Polypeptides of the invention may be conveniently prepared using solid phase
peptide synthesis (Merrifield, B. (1986) “SolidPhase Synthesis,” Science 232(4748):341-347,
en, RA. (1985) “General Method For Ihe Rapid Solid-Phase sis 0f Large
s OfPeptides: Specificity OfAntigen-Antibody Interaction At The Level OfIndividual
Amino Acids,” Proc. Natl. Acad. Sci. (USA) :5131-5135; Ganesan, A. (2006) “Solid-
Phase Synthesis In The Twenty-First Century,” Mini Rev. Med. Chem. 6(1):3-10).
In an ative, dies may be made recombinantly and expressed using any
method known in the art. Antibodies may be made recombinantly by first isolating the
antibodies made from host animals, obtaining the gene ce, and using the gene sequence
to express the antibody inantly in host cells (e.g., CHO cells). Another method that
may be employed is to express the antibody sequence in plants (e. g., tobacco) or transgenic
milk. Suitable methods for expressing antibodies recombinantly in plants or milk have been
disclosed (see, for example, Peeters et al. (2001) “Production OfAntibodies And Antibody
nts In Plants,” Vaccine 19:2756; Lonberg, N. et al. (1995) “Human Antibodies From
Transgenic Mice,” Int. Rev. Immunol 13 :65-93, and Pollock et al. (1999) “Transgenic MilkAs
A Method For The tion OfRecombinant Antibodies,” J. Immunol Methods 231:147-
157). Suitable methods for making tives of antibodies, e.g., humanized, single-chain,
etc. are known in the art, and have been described above. In r alternative, antibodies
may be made recombinantly by phage y technology (see, for example, US. Patents No.
,565,332, 5,580,717, 5,733,743, 6,265,150; and Winter, G. et al. (1994) “MakingAntibodies
By Phage Display Technology,” Annu. Rev. Immunol. 12433-455).
Vectors containing polynucleotides of interest (e.g., polynucleotides encoding the
polypeptide chains of the PD-1 X CTLA-4 bispeciflc molecules of the present invention) can
be introduced into the host cell by any of a number of appropriate means, including
electroporation, transfection employing calcium chloride, rubidium chloride, calcium
phosphate, DEAE-dextran, or other sub stances, microproj ectile bombardment, lipofection; and
infection (e.g., where the vector is an infectious agent such as ia virus). The choice of
introducing s or cleotides will often depend on features of the host cell.
Any host cell capable of overexpressing heterologous DNAs can be used for the
purpose of expressing a polypeptide or n of st. Non-limiting examples of suitable
mammalian host cells include but are not limited to COS, HeLa, and CHO cells.
The invention includes polypeptides comprising an amino acid ce of the
PD-l X CTLA-4 bispecific molecule of this invention. The polypeptides of this invention can
be made by procedures known in the art. The polypeptides can be produced by proteolytic or
other degradation of the antibodies, by inant methods (i.e., single or fusion
polypeptides) as described above or by chemical synthesis. Polypeptides of the antibodies,
especially shorter ptides up to about 50 amino acids, are conveniently made by chemical
synthesis. s of chemical synthesis are known in the art and are commercially available.
] The invention includes variants of PD-l X CTLA-4 bispecific molecules,
including functionally equivalent polypeptides that do not significantly affect the properties of
such molecules as well as variants that have enhanced or sed activity. Modification of
polypeptides is e practice in the art and need not be described in detail . Examples
of modified polypeptides include polypeptides with conservative tutions of amino acid
residues, one or more deletions or additions of amino acids which do not significantly
deleteriously change the functional activity, or use of chemical analogs. Amino acid residues
that can be vatively substituted for one another include but are not limited to:
glycine/alanine, serine/threonine; /isoleucine/leucine, asparagine/glutamine, aspartic
acid/glutamic acid; lysine/arginine; and phenylalanine/tyrosine. These polypeptides also
include glycosylated and non-glycosylated ptides, as well as polypeptides with other
post-translational modifications, such as, for example, glycosylation with different sugars,
acetylation, and phosphorylation. Preferably, the amino acid substitutions would be
conservative, i.e., the substituted amino acid would possess similar chemical properties as that
of the original amino acid. Such conservative substitutions are known in the art, and es
have been provided above. Amino acid modifications can range from changing or modifying
one or more amino acids to complete redesign of a region, such as the Variable Domain.
Changes in the Variable Domain can alter binding affinity and/or specificity. Other methods of
modification include using coupling techniques known in the art, including, but not limited to,
enzymatic means, oxidative substitution and chelation. Modifications can be used, for
example, for attachment of labels for immunoassay, such as the attachment of radioactive
moieties for radioimmunoassay. Modified polypeptides are made using established procedures
in the art and can be screened using standard assays known in the art.
The invention encompasses fusion proteins comprising one or more of the
polypeptides or antibodies of this invention. In one embodiment, a fusion polypeptide is
provided that ses a light chain, a heavy chain or both a light and heavy chain. In r
embodiment, the fusion polypeptide contains a heterologous immunoglobulin constant region.
In another embodiment, the fusion polypeptide contains a Light Chain Variable Domain and a
Heavy Chain le Domain of an antibody produced from a publicly-deposited hybridoma.
For purposes of this invention, an antibody fusion protein contains one or more polypeptide
domains that specifically bind to PD-l and/or CTLA-4 and r amino acid sequence to
which it is not attached in the native molecule, for example, a heterologous sequence or a
gous sequence from another region.
X. Uses of the PD-l x CTLA-4 Bispecific Molecules of the Present Invention
The present invention encompasses compositions, including ceutical
compositions, comprising the PD—l X CTLA-4 bispecific molecules of the present invention
(e.g., bispeciflc antibodies, bispeciflc diabodies, trivalent binding molecules, etc),
polypeptides derived from such molecules, polynucleotides comprising ces encoding
such les or polypeptides, and other agents as described herein.
As discussed above, both PD—l and CTLA-4 play important roles in negatively
regulating immune responses (e.g., immune cell proliferation, function and homeostasis). The
PD-l X CTLA-4 bispecific molecules of the present invention have the ability to inhibit PD-l
function, and thus reverse the PD-l-mediated immune system inhibition. In addition, the PD-
1 X CTLA-4 bispeciflc les of the present invention have the ability to inhibit CTLA-4
function and thus augment the immune system by blocking immune system tion mediated
by PD-l and CTLA-4. The PD-l X CTLA-4 bispeciflc molecules of the present invention also
allow for full de of both PD—l and CTLA-4, as well as blockade that is biased toward
CTLA-4 when co-expressed with PD-l. Thus, the PD-l X CTLA-4 bispeciflc les ofthe
invention are useful for relieving T-cell exhaustion and/or augmenting an immune response
(e.g., a T-cell and/or NK-cell mediated immune se) of a subject. In particular, the PD-l
X CTLA-4 bispecific molecules of the invention and may be used to treat any e or
condition associated with an undesirably suppressed immune system, including cancer and
diseases that are associated with the presence of a pathogen (e.g., a bacterial, fungal, viral or
protozoan infection).
The cancers that may be treated by the PD-1 x CTLA-4 bispecific molecules of the
present invention include s characterized by the presence of a cancer cell selected from the
group consisting of a cell of: an adrenal gland tumor, an AIDS-associated cancer, an alveolar soft
part sarcoma, an astrocytic tumor, bladder cancer, bone cancer, a brain and spinal cord cancer, a
atic brain tumor, a breast cancer, a carotid body tumors, a cervical cancer, a
chondrosarcoma, a chordoma, a chromophobe renal cell carcinoma, a clear cell carcinoma, a
colon cancer, a colorectal cancer, a cutaneous benign fibrous histiocytoma, a desmoplastic small
round cell tumor, an ependymoma, a Ewing’s tumor, an extraskeletal myxoid chondrosarcoma,
a fibrogenesis ecta ossium, a fibrous dysplasia of the bone, a gallbladder or bile duct
cancer, gastric cancer, a ional trophoblastic e, a germ cell tumor, a head and neck
cancer, hepatocellular carcinoma, an islet cell tumor, a Kaposi’s Sarcoma, a kidney cancer, a
leukemia, a lipoma/benign lipomatous tumor, a liposarcoma/malignant lipomatous tumor, a liver
cancer, a lymphoma, a lung cancer, a medulloblastoma, a melanoma, a meningioma, a multiple
endocrine neoplasia, a multiple myeloma, a myelodysplastic syndrome, a neuroblastoma, a
ndocrine tumors, an ovarian cancer, a atic cancer, a ary thyroid carcinoma, a
parathyroid tumor, a pediatric , a peripheral nerve sheath tumor, a phaeochromocytoma, a
pituitary tumor, a prostate , a posterior uveal melanoma, a rare hematologic disorder, a
renal metastatic cancer, a rhabdoid tumor, a rhabdomyosarcoma, a sarcoma, a skin cancer, a softtissue
sarcoma, a squamous cell cancer, a h , a synovial sarcoma, a testicular cancer,
a thymic carcinoma, a thymoma, a thyroid metastatic cancer, and a uterine cancer.
In particular, PD-1 x CTLA-4 bispecific molecules of the present invention may be
used in the treatment of colorectal cancer, hepatocellular carcinoma, glioma, kidney cancer,
breast , multiple myeloma, bladder cancer, neuroblastoma; sarcoma, dgkin’s
ma, all cell lung cancer, ovarian cancer, pancreatic cancer and rectal cancer.
Infections that may be treated by the PD-1 X CTLA-4 bispecific molecules of the
present invention include chronic viral, bacterial, fungal and tic infections. Chronic
infections that may be treated by the PD-1 X CTLA-4 bispecific molecules of the present
invention include Epstein Barr virus, Hepatitis A Virus (HAV); Hepatitis B Virus (HBV);
Hepatitis C Virus (HCV); herpes viruses (e.g. HSV-1, HSV-2, HHV-6, CMV), Human
deficiency Virus (HIV), Vesicular Stomatitis Virus (VSV), Bacilli, acler,
Cholera, Diphtheria, Enterobacter, Gonococci, Helicobacler pylori, Klebsiella, ella,
Meningococci, mycobacteria, Pseudomonas, Pneumonococci, rickettsia bacteria, Salmonella,
Serratia, lococci, Streptococci, Tetanus, Aspergillus (A. fumigatus, A. niger, etc),
Blasz‘omyces dermatilia’is, Candida (C. ns, C. , C. glabraia, C. lropicalis, eta),
Cryptococcus neoformans, Genus Mucorales (mucor, absia’ia, rhizopus), Sporothrix ii,
Paracoccidioides brasiliensis, ioia’es immitis, Histoplasma capsulalum, pirosis,
ia burgdorferi, helminth parasite (hookworm, tapeworms, flukes, flatworms (e. g.
Schistosomia), Giardia Zambia, trichinella, Dientamoeba Fragilis, Trypanosoma brucei,
Trypanosoma cruzi, and Leishmania donovani.
XI. Pharmaceutical Compositions
The compositions of the invention include bulk drug compositions useful in the
manufacture of pharmaceutical compositions (e.g., impure or non-sterile compositions) and
pharmaceutical compositions (i.e., compositions that are suitable for stration to a subject
or patient) that can be used in the preparation of unit dosage forms. Such compositions
comprise a prophylactically or therapeutically effective amount of the PD-l X CTLA-4
ific molecules of the present invention, or a combination of such agents and a
pharmaceutically acceptable carrier. Preferably, compositions of the invention comprise a
prophylactically or therapeutically effective amount of the PD-l X CTLA-4 bispeciflc
molecules of the present invention and a pharmaceutically acceptable carrier. The invention
also encompasses such pharmaceutical itions that additionally include a second
eutic antibody (e.g., tumor-specific monoclonal antibody) that is specific for a particular
cancer antigen, and a pharmaceutically acceptable carrier.
In a specific embodiment, the term “pharmaceutically acceptable” means
approved by a regulatory agency of the Federal or a state government or listed in the US.
Pharmacopeia or other generally recognized pharmacopeia for use in s, and more
particularly in humans. The term “carrier” refers to a diluent, adjuvant (e.g, Freund’ s adjuvant
(complete and incomplete), excipient, or vehicle with which the therapeutic is administered.
Generally, the ingredients of compositions of the invention are supplied either separately or
mixed together in unit dosage form, for example, as a dry lyophilized powder or water free
concentrate in a hermetically sealed container such as an ampoule or sachette indicating the
ty of active agent. Where the composition is to be administered by infusion, it can be
dispensed with an on bottle containing sterile pharmaceutical grade water or saline.
Where the composition is administered by injection, an ampoule of sterile water for injection
or saline can be provided so that the ingredients may be mixed prior to administration.
The invention also provides a pharmaceutical pack or kit comprising one or more
containers filled with a PD-l X CTLA-4 bispecific molecule of the present invention, alone or
with such pharmaceutically acceptable carrier. Additionally, one or more other prophylactic
or therapeutic agents useful for the treatment of a disease can also be included in the
pharmaceutical pack or kit. The invention also provides a pharmaceutical pack or kit
comprising one or more containers filled with one or more of the ingredients of the
ceutical compositions of the invention. Optionally associated with such container(s)
can be a notice in the form prescribed by a governmental agency regulating the manufacture,
use or sale of ceuticals or biological ts, which notice reflects approval by the
agency of manufacture, use or sale for human administration.
The t invention es kits that can be used in the above methods. A kit
can comprise any of the PD—l X CTLA-4 bispecific molecules of the present invention. The
kit can further comprise one or more other prophylactic and/or therapeutic agents useful for the
ent of cancer, in one or more containers.
XII. Methods of Administration
The compositions of the present invention may be provided for the treatment,
prophylaxis, and amelioration of one or more symptoms associated with a disease, disorder or
infection by administering to a subject an effective amount of a fusion protein or a conjugated
molecule of the invention, or a pharmaceutical composition comprising a fusion protein or a
conjugated molecule of the invention. In a preferred aspect, such compositions are
substantially purified (i.e., ntially free from substances that limit its effect or produce
undesired side effects). In a specific ment, the subject is an animal, preferably a
mammal such as non-primate (e.g., bovine, equine, feline, canine, rodent, etc.) or a primate
(e.g., monkey such as, a cynomolgus monkey, human, etc). In a preferred embodiment, the
t is a human.
s ry systems are known and can be used to administer the
compositions ofthe invention, e.g., encapsulation in liposomes, microparticles, microcapsules,
recombinant cells capable of expressing the antibody or fusion n, receptor-mediated
endocytosis (See, e.g., Wu et a]. (1987) “Receptor-MediatedIn Vitro Gene Transformation By
A Soluble DNA Carrier System, ”J. Biol. Chem. 262:4429-4432), construction of a nucleic acid
as part of a retroviral or other vector, etc.
Methods of administering a molecule of the invention include, but are not limited
to, parenteral administration (e.g, intradermal, intramuscular, intraperitoneal, intravenous and
subcutaneous), epidural, and mucosal (e. g., intranasal and oral routes). In a specific
embodiment, the PD-l X CTLA-4 ific molecules of the present ion are
administered intramuscularly, intravenously, or subcutaneously. The compositions may be
administered by any ient route, for example, by infusion or bolus injection, by
absorption through epithelial or mucocutaneous s (e.g., oral , rectal and intestinal
mucosa, etc.) and may be administered together with other biologically active .
Administration can be systemic or local. In on, pulmonary administration can also be
employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.
See, e.g., US. Patents No. 6,019,968; 5,985, 320, 5,985,309, 5,934,272, 5,874,064; 5,855,913,
,290,540, and 4,880,078; and PCT Publication Nos. WO 92/19244, WO 97/32572; WO
97/44013, WO 98/31346, and WO 99/66903, each h is incorporated herein by reference
in its entirety.
The invention also provides that preparations of the PD-l X CTLA—4 bispeciflc
molecules of the present invention are ed in a hermetically sealed ner such as an
ampoule or te indicating the quantity of the le. In one embodiment, such
molecules are supplied as a dry sterilized lyophilized powder or water free concentrate in a
hermetically sealed container and can be reconstituted, e.g., with water or saline to the
appropriate concentration for administration to a subject. Preferably, the PD-l X CTLA-4
bispeciflc molecules of the present ion are supplied as a dry sterile lyophilized powder
in a hermetically sealed container.
] The lyophilized preparations of the PD-l X CTLA-4 bispeciflc molecules of the
present invention should be stored at between 2°C and 8°C in their original container and the
molecules should be administered within 12 hours, preferably within 6 hours, within 5 hours,
within 3 hours, or within 1 hour after being reconstituted. In an alternative embodiment, such
molecules are supplied in liquid form in a hermetically sealed container indicating the quantity
and concentration of the molecule, fusion protein, or ated molecule. Preferably, such
PD-l X CTLA-4 bispecific molecules when ed in liquid form are supplied in a
hermetically sealed container.
The amount of such preparations of the invention that will be effective in the
treatment, prevention or amelioration of one or more symptoms associated with a disorder can
be determined by standard clinical techniques. The precise dose to be ed in the
formulation will also depend on the route of administration, and the seriousness of the
condition, and should be decided according to the judgment of the practitioner and each
patient’s circumstances. ive doses may be extrapolated from dose-response curves
derived from in vitro or animal model test systems.
As used herein, an “effective ” of a pharmaceutical ition, in one
embodiment, is an amount sufficient to effect beneficial or desired results including, without
limitation, al results such as decreasing ms resulting from the disease, attenuating
a symptom of infection (e.g., viral load, fever, pain, sepsis, etc.) or a symptom of cancer (e.g.,
the proliferation, of cancer cells, tumor presence, tumor metastases, etc), thereby increasing
the quality of life of those suffering from the disease, decreasing the dose of other medications
required to treat the disease, enhancing the effect of another medication such as via targeting
and/or internalization, delaying the progression of the disease, and/ or prolonging survival of
individuals.
An effective amount can be administered in one or more administrations. For
purposes of this invention, an effective amount of drug, compound, or pharmaceutical
composition is an amount sufficient: to kill and/or reduce the proliferation of cancer cells,
and/or to eliminate, reduce and/or delay the development of metastasis from a primary site of
; or to reduce the proliferation of (or the effect of) an ious pathogen and to reduce
and/or delay the development of the pathogen-mediated disease, either directly or indirectly.
In some embodiments, an effective amount of a drug, compound, or pharmaceutical
ition may or may not be achieved in conjunction with another drug, compound, or
ceutical composition. Thus, an “effective amount” may be considered in the context of
administering one or more chemotherapeutic , and a single agent may be considered to
be given in an effective amount if, in conjunction with one or more other agents, a desirable
result may be or is achieved. While individual needs vary, determination of l ranges of
effective amounts of each component is within the skill of the art.
For the PD-1 x CTLA-4 bispecific molecules encompassed by the invention, the
dosage administered to a t is preferably determined based upon the body weight (kg) of the
recipient subject. For the PD-1 x CTLA-4 ific molecules encompassed by the ion,
the dosage administered to a patient is typically from about 0.01 μg/kg to about 150 mg/kg or
more of the subject’s body weight.
The dosage and frequency of administration of a PD-1 x CTLA-4 bispecific
molecule of the present invention may be reduced or altered by enhancing uptake and tissue
penetration of the molecule by modifications such as, for example, lipidation.
The dosage of a PD-1 x CTLA-4 ific molecule of the invention administered
to a patient may be calculated for use as a single agent therapy. Alternatively, the molecule may
be used in combination with other therapeutic compositions and the dosage administered to a
patient are lower than when the molecules are used as a single agent therapy.
The pharmaceutical compositions of the invention may be administered locally to
the area in need of treatment; this may be achieved by, for example, and not by way of limitation,
local infusion, by injection, or by means of an t, the implant being of a porous, non-porous,
or gelatinous material, including membranes, such as sialastic membranes, or fibers. Preferably,
when administering a molecule of the invention, care must be taken to use materials to which the
le does not absorb.
] The compositions of the invention can be delivered in a vesicle, in particular a
liposome (See Langer (1990) “New s Of Drug Delivery,” Science 249:1527-1533); Treat
et al., in LIPOSOMES IN THE THERAPY OF INFECTIOUSDISEASE AND , Lopez-Berestein and
Fidler (eds.), Liss, New York, pp. 353- 365 (1989); Berestein, ibid., pp. 3 17-327).
] Where the composition of the invention is a nucleic acid encoding a PD-1 x CTLA-
4 bispecific molecule of the t invention, the nucleic acid can be administeredin vivo to
e expression of its encoded PD-1 x CTLA-4 bispecific molecule by constructing it as part
of an appropriate nucleic acid expression vector and administering it so that it becomes
intracellular,e.g., by use of a retroviral vector (See U.S. Patent No. 4,980,286), or by direct
injection, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating
with lipids or cell surface receptors or transfecting agents, or by administering it in linkage to a
homeobox-like peptide which is known to enter the nucleus (See e.g., Joliot et al.
(1991) ‘Mntennapedia Homeobox Peptide Regulates Neural Morphogenesis,” Proc. Natl.
Acad. Sci. (USA) 88:1864—1868), etc. Alternatively, a nucleic acid can be introduced
intracellularly and orated within host cell DNA for expression by homologous
recombination.
] Treatment of a subject with a eutically or prophylactically effective amount
of a PD-l X CTLA-4 bispecific molecule ofthe t invention can include a single treatment
or, preferably, can include a series of treatments. In a preferred example, a subject is treated
with such a y one time per week for between about 1 to 10 weeks, preferably between 2
to 8 weeks, more preferably between about 3 to 7 weeks, and even more preferably for about
4, 5, or 6 weeks. The pharmaceutical compositions of the invention can be administered once
a day, twice a day, or three times a day. Alternatively, the pharmaceutical itions can
be administered once a week, twice a week, once every two weeks, once a month, once every
six weeks, once every two months, twice a year or once per year. It will also be appreciated
that the effective dosage of the molecules used for treatment may increase or decrease over the
course of a ular treatment.
XIII. Exemplary Embodiments
The invention is particularly directed to the embodiments E1-E26:
E1. A bispecific molecule possessing both one or more epitope-binding sites
capable of immunospeciflc binding to (an) epitope(s) of PD—l and one or more
epitope-binding sites capable of immunospeciflc binding to (an) epitope(s) of
CTLA-4, wherein such molecule comprises:
(A) a Heavy Chain Variable Domain and a Light Chain Variable Domain of
an antibody that binds PD—l; and
(B) a Heavy Chain Variable Domain and a Light Chain Variable Domain of
an dy that binds CTLA-4,
wherein such molecule is:
(i) a diabody, such diabody being a covalently bonded complex that
comprises two, three, four or five polypeptide chains; or
(ii) a trivalent binding molecule, such trivalent binding le being a
covalently bonded x that comprises three, four, five, or more
polypeptide chains.
E2. The bispecific molecule of Embodiment El, wherein such molecule exhibits an
activity that is enhanced relative to such activity exhibited by two monospecific
molecules one ofwhich possesses such Heavy Chain Variable Domain and such
Light Chain Variable Domain of such antibody that binds PD-l and the other of
which possesses such Heavy Chain Variable Domain and such Light Chain
Variable Domain of such antibody that binds CTLA-4.
E3. The bispecific molecule ofEmbodiment E1 or E2, wherein such le elicits
fewer immune-related e events (irAEs) when administered to a subject in
need thereof relative to such iREs elicited by the administration of a
monospecific antibody that binds CTLA-4.
E4. The bispecific molecule of Embodiment E3, n said monospecific
antibody that binds CTLA-4 is umab.
E5. The ific molecule of any one of Embodiments E1-E4, wherein such
molecule comprises an Fc Region.
E6. The ific molecule ofEmbodiment E5, wherein such Fc Region is a variant
Fc Region that comprises:
(A) one or more amino acid modifications that reduces the affinity of the
variant Fc Region for an FcyR, and/or
(B) one or more amino acid modifications that enhances the serum ife
of the variant Fc Region.
E7. The bispecific molecule of Embodiment E6, wherein such modifications that
reduces the affinity of the variant Fc Region for an FcyR comprise the
tution of L234A, L23 5A, or L234A and L23 5A, wherein such numbering
is that of the EU index as in Kabat.
E8. The bispecific molecule of Embodiment E6 or E7, wherein such modifications
that that enhances the serum ife of the variant Fc Region comprise the
substitution of M252Y, M252Y and SZS4T, M252Y and T256E, M252Y,
$254T and T256E; or K288D and H43 5K, wherein such numbering is that of
the EU index as in Kabat.
-lOO-
E9. The ific molecule of any one of Embodiments E1-E8, wherein such
molecule is such diabody and comprises two epitope-binding sites capable of
immunospecific binding to an epitope of PD-l and two epitope-binding sites
capable of immunospecific binding to an epitope of CTLA-4.
E10. The bispecific molecule of any one of Embodiments E1-E8, wherein such
molecule is such ent binding molecule and comprises two epitope-binding
sites capable of immunospecific binding to an epitope of PD-l and one epitope-
binding site e of immunospecific binding to an epitope of CTLA-4.
E11. The ific molecule of any one of Embodiments El—ElO, wherein such
molecule is capable of binding to PD-l and CTLA-4 les present on the
cell e.
E12. The ific molecule of any one of Embodiments El—Ell, wherein such
molecule is capable of simultaneously binding to PD-l and CTLA-4.
E13. The bispecific le of any one of Embodiments E1-E12, wherein such
molecule promotes the stimulation of immune cells.
E14. The bispecific molecule of Embodiment E13, wherein such stimulation of
immune cells results in:
(A) immune cell proliferation; and/or
(B) immune cell production and/or release of at least one cytokine; and/or
(C) immune cell production and/or release of at least one lytic molecule;
and/or
(D) immune cell expression of at least one activation marker.
E15. The bispecific molecule of Embodiment E13 or E14, wherein such immune cell
is a T-lymphocyte or an NK-cell.
E16. The bispecific molecule of any one of Embodiments El-ElS, wherein such
epitope-binding sites capable of immunospecific binding to an epitope of PD-l
(A) the VH Domain of PD-l mAb l (SEQ ID NO:47) and the VL Domain
ofPD—l mAb l (SEQ ID NO:48); or
(B) the VH Domain of PD-l mAb 2 (SEQ ID NO:49) and the VL Domain
of PD—l mAb 2 (SEQ ID NO:50); or
(C) the VH Domain of PD-l mAb 3 (SEQ ID NO:51) and the VL Domain
ofPD-l mAb 3 (SEQ ID ; or
(D) the VH Domain of PD-l mAb 4 (SEQ ID NO:53) and the VL Domain
of PD-l mAb 4 (SEQ ID NO:54); or
(E) the VH Domain of PD-l mAb 5 (SEQ ID NO:55) and the VL Domain
ofPD-l mAb 5 (SEQ ID NO:56); or
(F) the VH Domain of PD—l mAb 6 (SEQ ID NO:57) and the VL Domain
of PD-l mAb 6 (SEQ ID NO:58); or
(G) the VH Domain of PD-l mAb 6—1 VH (SEQ ID NO:86) and the VL
Domain of PD-l mAb 6-SQ VL (SEQ ID NO:87); or
(H) the VH Domain of PD-l mAb 7 (SEQ ID NO:59) and the VL Domain
of PD—l mAb 7 (SEQ ID NO:60); or
(I) the VH Domain of PD-l mAb 8 (SEQ ID NO:61) and the VL Domain
of PD-l mAb 8 (SEQ ID NO:62).
E17. The bispecific molecule of any one of Embodiments El—El6, wherein such
epitope-binding site(s) capable of immunospecific binding to an e of
CTLA-4 comprise:
(A) the VH Domain of CTLA-4 mAb 1 (SEQ ID NO:76) and the VL
Domain of CTLA-4 mAb l (SEQ ID NO:77); or
(B) the VH Domain of CTLA—4 mAb 2 (SEQ ID NO:78) and the VL
Domain of CTLA-4 mAb 2 (SEQ ID NO:79); or
(C) the VH Domain of CTLA—4 mAb 3 (SEQ ID NO:90) and the VL
Domain of CTLA-4 mAb 3 (SEQ ID NO:91).
E18. The bispecific molecule of Embodiment 17, n:
(A) such e-binding sites capable of immunospecific binding to an
epitope of PD-l comprise the VH Domain of PD-l mAb 6—1 VH (SEQ
ID NO:86) and the VL Domain of PD-l mAb 6-SQ (SEQ ID NO:87);
(B) such epitope-binding site(s) capable of immunospecific binding to an
epitope of CTLA-4 comprise(s) the VH Domain of CTLA-4 mAb 3
-lO2-
(SEQ ID NO:90) and the VL Domain of CTLA-4 mAb 3 (SEQ ID
NO:91).
E19. The bispecific molecule of any one of Embodiments El—E18, n such
molecule comprises:
(A) two polypeptide chains having SEQ ID NO:95, and two polypeptide
chain having SEQ ID NO:96; or
(B) two polypeptide chains having SEQ ID NO:97, and two polypeptide
chain having SEQ ID NO:98; or
(C) two polypeptide chains having SEQ ID NO:99, and two polypeptide
chain having SEQ ID NO:100; or
(D) two polypeptide chains having SEQ ID NO:102, and two polypeptide
chain having SEQ ID NO:103; or
(E) two polypeptide chains having SEQ ID , and two polypeptide
chain having SEQ ID NO:100; or
(F) one polypeptide chains having SEQ ID NO:104, one polypeptide chain
having SEQ ID NO:105, one polypeptide chain having SEQ ID
NO:106, and one polypeptide chain having SEQ ID NO:107; or
(G) one polypeptide chains having SEQ ID NO:108, one ptide chain
having SEQ ID NO:105, one polypeptide chain having SEQ ID
NO:109, and one polypeptide chain having SEQ ID NO:107.
E20. A pharmaceutical composition that comprises an effective amount of the
bispeciflc molecule of any of Embodiments E1-E19 and a pharmaceutically
acceptable carrier.
E21. The bispecific molecule of any one of Embodiments El—El9, wherein such
molecule is used to promote ation of an immune-mediated response of a
subject in need thereof.
E22. The bispeciflc le of any one of ments , wherein such
molecule is used in the treatment of a disease or condition associated with a
suppressed immune system.
E23. The bispecific le of Embodiment E22, wherein the disease or condition
is cancer or an infection.
-lO3-
E24. The bispecific molecule of Embodiment E23, wherein such cancer is characterized
by the presence of a cancer cell selected from the group consisting of a cell of: an
l gland tumor, an ssociated , an alveolar soft part sarcoma, an
astrocytic tumor, bladder cancer, bone cancer, a brain and spinal cord cancer, a
atic brain tumor, a breast cancer, a carotid body tumors, a cervical cancer,
a chondrosarcoma, a chordoma, a chromophobe renal cell carcinoma, a clear cell
carcinoma, a colon cancer, a colorectal cancer, a cutaneous benign fibrous
histiocytoma, a desmoplastic small round cell tumor, an ependymoma, a Ewing’s
tumor, an keletal myxoid chondrosarcoma, a fibrogenesis imperfecta
ossium, a fibrous sia of the bone, a gallbladder or bile duct cancer, gastric
cancer, a gestational trophoblastic disease, a germ cell tumor, a head and neck
cancer, hepatocellular carcinoma, an islet cell tumor, a Kaposi’s Sarcoma, a
kidney , a leukemia, a lipoma/benign lipomatous tumor, a
liposarcoma/malignant lipomatous tumor, a liver cancer, a lymphoma, a lung
cancer, a medulloblastoma, a melanoma, a meningioma, a multiple endocrine
neoplasia, a multiple myeloma, a myelodysplastic syndrome, a neuroblastoma, a
neuroendocrine tumors, an ovarian , a pancreatic cancer, a papillary d
carcinoma, a parathyroid tumor, a pediatric cancer, a peripheral nerve sheath
tumor, a hromocytoma, a pituitary tumor, a prostate , a posterior
uveal melanoma, a rare hematologic disorder, a renal metastatic , a rhabdoid
tumor, a rhabdomyosarcoma, a sarcoma, a skin cancer, a soft-tissue a, a
squamous cell cancer, a stomach cancer, a synovial sarcoma, a testicular cancer,
a thymic carcinoma, a thymoma, a thyroid metastatic cancer, and a uterine cancer.
E25. The bispecific le of Embodiment E24, wherein such infection is
characterized by the presence of a bacterial, fungal, viral or protozoan pathogen.
E26. The bispecific molecule of Embodiment E25, wherein such infection is
characterized by the presence of Epstein Barr virus, Hepatitis A Virus (HAV);
Hepatitis B Virus (HBV); Hepatitis C Virus (HCV); herpes viruses (e.g. HSV-1,
HSV-2, HHV-6, CMV), Human Immunodeficiency Virus (HIV), Vesicular
Stomatitis Virus (VSV), Bacilli, acter, Cholera, Diphtheria, Enterobacter,
Gonococci, Helicobacter pylori, Klebsiella, Legionella,
Meningococci, cteria, Pseudomonas, Pneumonococci, rickettsia
bacteria, Salmonella, Serrall'a, Staphylococci, Streptococci, Tetanus,
Aspergillus (A. fumigalus, A. niger, etc), myces dermatitia’is,
Candida (C. albicans, C. krusez', C. ta, C. tropicalz's, etc. ), Cryptococcus
neoformans, Genus Mucorales (mucor, absidl'a, rhizopus), Sporothrz'x schenkn',
Paracoccz'dioia’es brasilz'ensis, Coccidioz'a’es immitis, Histoplasma capsulatum,
Leptospirosis, Borrell'a burga’orferi, helminth parasite (hookworm, tapeworms,
flukes, flatworms (e.g. Schistosomia), Giara’l'a lambia, z'nella,
moeba Fragilz's, Trypanosoma brucei, Trypanosoma cruzz', and
Leishmania donovani.
Having now generally described the invention, the same will be more readily
understood h reference to the following Examples. The following examples illustrate
various methods for compositions in the diagnostic or treatment s of the invention. The
examples are intended to illustrate, but in no way limit, the scope of the invention.
Example 1
Bispecific Molecules Provide Enhanced Stimulation of Immune Responses
A bispeciflc molecule having specificity for distinct cell surface ns that
modulate two immunomodulatory pathways, PD-l and LAG-3, was ted and designated
“DART A.”
DART A is a bispecific, four chain, Fc Region-containing y having two
binding sites specific for PD-l, two binding sites specific for LAG-3, a variant IgG4 Fc Region
ered for ed half-life, and cysteine-containing E/K-coil Heterodimer—Promoting
Domains. As provided in more detail below, DART A comprises the binding specificities (i.e.,
the VH and VL Domains) of a humanized anti-PD-l antibody (hPD-l mAb 6) and a humanized
anti-LAG—3 dy 3 mAb 1). The amino acid sequence of the first and third
polypeptide chains of DART A is (SEQ ID NO:63):
DIQWTQSPSS LSASVGJRVT TCRASQDVS SVVAWYQQKP GKAPKLLIYS
ASYRYTGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ HYSTPWTTGG
GTKLEIKGGG SGGGGQVQLV QSGAEVKKPG ASVKVSCXAS GYSFTSYWMN
WVRQAPGQGT EW GVTHPSD SjTWLDQKFK DRVTITVDKS TSTAYWEUSS
AVYY CAREHYGTS? FAYWGQGTLV TVSSGGCGGG fiVAACfiKfiVA
ALEKEVAAL? KEVAALEKES KYGPPCPPCP A?EFLGG?SV FLFPPK?KDT
LY TREPfiVT SQflD PfiVQFNWYVD GVEVHNAKTK PREEQFNSTY
RVVSVLTVLH QDWLNGKEYK C(VSNKGLPS S fiKT SKAK GQPREPQVYT
LPPSQEEWTK NQVSUTCWVK GTYPSDIAVE WESNGQPENN VLDS
DGSFFLYSRL TVDKSRWQEG NVFSCSVMHE ALINHYTQKS LSLSLG
In SEQ ID NO:63, amino acid residues 1-107 pond to the amino acid
sequence of a VL Domain of a humanized monoclonal antibody capable of binding to LAG-3
3 mAb 1); residues 108-115 correspond to the intervening spacer peptide (Linker 1:
GGGSGGGG (SEQ ID NO:5)); residues 116-234 correspond to the VH Domain of a
monoclonal antibody capable of binding to PD-1 (hPD-1 mAb 6, SEQ ID NO:57, wherein X1
is I); residues 235-240 correspond to an ening spacer peptide (Linker 2: GGCGGG (SEQ
ID ; residues 8 correspond to a ne-containing Heterodimer-Promoting (E-
coil) Domain (41VAAC +1K—RVAALFK— 41VAAT. +1K— 41VAAL *ZK (SEQ ID ); es
0 correspond to a stabilized IgG4 Hinge Region (SEQ ID NO:36); residues to 281-496
correspond to a variant of IgG4 CH2-CH3 Domain comprising substitutions
M252Y/SZS4T/T256E and lacking the C-terminal residue.
The amino acid sequence of the second and fourth polypeptide chains of DART A
is (SEQ ID NO:64):
EIVLTQSPAT LSLS?GERAT LSCRASESVD NYGMSFMNWF QQKPGQPPKL
LIHAASNQGS GVPSRFSGSG SGTDFTLTIS SLEPEDEAVY ECQQSKEVPY
TFGGGTKVEI KGGGSGGGGQ VQLVQSGAEV KKPGASVKVS CKASGYTFTD
YNMDWVRQAP GQGLEWMGDI WPDNGVTIYN QKFEGQVTMT TDTSTSTAYM
ELRSLRSJJT AVYYCAREAD YFYFDYWGQG TTLTVSSGGC GGGKVAACKE
KVAALKE<VA.ALKEKVAAL< E
In SEQ ID NO:64, amino acid residues 1-111 correspond to the amino acid
sequence of a VL Domain of a monoclonal antibody capable of binding to PD-1 (hPD-1 mAb
6, SEQ ID NO:58 wherein X1 is S and X2 is Q); residues 112-119 correspond to an intervening
spacer peptide (Linker 1: GGGSGGGG (SEQ ID NO:5)); residues 120-237 correspond to a VH
Domain of a humanized onal antibody e of binding LAG-3 (hLAG—3 mAb 1);
residues 23 8-243 correspond to a cysteine-containing spacer linker peptide (Linker 2:
GGCGGG (SEQ ID NO:6)); residues 244-271 correspond to a cysteine-containing
Heterodimer—Promoting (K-coil) Domain (KVAACKR—KVAALKT.—KVAAT.KF.—KVAAT.KT.
(SEQ ID NO:21)).
The ability of DART A to stimulate T-cells was examined in a Staphylococcus
aureus enterotoxin type B (“SEB”) assay. SEB is a microbial superantigen capable of
activating a large proportion of s (5-30%) in SEB-responsive donors. SEB binds to MHC
II outside the peptide binding grove and thus is MHC II dependent, but unrestricted and TCR
mediated. SEB-stimulation of T-cells results in oligoclonal T-cell proliferation and cytokine
production (although donor variability may be observed). Within 48 hours of SEB-stimulation
PMBCs upregulate PD-1 and LAG—3 with a further enhancement at day 5, post-secondary
culture in 96-well plate with SEB-stimulation. Upregulation of the immune check point
proteins PD-l and LAG-3 following SEB-stimulation of PBMCs limits cytokine release upon
SEB ulation. The ability of DART A to enhance cytokine release through checkpoint
inhibition was examined and compared to the activity of the parental D-l and anti—LAG-
3 antibodies alone and in combination.
] Briefly, PBMCs were purified using the Ficoll-Paque Plus (GE Healthcare)
density gradient centrifugation method according to manufacturer’s instructions from whole
blood ed under informed consent from healthy donors (Biological Specialty Corporation)
and T-cells were then purified using the Dynabeads® Untouched Human T-Cells Kit (Life
Technologies) ing to manufacturer’s instructions. Purifled PBMCs were cultured in
RPMI—media + 10% heat inactivated FBS + 1% Penicillin/Streptomycin in T-25 bulk flasks for
2-3 days alone or with SEB -Aldrich) at 0.5 ng/mL (primary stimulation). At the end
of the first round of SEB-stimulation, PBMCs were washed twice with PBS and immediately
plated in 96-well tissue culture plates at a tration of 1-5 X 105 cells/well in media alone,
media with a control antibody, media with SEB at 0.5 ng/mL (secondary stimulation) and no
antibody, or media with SEB and DART A, a control IgG or an anti-PD-l antibody +/- an anti-
LAG—3 mAb, and ed for an onal 2-3 days. At the end of the second stimulation,
tants were harvested to measure cytokine secretion using human DuoSet ELISA Kits
for IFNy, TNFOL, IL-10, and IL-4 (R&D Systems) according to the manufacturer’s ctions.
In these assays DART A (a PD-l X LAG-3 bispeciflc molecule) and the anti-PD-
1 and anti-LAG—3 antibodies were used at a concentration of 0.0061, 0.024, 0.09, 0.39, 1.56,
6.25 or 25 nM. For these studies, where a combination of dies is used each antibody is
provided at the indicated concentration and thus the total antibody concentration is twice the
concentration used for each dy (i.e., 0.0122, 0.048, 0.18, 0.78, 3.12, 12.5 or 50 nM).
Figure 7 shows the IFNy secretion profiles from SEB-stimulated PBMCs from a representative
donor (D: 56041). Similar results were seen for PD—l X LAG-3 bispecific molecules
comprising VH/VL domains from alternative PD—l and LAG-3 antibodies, and for PD—l X
LAG-3 ific molecules have alternative ures (see, e.g., Figure 3C, and for numerous
donors.
The results of these studies demonstrate that PD-l X LAG-3 bispecific molecules
dramatically enhanced IFNy production from SEB-stimulated PBMCs upon restimulation.
These results show that ific molecules that target two modulatory pathways were
more potent than the combination of separate antibodies targeting the same pathways.
Example 2
PD-l x CTLA-4 Bispecific Molecules
Bispecific molecules having specificity for PD-l and CTLA—4 may be generated
using methods provided herein and known in the art. The general structure of the polypeptide
chains of l PD-l X CTLA-4 bispecific molecules is provided in Table 8. In ular,
bispecific bivalent diabody molecules, comprising two polypeptide chains, having one binding
site for PD-l and one g site for CTLA-4 may be generated n the polypeptide
chains have the general structure of Variation I (also see, e.g., Figure 1). Bispecific bivalent
diabody molecules, comprising three polypeptide chains, having one binding site for PD-l, one
g site for CTLA-4 and an Fc Region may be generated wherein the polypeptide chains
have the general structure of Variation II (also see, e. g., Figure 4A). Bispecific tetravalent
diabody molecules, comprising four polypeptide chains, having two identical binding sites for
PD-l, two identical binding sites for CTLA-4 and an Fc Region may be ted wherein the
polypeptide chains have the l structure of Variations III or IV (also see, e.g., Figures
3A-3C). In addition, bispecific trivalent molecules, comprising four polypeptide chains,
having two binding sites for PD-l and one binding site for CTLA-4 (or two binding sites for
CTLA-4 and one binding site for PD-l), and an Fc Region may be generated wherein the
polypeptide chains have the general structure of Variation V (also see, e.g., Figure 6A). In
addition, bispecific bivalent antibody les comprising four polypeptide chains having
one binding site for PD-l, one binding site for CTLA-4 and an Fc Region may be ted
wherein the polypeptide chains have the general structure of Variation VI (also see, e.g., United
States Patent No. 7,695,936 and PCT Patent Publication
. . Polypeptide
First VL1 — Linkerl — VH2 — Linker2 — I'D
S—econdVL2—Linkerl — VH1 — Linker2 — HPD
Fir (VL1)— (Linker 1)— (VH2)— (Linker 2)— (HPD)— (Linker
3 — modified CH2-CH3 Domain
11 Second VL2 — Linkerl — VH1 — Linker2 — HPD
Third (Linker3) — (modified CH2-CH3 Domain)
a—ndFirst (VL1)— (Linker 1)— (VH2)— (Linker 2)— (HPD)— r
Third 3 — CH2-CH3 Domain
Second and
(VL2)— (Linker 1)— (VH1)— (Linker 2)— (HPD)
Fourth
First and (VL1) — (Linker 1) — (VH2) — (Linker 2) — (CH1) — (Hinge)
Third — CH2-CH3 Domain
Second and
(VL2) — (Linker 1) — (VH1) — (Linker 2) — (CL)
Fourth
(—VL1)—(Linker1)—(VH2)—(Linker2)—(HPD)— (Linker
F'1rst
V Second 3VL— modified CH2-CH3 Domain
Third
Fourth
(VL1) — (Linker 1) — (VH2) — r 2) — (HPD) — (Linker
First
3 — modified CH2-CH3 Domain
VI Second VL2 — l — VH1 — 2 — HPD
(VL3)— (Linker 4)— (VH3)— (CH1) — (Hinge) — (modified
Th' d1r
C-—H2CH3Domain
First
second
Third
Fourth
HPD = Heterodimer—Promoting Domain
For each Variation of the bispecific molecules provided in Table 8:
(a) VL1 and VH1 are the variable domains of an anti-PD-l antibody and VL2 and
VH2 are the variable s of an anti-CTLA-4 antibody; or
(b) VL1 and VH1 are the variable domains of an anti-CTLA-4 antibody and VL2
and VH2 are the variable domains of an anti-PD-l antibody.
For Variations V and VI: VL3 and VH3 are the variable domains of an anti-PD-l antibody or
are the variable domains of an anti-CTLA-4 dy.
] Linkers, Heterodimer—Promoting s and constant regions (e.g., CH1,
Hinge, CH2-CH3 Domains) useful in the generation of such bispecific molecules are provided
above. In particular, as detailed herein, for molecules whose first and third polypeptide chains
are not identical the CH2—CH3 s are modified to promote heterodimerization and
reduce or prevent homodimerization, for example by modifying the CH2-CH3 Domain one
chain to comprise a “hole” and modifying the 3 Domains on the other chain to
comprise a ” As detailed above, the Hinge and/or CH2-CH3 Domains may comprise
amino acid substitutions, which stabilize the bispecific molecules and/or alter effector on
and/or enhance serum half-life.
Example 3
Universal Bispecific Adaptor (“UBA”) Molecules
Alternatively, a bispecific molecule (e. g., a bispecific antibody, a ific
diabody, trivalent binding molecule, etc.) may be constructed that ses one epitope-
binding site that specifically binds to PD—l (or CTLA-4) and a second epitope-binding site that
specifically binds a hapten, e.g. fiuorescein isothiocyanate (also known as fluoroisothiocyanate
or FITC). Such a bispecific molecule serves as a universal bispecific adaptor (“UBA”)
molecule able to co—ligate a binding domain specific for PD—l (or CTLA-4) with a fiuorescein-
conjugated binding molecule (e.g., an antibody, scFv, etc.) specific for CTLA-4 (or PD-l). For
example, the eactive arm of such a universal bispecific adaptor molecule may be used
to bind to a FITC labeled dy that binds CTLA-4 (or PD-l) thereby generating a universal
ific r molecule that is adapted to bind PD-l and CTLA-4. Such universal
bispecific adaptor molecules are useful for the rapid assessment of bispecific les.
The anti-fiuorescein antibody, 420 (“mAb 420”) may be employed as a
source of FITC-specific binding domains (Gruber, M. et al. (1994) “Efiicient Tumor Cell Lysis
MediatedBy A Bispecific Single Chain Antibody Expressed In Escherichia coli,” J. Immunol.
152(11): 5368-5374).
Amino Acid Sequence Of The Heavy Chain Variable Domain Of mAb 420
(SEQ ID NO:65) (CDRH residues are underlined):
EVKLDETGGG LVQPGRPMKL SCVASGFTFS DYWMNWVRQS BilKGTmZWVAQ
IRNKPYNYET YYSDSVKGR:' T-.SRDDSKSS VYLQMNNLRV *ZDMG YYC'l'G
YWGQ GTSVTVSS
-llO-
Amino Acid Sequence Of The Light Chain Variable Domain Of mAb 420
(SEQ ID NO:66) (CDRL residues are underlined):
DVVMTQTPFS DQAS :SCRSSQSLV HSNGNTYLRW YLQKPGQSPK
VLIYKVSNRF FSGS GSGTDFTLKI SRVEAEDLGV THVP
ETFGGGTKLE IK
] Any of the bispecific formats provided herein may be utilized (see, e.g., Tables
1, 2, 3, and 4). Preferred bispecific molecules comprise only one hapten (e.g., fluorescein)
binding site and will bind a single hapten-labeled antibody, thereby exhibiting a 1:1 ratio of
universal adaptor bispecific molecule to hapten-labeled antibody in the resulting complexes.
Such universal bispeciflc adaptor molecules may be constructed using, for example, the VL
and VH Domains of an anti-PD-l antibody and an anti-fluorescein antibody. Preferably, such
a universal bispeciflc adaptor molecule is ntly bonded diabody or a trivalent binding
molecule sing two, three, four, five, or more polypeptide chains. Representative
universal bispeciflc adaptor molecules which may be ucted are provided below.
A. UBA 1
] One universal ific adaptor molecule that may be generated is a covalently
bonded diabody composed of two polypeptide chains comprising one PD—l epitope-binding
site and one fluorescein binding site (“UBA 1”).
The first polypeptide chain of UBA 1 comprises, in the inal to inal
direction, an N-terminus, the VL Domain of mAb 420 (SEQ ID NO:66), an intervening
spacer peptide (Linker 1, GGGSGGGG (SEQ ID NO:5)), the VH Domain ofPD-l mAb 6 (SEQ
ID NO:57, wherein X1 is I)), an intervening spacer peptide (Linker 2, GGCGGG (SEQ ID
NO:6)), the E—coil Heterodimer—Promoting Domain: EVAALHK—+:VAAL4:K—b1VAALr:K—
+1VAAT. 41K (SEQ ID NO:18)), and a C-terminus.
Thus, the amino acid sequence of the first polypeptide chain of UBA 1 is (SEQ
ID NO:67):
DVVMTQTPFS LPVSLGDQAS :SCQSSQSLV HSNGNTYLRW YLQKPGQSPK
VLIYKVSNRF SGVPDRFSGS GSGTDFTLKI SRVEAEDLGV THVP
WTFGGGT<LE IKGGGSGGGG QVQLVQSGAE VKKPGASVKV SCKASGYSFT
V?QA.PGQGLEWIGV liPSDSLTWL DQKFKDQVTI TVDKSTSTAY
MELSSLRSED TAVYYCAREH YGTSPFAYWG QGTLVTVSSG GCGGGEVAAL
FKfiVAALfiKfi VAALjKfiVAA EEK
-lll-
The second polypeptide chain of UBA 1 comprises, in the N—terminal to C-
al direction, an N—terminus, a VL Domain of PD-l mAb 6 (SEQ ID NO:58, wherein X1
is S and X2 is Q)), an intervening spacer e r 1, GG (SEQ ID NO:5)), the
VH Domain of mAb 4-4—20 (SEQ ID NO:65)), an intervening spacer peptide (Linker 2,
GGCGGG (SEQ ID NO:6)), the K-coil Heterodimer—Promoting Domain: KVAALKE—
KVAALKE—KVAALKE—KVAALKE (SEQ ID NO:19)) and a C-terminus.
Thus, the amino acid ce of the second polypeptide chain ofUBA 1 is (SEQ
ID NO:68):
EIVLTQSPAT LSLS?GERAT LSCRASESVD NYGMSFMNWF QQKPGQPPKL
LIHAASNQGS GVPSRFSGSG SGTDFTLTTS SLEPEDEAVY EVPY
TFGGGTKVEI KGGGGSGGGG EVKLDETGGG LVQPGRPMKL SCVASGFTFS
DYWMNWVQQS PEKGLEWVAQ :QNKPYNYET YYSDSVKGRF TISRDDSKSS
VYLQMNNWRV EUMGTYYCTG SYYGMDYWGQ SSGG CGGGKVAALK
EKVAALKEKV AALKEKVAAL.L K?
B. UBA 2
As provided above, incorporating an IgG CH2-CH3 s onto one
polypeptide chain of a diabody such as UBA 1 will permit a more complex four-chain
bispecific Fc Region-containing diabody to form. Thus a second universal bispecific adaptor
molecule that may be generated is a covalently bonded diabody composed of four polypeptide
chains comprising two PD-l epitope-binding sites, two fluorescein binding sites, and an Fc
Region (“UBA 2”). It will be noted that UBA 2 may bind two fluorescein labeled molecules
via the two fluorescein binding sites.
The first and third polypeptide chains of UBA 2 comprises, in the N—terminal to
inal direction, an N-terminus, a VL Domain of a mAb 420 (SEQ ID NO:66), an
intervening spacer peptide r 1, GGGSGGGG (SEQ ID NO:5)),the VH Domain of PD-l
mAb 6 (SEQ ID NO:57, n X1 is I)), an intervening spacer peptide (Linker 2, GGCGGG
(SEQ ID NO:7)), the E—coil Heterodimer-Promoting Domain: 41VAAL+:K—PIVAALJ«:K—
41VAAT.4'.K—F.VAA’.F.K (SEQ ID NO:18)), an intervening spacer peptide (Linker 3,
GGGDKTHTCPPC? (SEQ ID NO:31)), an IgGl Fc Region comprising substitutions
L234A/LZ35A (SEQ ID NO:43), wherein X is K), and a C-terminus.
Thus, the amino acid sequence of the first and third polypeptide chains of UBA 2
is (SEQ ID NO:69):
DVVMTQTPFS LPVSLGDQAS :SCRSSQSLV HSNGNTYLRW YLQKPGQSPK
VLIYKVSNRF FSGS GSGTDFTLKI SRVEAEDLGV YFCSQSTHVP
WTFGGGT<LE IKGGGSGGGG QVQLVQSGAE VKKPGASVKV SCKASGYSFT
SYWMNWVRQA PGQGLEWHGV liPSDSjTWL DQKFKDQVTI TVDKSTSTAY
MEWSSLRSED AREH YGTSPFAYWG QGTLVTVSSG GCGGGEVAAL
FKfiVAALfi<fi VAALJKfiVAA.L LEKGGGD<TH TCPPCPAPEA AGGPSVFLFP
PKPKDTLWIS CVVV DVSHEDPZVKJ. FNWYVDGVFV HNAKTKPREE
QYWSTYQVVS VLTVLHQDWL NGKEYKC<VS NKALPAP E T SKAKGQPR
LPPS REEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT
PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS
The second and fourth polypeptide chains of UBA 2 are identical to the second
polypeptide chain of UBA 1. Thus, the second and fourth polypeptide chains of UBA 2 each
have the amino acid sequence of SEQ ID NO:68.
C. UBA 3
A third universal bispecific adaptor molecule that may be generated is a
covalently bonded diabody composed of three polypeptide chains sing one PD-l
e-binding site, one fluorescein binding site, and an Fc Region (“UBA 3”).
The first ptide chain of UBA 3 ses, in the inal to C-terminal
direction, an N—terminus, the VL Domain of mAb 420 (SEQ ID NO:66), an ening
spacer peptide r 1, GGGSGGGG (SEQ ID NO:5)), the VH Domain ofPD-l mAb 6 (SEQ
ID NO:57, wherein X1 is I)), an intervening spacer peptide (Linker 2, GGCGGG (SEQ ID
NO:6)), the E-coil Heterodimer—Promoting Domain: EVAALHK—+:VAAL*:K—b1VAALr:K—
+1VAAT~1K (SEQ ID NO:18)), an intervening spacer peptide (Linker 3, GGGDKTHTCPPCP
(SEQ ID NO:31)), a “knob-bearing” IgGl Fc Region comprising substitutions L234A/L235A
(SEQ ID NO:44, wherein X is K)), and a C-terminus.
Thus, the amino acid sequence of the first polypeptide chain of UBA 3 is (SEQ
ID NO:70):
DVVMTQTPFS LPVSLGDQAS :SCRSSQSLV HSNGNTYLRW YLQKPGQSPK
VLIYKVSNRF SGVPDRFSGS GSGTDFTLKI SRVEAEDLGV YFCSQSTHVP
WTEGGGTKLfi KGGGSGGGG QVQLVQSGAE VKKPGASVKV SCKASGYSFT
SYWMNWVRQA WLGV iHPSDSETWL DQKEKDRVTI TVDKSTSTAY
-ll3-
MELSSLRSED AREH YGTSPFAYWG QGTLVTVSSG GCGGGEVAAL
FKfiVAALH<fi VAALEKEVAA LEKGGGDKTH TCBPCBAPS§_§GGPSVFLFP
PK?KDTLMIS RTPEVTCVVV DVSHED?EVK FNWYVDGVEV HNAKTKPREE
QYWSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALBAP 5K T PR
EPQVYTLPPS REEMTKNQVS TWCTVKGFYP SDIAVEWESN GQPENWYKTT
PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS
The second polypeptide chain of UBA 3 may be identical to the second
polypeptide chain ofUBA 1. Thus, the second polypeptide chain ofUBA 3 has the amino acid
sequence of SEQ ID NO:68.
The third polypeptide chains ofUBA 3 comprises, in the N—terminal to inal
direction, an N—terminus, a spacer peptide r 3, DKTHTCPPCP (SEQ ID NO:26)), a
bearing” IgGl Fc Region comprising substitutions L235A (SEQ ID NO:45,
wherein X is K)), and a C-terminus.
Thus, the amino acid sequence of the third polypeptide chain of UBA 3 is (SEQ
ID NO:71):
DKTHTCBPCP APLAAGGBSV PKDT RM SRTBfiVT CVVVDVSHED
PEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLWGKEYK
CKVSNKALBA.P fiKTTSKAK GQPREPQVYT LEBSRZfiWTK CAV<.L
GEYBSDLAV: WESNGQPENN YKTTPPVLDS DGSFFLVSKL TVDKSRWQQG
NVFSCSVMHE ALTNRYTQKS LSLSPGK
D. UBA 4
A fourth sal bispecific adaptor molecule that may be generated is a
covalently bonded trivalent binding molecule composed offour polypeptide chains comprising
two PD-1 epitope-binding sites, one fluorescein binding site, and an Fc Region (“UBA 4”).
The first polypeptide chain of UBA 4 is identical to the first polypeptide chain of
UBA 3. Thus, the first polypeptide chains of UBA 4 has the amino acid sequence of SEQ ID
NO:70.
The second polypeptide chain of UBA 4 is identical to the second polypeptide
chain of UBA 1. Thus, the second polypeptide chain of UBA 4 has the amino acid sequence
of SEQ ID NO:68.
—114—
The third polypeptide chain ofUBA 4 comprises, in the inal to C-terminal
direction, the VH Domain of PD-l mAb 6 (SEQ ID NO:57, wherein X1 is 1)), an IgGl CH1
Domain (SEQ ID NO:40), an IgGl Hinge Region (SEQ ID NO:33), a bearing” IgGl
Fc Region comprising substitutions L234A/L235A (SEQ ID NO:45, wherein X is K)), and a
C-terminus.
Thus, the amino acid sequence of the third ptide chain of UBA 4 is (SEQ
ID NO:72):
QVQLVQSGAE VKKPGASVKV SC<ASGYSFT SYWMNWVRQA PGQGLEWIGV
ETWL DQKFKDRVTI TVDKSTSTAY MELSSLRSED TAVYYCAREH
YGTSPFAYWG QGTLVTVSSA ST {GPSVFPL APSSKSTSGG TAALGCLVKD
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY
ICWVNHKPSN T<VDKRVEPK SC PP CPAPEAAGGP SVFLFPPKP<
DTLMISRTPE VTCVVVDVSH EDBEVKENWY VDGVEVHNAK TKPREEQYNS
TYRVVSVLTV LHQDWLNGKE YKCKVSN<AL PAPIEKTISK AKGQPREPQV
YTLPBSRfifiM TKNQVSLSCA.VKGEYPSDLA GQPE PPVL
DSDGSFFTVS KWTVDKSRWQ QGNVFSCSVM HEALHNRYTQ KSLSLS?GK
The fourth polypeptide chain of UBA 4 comprises, in the N-terminal to C-
terminal direction, the VL Domain of PD-l mAb 6 (SEQ ID NO:58, n X1 is S and X2
is Q)), a CL Domain (e.g., an IgG Kappa Domain (SEQ ID N0:38), and a C-terminus.
] Thus, the amino acid sequence of the fourth polypeptide chain of UBA 4 is (SEQ
ID NO:73):
SPAT ERAT LSCRASESVD NYGMSFMNWF QQKPGQ?PKL
LIHAASNQGS GVPSRFSGSG SGTDFTLT S SLfiPfiDhAVY ECQQSKEVPY
TFGGGTKVE“ PSVE EPBS)HQLK SGTASVVCLL WNFYPREAKV
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTWSKADY EKHKVYACEV
THQGLSSPVT KSFNRGEC
E. UBA 5
A fifth universal bispeciflc adaptor molecule that may be generated is a covalently
bonded trivalent binding molecule composed of three polypeptide chains comprising two PD-
1 epitope-binding sites, one fluorescein binding site, and an Fc Region (“UBA 4”) (see, e.g.,
Figure 6C-6D).
The first polypeptide chain of UBA 5 is identical to the first polypeptide chain of
UBA 3. Thus, the first polypeptide chains of UBA 5 has the amino acid sequence of SEQ ID
NO:70.
The second polypeptide chain of UBA 5 is identical to the second ptide
chain of UBA 1. Thus, the second polypeptide chain ofUBA 5 has the amino acid sequence
of SEQ ID NO:68.
The third polypeptide chain ofUBA 5 comprises, in the N—terminal to C-terminal
direction, the VL Domain of PD-l mAb 6 (SEQ ID NO:58, wherein X1 is S and X2 is Q)), an
ening spacer peptide (Linker 4, GGGGSGGGGSGGGGS (SEQ ID NO:37)), the VH
Domain of PD-l mAb 6 (SEQ ID NO:57, n X1 is 1)), an IgGl CH1 Domain (SEQ ID
NO:40), an IgGl Hinge Region (SEQ ID NO:33), a “hole-bearing” IgGl Fc Region
sing substitutions L234A/L235A (SEQ ID NO:45, wherein X is K)), and a C-terminus.
] Thus, the amino acid sequence of the third polypeptide chain of UBA 5 is (SEQ
ID NO:74):
EIVLTQSPAT LSLSPGERAT LSCRASESVD NYGMSFMNWF PPKL
LIHAASNQGS GVPSRFSGSG SGTDFTLTTS SLEPEDEAVY ECQQSKEVPY
TFGGGTKVZ.L KGGGGSGGGG SGGGGSQVQL VQSGAEVKKP GASVKVSCKA
SGYSFTSYWM NWVRQAPGQG LfiWlGV HBS DSLTWLDQKF KDRVTITVDK
STSTAYMELS SLRSEDTAVY YGTS PFAYWGQGTL VTVSSASTKG
PSVFPLAPSS KSTSGGTAAL GCLVKDYFPE PVTVSWWSGA LTSGV TFPA
VLQSSGLYSL SSVVTVPSSS LGTQTYICNV NHKPSNTKVD KRVEPKSCDK
THTCPPCPAP EAAGGPSVFL FPPKPKDTTM SQTPfiVTCV VVDVS fiDPfi
VKFWWYVDGV EVHNAKTKPR EEQYNSTYRV WLNGKEYKCK
VSN<ALPAPI EKTISKAKGQ PQEPQVYTLP VSLSCAVKGF
YPSDLAVfiWfi SNGQPENNYK TTPPVLDSDG SFFLVSKLTV DKSRWQQGNV
HEAL HNRYTQKSLS LS?GK
Using tional s, TLA-4 antibodies may be labeled with
fluorescein. When such labeled molecules are incubated in the presence of a universal
bispeciflc adaptor molecule provided above having an epitope-binding site that binds to PD-l
and an epitope-binding site that binds to fluorescein, they form a PD-l X CTLA—4 bispecific
molecule, which may be assayed as described below.
It will be appreciated in view of the teachings provided herein that different VH
Domains, VL Domains, linkers, heterodimer promoting domains, and/or IgG Constant
Domains could be utilized to generate alternative universal bispecific adaptor molecules. For
e, the VH and VL Domains of an anti-CTLA-4 antibody and/or a different anti-PD-l
antibody could be used in place of the VH and VL Domains of the employed D-l
antibody to generate alternative or lent universal bispecific adaptor molecules.
-ll6-
Alternatively, the VH and VL Domains of an anti-CTLA-4 antibody may be used in place of
the VH and VL Domains of the anti-fluorescein antibody to generate PD-l X CTLA—4
bispecific les having the general structure of Variations I, II, III, V and VI provided
above, Such PD-l X CTLA—4 bispecific molecules may be used directly in the assays described
below.
Example 4
Assays
The PD-l X CTLA-4 bispecif1c molecules of the t invention may be
characterized in any of a variety of ways. In particular, PD-l X CTLA-4 bispecific molecules
of the invention may be d for their ability to immunospecifically bind to the PD-l and
CTLA-4 molecules (e.g., as present on a cell surface, etc), and/or the binding kinetics of the
interactions with antigen may be determined. Where the bispecific molecules comprise an Fc
region (or portion thereof), their ability to exhibit R interactions, e.g., specific binding
of an Fc region (or portion thereof) to an FcyR, ion of effector function, signal
transduction, etc, may be assayed. The immunomodulatory activity and/or in vivo anti-tumor
efficacy of the PD-l X CTLA-4 bispecific molecules of the invention may be assayed using in
vitro and in vivo assays known in the art.
A. Preparation of Immune Cells and Cell Expressing PD-l and/or CTLA-4
1. Isolation of PBMCs and Immune Cell ulations from
Human Whole Blood
PBMCs from healthy human donors are isolated from whole blood, for example,
using Ficoll gradient centrifugation. Briefly, whole blood is diluted 1:1 with sterile phosphate
buffered saline (PBS). The diluted blood (35 mL) is d onto 15 mL ofFicoll-PaqueTM Plus
in a 50 mL tube and the tubes are centrifuged at 400 x g (1320 rpm) for 30 minutes with the
brake off. The buffy—coat layer between the two phases is collected into 50 mL tubes and
centrifuged at 600 x g (1620 rpm) for 5 minutes. The supernatant is discarded and the cell pellet
is washed 3 times with PBS (e.g., by centrifuging the tubes at 600 x g (1620 rpm) for
minutes). Viable cell count is determined using Trypan Blue dye. The PBMCs are
ended in complete culture medium (e.g., RPMI 1640, 10% PBS, 1% pen/strep) and
incubated at 37°C with 5% C02 overnight or are r processed to isolate a desired immune
cell ulation such as T cells, (e.g., T regs, CD8, CD4), NK cells, dendritic cells and
monocytes as described below.
-ll7-
] Particular immune cell ulations are readily isolated from PBMCs using a
commercial preparation kit (e.g., the UntouchedTM human T cell isolation kits for isolation of
s, CD4 T-cells, CD8 s, tes, Dendritic Cells (Life
Technologies/ThermoFisher Scientific); the DYNABEADS® Regulatory CD4+/CD35+ T
Cell Kit for isolation of T regulatory cells (CD4+/CD25+) (ThermoFisher), etc), according to
the manufacturer’s instructions. After isolation, the immune cell subpopulation (e.g., T cells)
are resuspended in the appropriate complete culture medium (e.g., RPMI 1640, 10% PBS, 1%
penicillin/ streptomycin, which may be supplemented with cytokines (e.g., IL-2, GM-CF, IL-
4, TNF-a, etc.) and incubated at 37°C with 5% C02 overnight. As provided herein such
purified subpopulations are useful to evaluate cell e expression of PD-l and/or CTLA-4
and for evaluation of the immune atory activity of the PD-1 X CTLA-4 bispecific
molecules of the invention.
2. Isolation Of PBMCs From Cynomolgus Monkey Or Rhesus
Monkey Whole Blood
PMBCs from Cynomolgus monkey or Rhesus monkey are ed from whole
blood, for example using Ficoll gradient centrifugation. Briefly, whole blood is diluted 1:3
with sterile PBS. Diluted blood (35 mL) is layered onto 15 mL of 90% -PaqueTM Plus
(90 mL Ficoll + 10 mL PB S) in a 50 mL polypropylene centrifuge tube and centrifuged at 931
X g (2000 rpm) for 30 minutes at room temperature with the brake off. The buffy—coat layer
between the two phases is collected and transferred to a clean 50 mL tube and washed with 45
mL PBS by centrifuging the tubes at 600 x g (1620 rpm) for 5 minutes. The supernatant is
discarded and the pellet is rinsed 3X with PBS. Cynomolgus or Rhesus monkey PBMCs are
then resuspended in 30 mL of te culture medium and viable cell count is determined by
Trypan Blue dye exclusion.
Particular immune cell ulations are readily isolated from non-human
primate PBMCs using a commercial preparation kit (e.g., Pan T-cell, CD4+ T-Cell, and
CD4+/CD25+ Treg isolation kits (Miltenyl Biotech)), according to the manufacturer’s
instructions. Alternatively, flow cytometric sorting using non-human primate specific or cross-
reactive mAbs can be used for sorting.
3. Generation Of Human Immature Or Mature d-Derived
Dendritic Cells (mDC) Cells From Isolated Human Monocytes
Human monocytes are isolated from donor derived purified PBMCs using a
commercial preparation kit (e.g., the UntouchedTM human monocyte kit (Life
Technologies/ThermoFisher ific) according to manufacturer’s instructions. Isolated
human monocytes are induced to differentiate into human immature mDCs by culturing
monocytes (e.g., in alpha m Essential Media with nucleosides (OLMEM) media + 2%
human AB-negative serum + 1% penicillin/streptomycin) for 5-7 days in the presence of
recombinant human granulocyte macrophage-colony stimulating factor (e.g., hGM-CSF,
Peprotech, 100 ng/ml) and recombinant human interleukin-4 (hIL-4, Peprotech, 40 ng/ml).
Immature mDCs are harvested and washed with PBS by centrifuging the tubes at 600 x g (1620
rpm) for 5 s for use as stimulator cells in allogeneic mixed lymphocyte reaction (allo-
MLR) assays, such as those detailed below.
In certain allo—MLR experiments immature mDCs are induced to differentiate by
adding TNFOL or a cocktail of additional cytokines (TFNv, E-IB) and mitogens (LPS) for two
additional days of culture (see, e.g., Han, T. (2009) “Evaluation of 3 al Dendritic Cell
Maturation Protocols Containing LPS and IFN-gamma, ” J Immunother 321399). The purity,
maturation and activation of mDCs may be ted by flow cytometry using one or more of
the ing antibodies: D14, D80, anti-CD83, anti-CD86, anti-HLA-DR; and
the appropriate isotype ls. The flow cytometric data from such evaluations may be
acquired on a FACSCalibur/Fortessa n Dickinson/BD Biosciences) and analyzed using
FlowJo software (TreeStar).
4. sion of PD-l and CTLA-4
Cells expressing PD-l and/or CTLA-4 may be generated using methods known
in the art. For example, cells (e.g., NSO, Jurkat, CHO, etc.) may be engineered to express PD-
1 and/or CTLA-4 using retroviral vectors containing the appropriate gene (e.g., human PD-l
gene). Alternatively, immune cells may be stimulated to induce or increase the expression of
PD-l and/or . Briefly, purified immune cells (e.g., PBMCs, T-cells, dendritic cells,
etc.) isolated as described above are cultured for 2-6 days in the presence or absence of a
mitogen and the expression of PD-l and/or CTLA-4 is examined on the untreated (Naive) and
stimulated cells, for e using flow cytometry. Commercial anti-PD-l and anti-CTLA-4
antibodies can be used for preliminary evaluation of the expression patterns on Naive cells and
-ll9-
in response to mitogen stimulation. Additionally, or optionally the PD-l X CTLA-4 bispeciflc
les of the invention may be used.
Mitogens which may be utilized for such studies are well known in the art and
include, but are not limited to: CD3/CD28 beads, lipopolysaccharides (LPS), Staphylococcus
aureus enterotoxin types A-E (e.g., SEB), phorbol myristate acetate (PMA),
phytohemagglutinin (PHA), concanavalin A (conA), pokeweed n (PWM), etc.
Mitogen(s) identified as inducing/enhancing the expression of PD-l and/or CTLA-4 may be
used in functional assays to evaluate the stimulatory activity of the PD-l X CTLA—4 bispecif1c
molecules of the present invention. See for example the “SEB”, and “MLR” assays described
herein.
B. Binding Assays
Immunoassays that can be used to analyze speciflc binding to PD-l or
CTLA-4 molecules, binding cross-reactivity, or Fc-chR interactions include, but are not
limited to, competitive and non-competitive assay systems using techniques such as western
blots, radioimmunoassays, ELISA (enzyme linked immunosorbent , “sandwich”
immunoassays, precipitation assays, precipitin reactions, gel diffusion precipitin
reactions, immunochromatographic assays, immunodiffusion assays, agglutination assays,
complement—fixation assays, radiometiic assays, fluorescent immunoassays, and
protein A immunoassays, etc. (see, e.g., Ausubel et al., 2008, t ols in Molecular
Biology). Binding affinity for a target n is typically measured or determined by standard
antibody-antigen assays, such as Biacore itive assays, saturation assays, or
immunoassays such as ELISA or RIA. scence activated cell sorting (FACS), using any
of the techniques known to those skilled in the art, is used for immunological or functional
based assays to characterize the PD-l X CTLA-4 ific molecules of the invention.
For example, PBMCs may be prepared as described above. Where desired
immune cell subsets (e.g., T regulatory, T helper, APCs, etc.) may be isolated from the purified
PBMC. The isolated cells are then examined for PD-l and CTLA—4 expression on various cell
subsets (e.g, T tory, T helper, APCs, etc.) by co-staining and FACS analysis as described
below.
1. Cell Surface Binding (Saturation Assay)
] The ability of PD-1 X CTLA-4 bispecific les to bind to PD-l and/or
CTLA-4 expressed on the cell surface may be measured in saturation/dilution based assays
using a cell that expresses PD-l and/or CTLA-4 (target cells). Such cells may be immune cells
stimulated to expressed PD—l and/or CTLA-4, or a cell line (e.g., NSO cells) engineered to
stably over-express PD-l and/or CTLA-4 molecules. Briefly, cultured s cells (e.g., NSO
cell ered to s PD1+) are harvested and resuspended (e.g., about 5x106 cells/ml) in
blocking buffer (e.g., FACS buffer + 10% human AB Serum). Starting at equal molar
concentrations (e.g., 20nM in total of 200 pl) a PD—l X CTLA-4 bispecific molecule, an anti-
PD-l antibody, an anti-CTLA-4 or a combination of anti-PD-l and anti-CTLA-4 antibodies
are prepared for dilution in a separate microtiter plate and then serially diluted (e.g., 1:4, 1:5,
1:10, etc.) 5-12 times to generate a 5-12 point curve. The highest starting concentration in all
experiments is determined empirically. The same volume (e.g., 50 pl) of each dilution is added
to a new microtiter plate and target cells are added to each well (e.g., 0.25x106 cells/well) and
incubated (e.g., at 4-25°C for 30-120 minutes). The cells are washed 1-3 times (e.g., the
microtiter plate is spun at 600 x g (1620 rpm) for 5 minutes and then washed with blocking
buffer and spun again) and resuspended in blocking buffer. For ary staining, the
appropriate secondary regent is selected, for example a goat anti-Human Fc-APC may be used
to detect human primary antibodies, while a goat Anti-Mouse IgG Fc Alexa Fluor 647 is used
to detect mouse primary antibodies. The selected secondary reagent is d in blocking
buffer and based on the tration of the individual secondary, a stock solution is made and
the same volume/well of the secondary mixture is aliquoted to individual wells and incubated
(e.g, at 4-25°C 30-120 minutes). The cells are washed as described above and resuspended in
blocking buffer. The stained cells are ed by flow try. The flow cytometric data
may be acquired on a FACSCalibur/Fortessa (Becton Dickinson/Fortessa), ed as mean
fluorescent intensity using FlowJo software (TreeStar), and plotted and fitted using the
log(agonist) vs. response —Variable slope (four parameter) function in Prism6 software
(Graphpad).
2. Receptor/Ligand Binding and Signaling Assays
Assays that can be used to analyze the ability of the PD-l X CTLA—4 bispecific
molecules of the invention to modulate (e.g., block, inhibit, stimulate, etc.) ligand g and
signaling are provided in more detail below.
a. PD-l Receptor/Ligand Binding
The y of PD-l X CTLA-4 bispecific molecules to inhibit PD-l from binding
PD-Ll and/or PD-L2 may be evaluated using cells that express PD-l (target cells). Such cells
may be immune cells ated to s PD-l, or a cell line engineered to express PD-l
molecule, for example NSO—cells retrovirally transduced with the human PD-l gene. Briefly,
PD-l expressing cells (e.g., NSO/PDCDl (NSO-PD1+)) are harvested and resuspended (e.g.,
about 1.5x106 cells/ml) in blocking buffer (e.g., FACS buffer + 10% Human Ab Serum) and
plated in a microtiter plate (e.g., 0.25x106 cells/well). Starting at equal molar trations
(e.g, 20nM in total of 200 pl) of a PD-1 X CTLA-4 bispecific molecule, an anti-PD—l antibody,
an anti-CTLA-4, or a combination of anti-PD-l and TLA-4 dies are ed for
on in a separate microtiter plate and serially diluted (e.g., 1:4, 1:5, 1:10, etc.) 5-12 times
to generate a 5-12 point curve. The highest starting concentration in all experiments is
determined empirically. The same volume (e.g., 50 ul) of each dilution is added to each well
of the microtiter plate containing the target cells. To evaluate the inhibition of PD-Ll binding
a soluble PD-Ll fusion n (e.g., hPD-Ll (B7Hl) TEV-hIgGl—Fc-biotin (Ancell))is added
to each well with the exception of unstained negative control wells and incubated (e.g., at 4-
°C for 30-120 minutes). To evaluate the inhibition ofPD—L2 binding a soluble PD-L2 fusion
protein (e.g, CD273 ) mngG/biotin (Ancell)) is added to each well with the exception
of unstained negative control wells and incubated (e.g., at 4-25°C for 30-120 minutes). The
cells are washed 1-3 times (e.g., the microtiter plate is spun at 600 x g (1620 rpm) for 5 minutes
and then washed with blocking buffer and spun again). The cells are ended in blocking
buffer. With the exception of unstained negative control wells, the appropriate secondary
reagent for detection of the PD-Ll or PD-LZ fusion protein (e.g., streptavidin-PE labeled
secondary (eBiosciences)) is added and incubated (e. g., at 4-25°C for 15—120 s). The
cells are washed as described above and resuspended in blocking buffer. The stained cells may
be analyzed by flow cytometry. The flow tric data may be acquired on a
FACSCalibur/Fortessa (Becton Dickinson/Fortessa), and analyzed for the loss mean
fluorescent intensity of labeled sPD-Ll or sPD-L2 in the presence of a PD-l X CTLA-4
bispecific molecule, an anti—PD-l antibody, an anti-CTLA-4, or a combination of anti-PD-l
and anti-CTLA-4 antibodies using FlowJo software (TreeStar), and plotted and fitted using the
log(agonist) vs. response —variable slope (four parameter) function in Prism6 re
(Graphpad).
b. CTLA-4 Receptor/Ligand Binding
The ability of PD-1 x CTLA-4 bispecific molecules to inhibit CTLA-4 from
binding CD80 and/or CD86 may be evaluated using cells that express CTLA-4 t cells).
Such cells may be immune cells stimulated to express CTLA-4, or a cell line engineered to
express CTLA-4, for example lls retrovirally transduced with the human CTLA-4 gene.
Briefly, CTLA-4 expressing cells are harvested and resuspended in blocking buffer (e.g., FACS
buffer + 10% Human Ab Serum) and plated in a microtiter plate (e.g., 0.25x106-10x106
cells/well). ng at equal molar trations (e.g., 20nM in total of 200 pl) of a PD-l X
CTLA-4 bispecific molecule, an anti-PD-l antibody, an anti-CTLA-4, or a ation of anti-
PD-l and anti-CTLA-4 antibodies are prepared for dilution in a separate microtiter plate and
serially diluted (e.g., 1:4, 1:5, 1:10, etc.) 5-12 times to generate a 5-12 point curve. The highest
starting concentration in all experiments is determined empirically. The same volume (e.g., 50
ul) of each dilution is added to each well of the microtiter plate containing the target cells. To
evaluate the inhibition of CD80 binding a soluble CD80 fusion protein (e.g., hCD80-mng-
biotin (ADIPOGEN®)) is added to each well with the exception of unstained negative control
wells and incubated (e. g., at 4-25°C for 30-120 minutes). To evaluate the inhibition of CD86
binding a e CD86 fusion protein (e.g., hCD86-mng—biotin (ADIPOGEN®)) is added to
each well with the exception of unstained negative control wells and incubated (e.g., at 4-25°C
for 30—120 minutes). The cells are washed 1-3 times (e.g., the microtiter plate is spun at 600 x
g (1620 rpm) for 5 minutes and then washed with blocking buffer and spun again). The cells
are resuspended in blocking buffer. With the exception of unstained ve control wells,
the appropriate secondary reagent for detection of the CD80 or CD86 fusion protein (e.g.,
streptavidin-PE d secondary (eBiosciences)) is added and ted (e.g., at 4-25°C for
-120 s). The cells are washed as described above and resuspended in ng buffer.
The stained cells may be analyzed by flow cytometry. The flow cytometric data may be
acquired on a libur/Fortessa (Becton Dickinson/Fortessa), and analyzed for the loss
mean cent intensity of labeled CD86 or CD80 in the presence of a PD-l X CTLA-4
bispecific molecule, an anti-PD-l antibody, an anti-CTLA-4, or a combination of anti-PD-l
and anti-CTLA-4 antibodies using FlowJo software (TreeStar), and plotted and fitted using the
log(agonist) vs. se —variable slope (four parameter) function in Prism6 software
(Graphpad).
C. Reporter Assays
] The functional activity of PD—l X CTLA-4 bispecific molecules in blocking the
interaction ofPD-l with PD—Ll may be assessed using a commercial reporter system developed
by a according to the manufacturer’s direction. Briefly, two cell lines engineered to
function as either a stimulator line or reporter cell line are used. The ator line was
engineered from a CHO-parental line to express the PD-L1 molecule and a T cell activator,
which is a membrane bound anti-CD3 agonist mAb [CHO/PDLl cells]. The reporter cell line
was engineered from a CD3-positive Jurkat parental line to express a luciferase reporter
construct under the transcription control of nuclear factor of activated T-cells (NFAT) [NFAT-
luc2/PD-1 Jurkat cells]. When cultured together, the anti-CD3 agonist expressed on the CH0-
PDLl cell line drives rase expression by the NFAT signal transduction pathway mediated
by the engagement of the TCR/CD3 signaling complex present on the Jurkat-NFAT-luc/PD-l
cell line. In the absence of anti-PD-l or anti-PD—Ll dies, rase is sed at a
level relative to TCR/CD3 signaling but down-modulated or inhibited by the presence of the
PD-l/PD-Ll inhibitory axis, which functions as a brake. In the ce of molecules which
inhibit PD—l/PD-Ll signaling (e.g., anti—PD-l or anti-PD-Ll antibodies), this inhibitory axis
or “brake” is released, permitting ed luciferase expression that can be measured.
Accordingly, the PD-1 tory activity of PD-l X CTLA-4 bispecific molecules may be
evaluated by culturing Ll with ch/PDl Jurkat (3H-D5). Briefly, CHO-
PDL1 are plated into a microtiter plate (e.g., at 4.0x104 cells/well) and cultured overnight (e.g.,
in RPMI media ning 10% FBS + lOOug/mL Hygromycin B + 500ug/mL G418). The
next day, assay buffer (6.9., RPMI + 2% FBS is prepared along with a 5-12 point serial dilution
of a PD-l X CTLA-4 bispecific molecule, or an D-l antibody in assay buffer with highest
dilution point at equal molar equivalence (e. g., 100-200 nM) and 5-12 serial dilutions (e.g.,
1:4, 1:5, 1:10, etc.) are prepared. In the following order, a portion of cell the culture media is
removed from the microtiter plate containing adherent CHO/PDLl cells and aliquots of each
dilution are added to the CHO/PDLl cells. Cultured NFAT-lch/PD-l Jurkat cells are
harvested and resuspended in assay buffer and added (e.g., 5.0x104 cells/well in 40u1/well) to
the Ll cells. The co-culture is incubated (e.g., for 6 hours at 37°C). At the end of the
incubation, Bio-G10 substrate (Promega) is reconstituted and added to the ambient temperature
equilibrated iter plate. Following incubation (e. g., 5—10 minutes) the optical density of
each well is read on a VICTORTM X4 Multilabel Plate Reader (Perkin Elmer #2030-0040) at
450nm with luminescence relative light unit (RLU) as the readout. The data may then be plotted
—124—
and fitted using the log(agonist) vs. response —variable slope (four parameter) function in
Pri sm6 software (Graphpad).
Similar reporter assays are available for CTLA-4 ing (e.g., CTLA-4
Blockade Bioassay Kit (Promega)) and/or may be readily generated to analyze the functional
activity of PD-l X CTLA-4 bispecific molecules in ng the ction CTLA-4 with its
respective ligand(s).
D. Immunomodulatory Assays
Assays that can be used to analyze the immunomodulatory activity of the PD-l X
CTLA-4 ifrc molecules of the invention include n stimulation assays such as the
“SEB” assay detailed above, and Mixed Lymphocyte Reaction (MLR) assays such as those
provided in more detail below. The ability of the PD-l X CTLA-4 bispecifrc molecules of the
invention to modulate both the PD-l and the CTLA-4 inhibition pathways is expected to
provide enhanced stimulation in assays as compared to anti-PDl and anti— CTLA-4 antibodies
alone or the combination of such antibodies.
PBMCs or T cells are ed from the blood of the same (autologous) or
unrelated (allogeneic) patient(s) healthy donor(s) blood by centrifugation over a Ficoll-
PaqueTM gradient as described above and resuspended in te culture medium. For allo-
MLR assays that employ mDCs, monocytes are purified and d as be above. For
one-way (unidirectional) allo-MLR assays der cells (e.g., PBMCs) are co-cultured with
stimulating cells in a microtiter plate. Depending on the context, stimulating cells are DCs,
autologous PBMCs (for auto-MLR, i.e., negative control), or allogeneic PBMCs (for allo-
MLR, i.e., positive control). The ratio of responderzstimulating cells is typically 1:1 or 2: 1, but
may be varied. The co-cultures are performed in the presence of equal molar amounts of serial
(e.g., 1:4 1:5, 1:10, etc.) dilutions of a PD-l x CTLA-4 bispecifrc molecule, an anti-PD-l
antibody, an anti-CTLA-4, a combination of anti-PD-l and anti-CTLA-4 antibodies, or the
corresponding isotype mAbs. Serial antibody dilutions may be prepared as described above.
In addition, single cell populations ls ated with or without anti-CD3 +/- anti-CD28
mAbs may be used as controls in such experiments. ating cells (stimulators) are pre-
irradiated (e.g., at 45 grays[Gy] (4500 rads) using a Gammacell® 3000 Elan Blood/Cell
Irradiator (Theratronics)) to prevent eration ofthe stimulator cells and allow measurement
of only the proliferation of the responding cell (responders). After 5 -7 days (the time will be
adjusted to ensure expression of PD-1 and CTLA-4 during the assay), [3H]-thymidine (e.g., 1
uCi/well (Perkin Elmer)) is added for r 18-48 hours. The radioactivity incorporated into
DNA is measured in (e.g. in a TOPCount NXT B-scintillation counter n Elmer)). Results
are expressed as either mean counts per minute (cpm) or expressed as stimulation index (SI)
allowing the comparison of results from different donors. SI is calculated as follows: mean
counts per minute (cpm) from stimulated cells divided by mean cpm from non-stimulated cells.
MLR responses are considered positive when SI was 23 for PBMC-induced ation and
$12 6 for DC-induced stimulation. Alternatively, proliferation may be measured, using a
CEFSE-based proliferation assay (Boks, M.A., et al. (2010) “An optimized CFSE based T-cell
suppression assay to evaluate the suppressive ty ofregulatory T—cells induced by human
tolerogenic dendritic ” Scand J Immunol 72: 158—168).
Additional MLR assays which may be used to evaluate the immune stimulatory
activity of the PD-l x CTLA-4 bispecific molecules of the invention are known in the art. See,
for example,Davies, IK. et al. (2011) “Induction of alloantigen—specific anergy in human
peripheral blood mononuclear cells by tigen ation with co-stimulatory signal
blockade,” Journal of Visualized Experiments: JoVE, (49), 2673; Kruisbeek, A.M., et al.
(2004) “Proliferative Assays for T cell Function,” CURRENT PROTOCOLS IN IMMUNOLOGY,
60:III:3.12.1—3.12.20; Wallgren, AC. et al. (2006) “The Direct Pathway OfHuman T-Cell
Allorecognition Is Not Tolerized By Stimulation With Allogeneic Peripheral Blood
Mononuclear Cells Irradiates With High-Dose Ultraviolet,” Ba. Scand J of Immunol 63:90-
96, Levitsky, J. et al. (2009) “The Human 'Treg MLR' Immune Monitoring for Foxp3+ T
regulatory cell generation, Transplantation 88: 1303-1 1.
E. In Vivo Anti-Tumor Assays
The anti-tumor activity of the PD-l X CTLA-4 bispeciflc les of the
ion may be evaluated in various animal models known in the art. Treatment with the
PD-1 X CTLA-4 bispecific molecules of the invention is ed to inhibit tumor
establishment and/or tumor growth to a greater extent than treatment with anti-PD1 and anti-
CTLA-4 antibodies alone or the combination of such antibodies.
Murine xenograph tumor models are particularly . Briefly, mice are
implanted with a cancer cell line, or tumor cells of interest and are d with (i) a PD-1 X
CTLA-4 bispecific molecule (ii) an anti-PD-l antibody (iii) an anti-CTLA-4 antibody (iv) a
combination of anti-PD-1 and anti-CTLA-4 antibody, and (vi) no-treatment control which may
be vehicle alone and/or an irrelevant antibody. Treatment may begin prior to implantation
(e.g., 1 day before (i.e., day -1)); on the same day as implantation (i.e., day 0), or after
ishment of a tumor (e. g., day 7). The animals may receive a single treatment or may
receive multiple treatments (e.g., weekly post tation). The animals are monitored over
time to determine the in vivo effect of these molecules on tumor establishment and/or growth.
Growth of tumors may be monitored my measuring the tumors and determining the tumor
volume (height X width X length). Treated animals which show complete tumor regression can
be used to examine tumor-specific immunity by lenge using the same or tumor cells and
irrelevant tumor cells as a control. In addition, these models may be modified to include
combination treatment with standard of care treatments such as chemotherapy, radiation, etc.
Numerous transplantable cancer cell lines which may be utilized in such
xenograph models are known in the art and include, but are not limited to: MDSTS, SW480
and SW620 colorectal cancer cells; AGS gastric cancer cells, UACC-62, A2058, and LOX
IMVI melanoma cells, 22rv prostate cancer cells, AsPC-l and BXPc-3 pancreatic cancer cells,
Caki-l, A498 and 786-0 renal cancer cells; HT—1197 Bladder cancer cells; 4T1, MDA—l\/fl3-
231, mammary cancer cells, A549, WX322 Lung cancer cells, HT1080 Fibrosarcoma cells,
HBL-2 human mantle cell lymphoma cells, Raji Burkitt’s lymphoma cells. Particularly
preferred are Patient—Derived Xenograft (PDX) models. Such cancer cell lines, or patientderived
tumors are engrafted into immunocompromised mice strains (e.g., Nude mice, Scid
mice, NOD mice, Rag 1 null mice, etc. (see, e.g., Belizario, J.E., (2009) “Immunodeficient
Mouse Models: An Overview,” m Open 1874-2262/09) or humanized mice such as
enic human HLA-A2 mice (see, e. g., Shultz, L.D., et al. (2012) ized mice for
immune system investigation: progress, promise and challenges,” Nature Rev Immunol
12:786-798) as described above. In addition, for evaluation of molecules which te
immune checkpoint immune—deficient mice may be engrafted with human immune system
components (e.g., reconstituted with human PBMCs, stem cells, immune progenitor cells, etc.)
prior to or concurrently with implantation of the d tumor cells and treatment as detailed
above.
Example 5
PD-l x CTLA-4 Bispecific Molecules g Studies
] Several PD-l X CTLA-4 bispeciflc molecules were generated, including Fc
Region-containing diabodies and Fc-Region-containing trivalent les comprising four
polypeptides chains. Three diabodies having four polypeptide chains and comprising E/K—coil
Heterodimer—Promoting Domains were generated and accorded the designations “DART B,”
“DART C,” and “DART D.” One diabody having four chains and sing CHI/CL
Domains was generated and accorded the designation “DART E.” Two trivalent binding
molecules having four chains and comprising E/K-coil dimer-Promoting Domains and
CHI/CL Domains were ted and accorded the designations “TRIDENT A,” and
“TRIDENT B.”
In on, several antibodies having specificity for PD—l or CTLA-4 were
generated. One antibody specific for PD-l was generated and accorded the designation “PD-
1 mAb 6 G4P.” Three antibodies specific for CTLA-4 were generated and ed the
designations “CTLA-4 mAb 1,” “CTLA-4 mAb 3 GlAA,” and “CTLA-4 mAb 3 G4P.”
The structure and amino acid sequences of these PD-l X CTLA—4 bispecific
molecules, anti-PD-l antibodies, anti-CTLA-4 antibodies are provided above and are
summarized in Table 9 below.
Table 9
. . . SEQ ID Other
l 95
CTLA-4 mAb l IgG4 2 96
DART B E/K-Colls, see
PD-l mAb 6-ISQ (YTE) 3 95 F1gure 3B
4 96
1 97
CTLA-4 mAb 3 2 98 E/K-Coils; see
DART C IgG4
PD-l mAb 6-ISQ 3 97 Figure 3B
4 98
l 99
PD-l mAb 6-ISQ IgG4 2 100
DART D E/K-Cofls, see
CTLA-4 mAb 3 (YTE) 3 99 F1gure 3B
4 100
CTLA-4 mAb 3 IgG4 2 CL/CHl, see
DART E
PD-l mAb 6-ISQ (YTE) 3 Figure 3c
1 101
PD-l mAb 6-ISQ IgGl 2 100 E/K-Coils; see
DART F
CTLA-4 mAb 3 (AA/YTE) 3 101 Figure 3B
4 100
-l28-
Table 9
. . . SEQ ID Other
1 104
E/K-Coils and
PD-l mAb 6-ISQ IgG4 2 105
TRIDENT A .
CTLA-4 mAb 3 (YTE) 3 106 C1?CHl’ see1gure 6A
4 107
1 108
E/K-Coils and
PD—1 mAb 6-ISQ IgGl 2 105
TRIDENT B '
CTLA-4 mAb 3 (AA/YTE) 3 109 C1?CHl’ see1gure 6A
4 107
1 88
PD-l mAb 6 2 89 natural antibody
PD‘I mAb 6_ISQ IgG4
G4P 3 88 structure
4 89
CTLA-4 811111413343?b 1 l antibody
I G1 4 M
p g
mAb l . structure
repllca)
1 92
CTLA 4
2 94 natural amlbOdy
mAb 3 CTLA-4 mAb 3 IgGl (AA)
3 92 ure
4 94
1 93
CTLA-4 2 94 l antibody
CTLA'4 mAb 3 IgG4
mAb 3 G4P 3 93 structure
4 94
J: les incorporating IgG4 Fc regions also incorporate a stabilized IgG4 hinge region.
** the same amino acid sequence as ipilimumab (see, e.g., IMGT 3D and 2D Structural
Database Accession Nos. 8568_H and 8568_L)
] Additional PD—l X CTLA-4 ific molecules comprising alternative PD-l
and/or CTLA-4 epitope-binding sites may be readily generated by orating different VH
and VL Domains. Similarly, molecules comprising alternative linkers, Fc Regions, and/or
having alternative structures may be generated as provided herein (see, e.g., Table 8).
A. ELISA Binding Studies
ELISA studies were conducted to measure the binding of serially diluted binding
molecules (antibody CTLA—4 mAb 3 G4P, DART D, T A or DARTB) to soluble
hCTLAAvi-His (1 ug/mL) or hPD-l-His (l ug/mL) that had been coated onto support
plates. Goat anti—human-Fc-HRP (1:10,000) was employed as the secondary detection
molecule to detect binding. The results of such studies are shown in Table 10 and in Figures
8A-8B. The data shows that PD-l x CTLA-4 bispecific molecules having two binding sites
for PD-l and CTLA-4 (e.g, DART D and DART B) ted binding to PD-l and CTLA-4
that was similar to that of their respective parental anti-PD-l and anti—CTLA-4 antibodies. PD-
1 x CTLA-4 bispeciflc les having two binding sites for PD-l and one binding site for
CTLA-4 (e.g, TRIDENT A) exhibited binding to PD-1 that was similar to that of the parental
anti-PD-l antibody and exhibited reduced binding to CTLA-4 (relative to that of the parental
antibody) due to the d avidity of the trivalent molecule, which comprises only a single
binding site for CTLA-4. Similar g results were observed for DART F and T
B having IgGl CH1 and/or IgGl (AA/YTE) Fc regions.
Table 10
Construct ECso of CTLA-4 Bindin_ nM ECso of PD-l Bindin_ nM
CTLA-4 mAb 3 G4P O N
PD-l mAb 6 G4P
DART D 0
TRIDENT A ——l.0
DART B ——0.4
The effect of altering orientations and binding domains on binding was
igated by incubating PD-1 x CTLA-4 bispeciflc molecules comprising the CTLA-4
binding domains of CTLA-4 mAb l (e.g, DART B) and CTLA-4 mAb 3 (e. g., DART C and
DART D) in the presence of soluble human PD-1 (Figure 8C), or soluble human CTLA
Avi-His (Figure 8D), that had been coated onto support plates. Goat anti-human-Fcy-HRP
was employed as the secondary detection le to detect binding using PICO
chemiluminescent substrate. The results indicate that PD-l x CTLA-4 bispecific molecules
sing the CTLA-4 binding domains of CTLA-4 mAb 1 (e.g., DART B) and CTLA-4
mAb 3 (e.g, DART C and DART D) exhibit r binding to CTLA-4. The orientation of
the g domains (i.e., location on first or second chain) was not found to significantly alter
binding to PD-l or CTLA-4 (compare binding ofDART C and DART D).
B. ELISA Blocking Studies
A series of ELISA assays were conducted to evaluate the ability of bispeciflc
molecules of the invention to block ligand binding to PD-l and , alone and in
combination. Blockade of PD-Ll binding to PD-l was evaluated in the presence of equal
amounts of an irrelevant antigen and in the presence of equal amounts of CTLA-4. Plates were
coated with a 1:1 mix of His-tagged soluble human PD-1 (shPD-l) and a His-tagged irrelevant
antigen (irrAg) (2 ug/ml each), or a 1:1 mix of shPD—l and a His-tagged soluble human CTLA-
-l30-
4 (shCTLA-4) (2 ug/ml each). PD-l mAb 6 G4P, DART D, TRIDENT A or a CONTROL
TRIDENT (having two binding sites for RSV and one binding site for CTLA—4) at the indicated
concentrations were premixed for 5 mins with 6 ug/ml biotin-labeled PD-Ll and added to the
plates. PD—Ll binding was detected using streptavidin HRP 00). The results of this
evaluation are presented in s 9A-9B. All of the PD-l binding molecules tested were
found to be able to inhibit PD-Ll binding to PD-l.
Blockade of of B7-1 binding to CTLA-4 was evaluated in the ce of equal
amounts of an irrelevant antigen and in the presence of equal amounts of, or four-fold more
PD-l. Plates were coated with a 1:1 mix of shCTLA-4 and irrAg (2 ug/ml each), a 1:1 mix of
shCTLA-4 shPD-l (2 ug/ml each), or a 1:4 mix of shCTLA-4 (0.8 ug/ml) and shPD-l (3.2
. PD-1 mAb 6 G4P, DART D, T A, CTLA-4 mAb 3 G4P, or CONTROL
TRIDENT at indicated concentrations were premixed for 5 mins with 0.2 ug/ml biotin-labeled
B7-1 and added to the plates. B7-1 binding was detected using streptavidin HRP (13,000).
The results of this evaluation are presented in Figure 9C-9E. All of the CTLA-4 binding
molecules tested were found to be able to inhibit B7-1 g to CTLA-4. TRIDENT A
blocking of B7-1 binding was found to be enhanced by the interaction of its PD-1 binding arm
interacting with immobilized PD-l (compare to CONTROL TRIDENT which does not bind
PD-l) e 9D). Moreover, under the 1:4 CTLA-4:PD-1 condition, which better mimics
the relative expression levels seen on stimulated cells (see, Figure 19A), TRIDENT A blocking
of B7-1 binding was found to be further enhanced , the T A curve was further
shifted compared to the curve of the CONTROL TRIDENT, which does not bind PD-l)
(Figure 9E).
The results of these ELISA studies demonstrate that all of the PD-l binding
molecules tested were able to inhibit PD-Ll from binding to the PD-l (Figures 9A-9B). All
such molecules are nt for PD-l and exhibited similar inhibition profiles. All of the
CTLA-4 binding molecules tested were able to inhibit B7-1 from binding to immobilized
CTLA-4 (Figure 9C-9E) with les comprising two PD-l binding sites and one CTLA-4
binding site exhibiting stronger inhibition in the presence of PD-l (Figure 9D-9E). Thus, the
trivalent les comprising a single CTLA-4 binding site exhibit a PD-l biased blockade
of CTLA-4 ligands, trating that the CTLA-4 interaction can be tailored by adjusting the
valency.
-l3l-
C. E® Studies
The binding affinity of DART A, TRIDENT A, and CTLA-4 mAb 1 to human
CTLA-4 and cynomolgus monkey CTLA-4 was investigated using BIACORE® analysis.
Briefly, His-tagged soluble CTLA—4 (an extracellular portion ofhuman or cynomolgus monkey
CTLA-4 fused to a histidine-containing peptide) was captured on immobilized anti-PentaHis
and then ent concentrations 200 nM) ofthe CTLA-4 binding molecules were passed
over the lized CTLA-4 proteins. The kinetics of binding were determined Via
BIACORE® analysis (affinity by 1:1 ir binding model (simultaneous ka/kd), or avidity
by separate ka/kd 1:1 fit). The calculated ka, kd and KD from these studies are presented in
Table 11.
Table 11
Human CTLA-4 C no CTLA-4
Molecule ka kd KD ka kd Kl)
x105 xio'4 (nM) x105 x10'3 (11M)
—m“——-m
* avidity by
separate ka/kd 1:1 fit
1 y by 1:1 Langmuir binding model
] DART D is bivalent for CTLA-4 and exhibits binding affinities to human and
cynomolgus monkey CTLA—4 that are within about 2 to 4—fold that of the CTLA—4 mAb 1.
TRIDENT A is monovalent for CTLA-4 exhibits lower affinity for both human and
cynomolgus monkey CTLA-4 as expected in view of its reduced avidity.
The binding affinity of DART A, T A, PD-l mAb 6 G4P, and CTLA-4
mAb 3 GlAA to human PD-l was investigated using BIACORE® analysis. The binding
molecules were captured on immobilized F(ab)2 goat anti-human Fc and then different
concentrations (6.25-100 nM) of His-tagged soluble human PD-l were passed over the
immobilized binding molecules, and the kinetics of binding was determined via BIACORE®
analysis (Langmuir 1:1 binding fit). The ated ka, kd and KD from these studies are
presented in Table 12 (n.d., not detectable).
Table 12
Human PD-l
DART A, TRIDENT A, PD-l mAb 6 G4P are each bivalent for PD—l and exhibit
able g affinities. As expected, CTLA-4 mAb 3 GlAA did not exhibit any
detectable binding for human PD-l.
D. CTLA-4 Cell Based Assays
DART B, DART D, TRIDENT A, the anti-CTLA-4 antibodies CTLA-4 mAb 1,
CTLA-4 mAb 3 G4P, and an hIgG control dy were evaluated for binding to CHO cells
expressing cynomolgus monkey CTLA-4 (cynoCTLA-4) or human CTLA-4 (huCTLA-4).
The results of this evaluation are shown in Figures B. The binding molecules were
incubated in the presence of CHO cells that were sing either cynomolgus monkey
CTLA-4 (Figure 10A) or human CTLA-4 (Figure 10B). Binding to such cells was detected
using an anti-human Fc secondary antibody. The results show that all the molecules tested
were able to bind human and cynomolgus monkey CTLA—4 expressed on the surface of the
CHO cells. The anti-CTLA-4 antibodies exhibited similar binding profiles to huCTLA-4; the
bivalent, bispecific molecules DART B and DART D exhibited slightly reduced binding, and
the trivalent binding molecule. TRIDENT A, which is lent for CTLA-4 exhibited
lower binding than the molecules having higher valency for CTLA-4. The control antibody
did not bind. Similar results were seen for binding to cynoCTLA-4.
DART C, DART D, DART E, TRIDENT A, the anti-CTLA-4 antibodies CTLA-
4 mAb 1, CTLA-4 mAb 3 G1AA, and the anti-PD-l antibody PD-l mAb 6 G4P were ted
for binding to Jurkat cells which express huCTLA-4 but not PD-l on their surface. Binding of
the DART and TRIDENT molecules to human CTLA-4 was detected using anti-human FC
secondary Ab (FACS). The results of the tion are shown in Table 13 and Figure 11A
(DART C, DART D, DART E, CTLA-4 mAb 1, CTLA-4 mAb 3 G1AA, and PD-l mAb 6
G4P) and Figure 11B (CTLA-4 mAb l, CTLA—4 mAb 3 G1AA, PD-l mAb 6 G4P and
TRIDENT A). As shown in Figures 11A-11B, the PD-l antibody did not bind CTLA-4, but
all the CTLA-4 binding les tested were able to bind huCTLA-4 expressed on the surface
-l33-
of Jurkat cells. The anti-CTLA-4 antibodies exhibited r binding profiles; the bivalent,
bispeciflc molecules DART C, DART D, and DART E exhibited slightly d binding to
Jurkat cells and the trivalent binding molecule. TRIDENT A, which is monovalent for CTLA-
4 exhibited lower binding than the molecules having higher valency for CTLA—4.
Molecule EC50 (nM)
CTLA-4 mAb 1 0.4215
PD-1 mAb 6 G4P 6.557
CTLA-4 mAb 3 G1AA 0.3728
DART E 1.269
DART C 0.7575
DART D 08829
TRIDENT A 4.638
DART D, TRIDENT A and the anti-CTLA-4 antibodies CTLA-4 mAb l, CTLA-
4 mAb 3 GlAA were evaluated for their ability to block the CTLA-4 ligands B7-l and B7-2.
His-tagged derivatives of B7-1 and B7-2 were incubated in the presence of CTLA-4 Jurkat
cells. Binding of -1 and -2 was detected using an anti-His antibody. The results
of this evaluation are shown in Figure 12A (His-B7-1) and Figure 12B (His-B7—2). All the
molecules tested were found to be able to t B7-1 and B7-2 from binding CTLA-4
expressed on the surface of the Jurkat cells. The anti-CTLA-4 dies exhibited similar
inhibition profiles, the bivalent, bispeciflc molecule DART D was slight less potent an inhibitor
and the trivalent binding molecule. TRIDENT A, which is monovalent for CTLA-4 was less
potent than any of the molecules having higher valency for CTLA-4. The control antibody did
not t at all. The ELISA studies described above suggest that TRIDENT A, and r
les having two PD-l binding sites and one CTLA-4 binding site would be more potent
inhibitors in the presence of PD-l.
An lL-2/Luc Jurkat cell CTLA-4 reporter assay was used to evaluate the y
ofDART C, DART D, TRIDENT A, CTLA-4 mAb 3 GlAA and PD-l mAb 6 G4P to reverse
CTLA-4 immune checkpoint inhibitory signal as demonstrated by increased luciferase
expression. IL-2/Luc-Jurkat-CTLA-4 cells were therefore incubated in the presence of such
molecules (R:S= l : 0.3) for 30 min at 37 CC, after which time artificial antigen presenting Raji
cells were added and the incubation continued for 6 hours. The artificial antigen presenting
cells activate the TCR/CD3 complex on the Jurkat reporter cells. The results of the tion
are shown in Figure 13. All of the CTLA-4 binding molecules tested were able reverse the
—134—
CTLA-4 immune checkpoint inhibitory signal as determined by the luciferase assay.
TRIDENT A, which is monovalent for CTLA-4 was less potent in this assay than any of the
molecules having higher valency for CTLA-4. The control antibody did not inhibit at all. The
ELISA studies described above suggest that TRIDENT A, and similar molecules having two
PD-l binding sites and one CTLA-4 binding site would be more potent in the presence of PD-
E. PD-l Cell Based Assays
DART D, TRIDENT A, PD-l mAb 6 G4P, and CTLA-4 mAb 3 GlAA were
evaluated for their ability to bind NSO cells expressing PD-l but not CTLA-4. Binding
molecules were incubated in the presence of the cells and the mean fluorescence index of the
cells was measured. The s of this tion are presented in Figure 14. As expected,
the CTLA-4 antibody did not bind, all the bispeciflc binding les were found to be able
to bind PD-l expressed on the e ofN80 cells. All the iflc molecules are bivalent
for PD-l and exhibited similar binding to NSO cells.
DART D, TRIDENT A, PD—l mAb 6 G4P, and CTLA-4 mAb 3 GlAA were
ted for their ability to block binding between PD-l expressed on the cell surface and its
ligands PD-Ll and PD-L2. PD-Ll-PE or PD-L2-PE was incubated in the presence of such
binding molecules and their ability to bind to NSO-PD-l cells was evaluated using FACS. The
results of this evaluation are presented in Figure 15A ) and Figure 15B (PD-L2). As
expected, the CTLA-4 antibody did not t, all of the PD-l binding molecules tested were
able to inhibit both PD-Ll (Figure 15A) and PD-L2 (Figure 15B) from binding to the PD-l
expressed on the surface of the NSC cells. All the PD-l binding molecules are bivalent for
PD-l and exhibited similar inhibition profiles.
DART D, TRIDENT A, CTLA-4 mAb 3 GlAA, and PD-l mAb 6 G4P were also
evaluated in a PD-l blockade reporter assay. Such binding molecules were ted in the
presence of PD-Ll+ CH0 and Jurkat effector cells, and the ability of the binding molecules to
block immune inhibition (by blocking the PD-l / PD-Ll interaction) was assessed by following
the extent of CD3-mediated activation (as trated by increased luciferase expression in
the NFAT-luc/PD-l Jurkat assay; Promega). The results of this evaluation are presented in
Figure 16. All of the PD-l binding molecules tested were able to reverse the PD-l immune
checkpoint inhibitory signal as trated by increased luciferase expression. All the PD-l
-l35-
binding les are bivalent for PD-1 and exhibited similar y to inhibit PD-1 blockade
of T cell signaling. The CTLA-4 antibody did not inhibit at all in this system.
F. CTLA-4/PD-1 Cell Based Assays
DART D, TRIDENT A, and a ve control antibody were examined for their
ability to ate PD-1 and CTLA-4 in an enzyme-fragment complementation assay by
DiscoverX. In brief, aliquots of the U208 CTLA—4(1-195)—PK PD-1(1-199)-EA cell line #9
were plated in quadruplicate at 5,000 cells / well in DiscoverX CP5 plating media on 384-well
plates. Cells were allowed to attach for 4 hours at 37 oC / 5% C02. 11 point, 1:3 dilution series
of each of the binding molecules were then added to the PD-1 — CTLA-4 cells. The plates were
incubated overnight (16 hrs) at 37 °C / 5% C02. PathHunter detection reagent was added to
the wells, which were then ted for 1 hour at room temperature in the dark, and the plate
was then read on an Envision luminometer. The results of this tion are presented in
Table 14 and Figure 17 (U208 CTLA-4(1—195)—PK PD-1(1-199)—EA cell line #9). Both the
bispecific DART D and TRIDENT A molecules show comparable co-engagement ofPD-l and
CTLA-4 in cells that co-express both ors, as shown by enzyme-fragment
complementation, ting that the bispecific molecules of the invention are capable of
simultaneous binding of PD-l and CTLA-4, and further indicating that anchoring through PD-
1 compensates for the decreased CTLA-4 avidity of the T molecule when both target
receptors are expressed. This finding is consistant with the ELISA inhibition s described
above. The negative control elicited no significant increase in signal in the PD1-CTLA4 cell
line. Incubation with higher concentrations of TRIDENT A elicited a robust signal increase in
the U208 PD1-CTLA4 zation cell line (S:B=12.7). The response with DART D in
dose-response testing in the PD-1 — CTLA-4 cell line was smaller in magnitude (S:B=9.2) but
the EC50 values were similar for both these molecules (EC50=20 pM).
Table 14
—Negative Control TRIDENT A DART D
HillSlope ~15.99 1.103 0.8095
EC50 (nM) ~6.883 x 10-10 2.123 x 10-11 2.090 x 10-11
The ability ofDART D, TRIDENT A, CTLA-4 mAb 3 G1AA, PD—l mAb 6 G4P
and the combinations of CTLA-4 mAb 3 G1AA/PD-1 mAb 6 G4P (Ab Combo 1) to enhance
the response of a Mixed Lymphocyte Reaction (MLR) was evaluated. Monocyte-derived
dendritic cells were generated by ng CD14+ monocytes (isolated from PBMCs using
Miltenyi positive selection kit) with GM-CSF (100 ng/ml) and IL-4 (10 ng/ml) and then
culturing the cells for 7 days. On day 7, cells were harvested and plated into 96—well plates
and ed for 24 h. On day 8, CD4+ T-cells (isolated by negative selection using Myltenyi
kit) at 200,000 cells/well and test articles were added and cultured for 3 days. IFN—g levels in
culture supernatants were then measured using using human DuoSet ELISA Kits for IFN—y
(R&D Systems) according to the manufacturer’s instructions. When antibodies were used in
ation, each antibody was added at the indicated concentration so that the total
concentration of antibody added is d, The e y is plotted in Figure 18. Both
the bispecific DART D and TRIDENT A molecules were found to enhance the MLR response
to the same extent or slightly better than the combination of individual parental antibodies.
The ability ofDART D, T A, CTLA-4 mAb 3 GlAA, PD-l mAb 6 G4P
and the combination of CTLA-4 mAb 1/PD-1 mAb 1 (Ab Combo 1) to enhance cytokine
release through checkpoint inhibition was also evaluated in a Staphylococcus aureus
enterotoxin type B (SEB) re-stimulation assay. In general, PBMCs were d from whole
blood (e.g., using the Ficoll-Paque Plus density nt centrifugation method (GE
Healthcare) according to manufacturer’s instructions) from y donors. Purified PBMCs
were cultured in RPMI-media + 10% heat inactivated FBS + 1% Penicillin/Streptomycin in T-
bulk flasks for 2-3 days alone or with SEB (e.g., Sigma-Aldrich) at 0.5 ng/mL (primary
stimulation). At the end of the first round of SEB-stimulation, PBMCs are washed twice with
PBS and immediately plated in 96—well tissue culture plates at a concentration of 1-5 X 105
cells/well in media alone, media with a control or a test article, media with SEB at 0.5 ng/mL
(secondary stimulation) and no antibody, or media with SEB and a control IgG or a test e,
and were cultured for an additional 2-3 days. At the end ofthe second stimulation, supernatants
were harvested to measure cytokine secretion (e.g, using human DuoSet ELISA Kits for IFNy,
IL-2, TNFOL, IL-10, and IL-4 (R&D Systems) ing to the manufacturer’s instructions).
Figures 19A-19B show fluorescence-activated cell sorting (FACS) dot plots of
the expression of PD-l vs. CTLA-l by such PBMCs in the absence (Figure 19A) or presence
(Figure 19B) of SEB stimulation. Figure 19C shows the effect of the SEB stimulation on
IFN—y secretion. PBMCs were stimulated with Staphylococcus aureus enterotoxin type B
(SEB) at 0.5 ng/ml for 48 hours. Cells were then harvested, washed and re-plated in 96 well
plates with antibodies at various concentrations with fresh SEB for an additional 48 hours. The
supernatant was then harvested and ed by flow try ELISA for IFN—y production.
-l37-
Both the bispecific DART and the TRIDENT protein showed an increase in IFN—y response
that recapitulated the response observed with the combination of the dual parental mAbs.
Similar results were seen in a SEB Stimulation assay in which the PBMCs were cultured with
a high concentration (500 ng/mL) of SEB for 72 hours. To further investigate the affect of
PD] x CTLA-4 bispeciflc molecules on the T-cell response, PBMCs were stimulated with 0.5
ng/ml SEB for 48 hours, harvested, washed and re-plated in 96-well plates with fresh SEB and
either DART D, TRIDENT A, CTLA-4 mAb 3 GlAA, PD—l mAb 6 G4P or the ation
of CTLA-4 mAb 3 GlAA / PD-l mAb 6 G4P (Ab Combo 1) for an additional 48 hours, and
the released IL—2 was measured (Figure 19D). Figures D show that the administration
of PDl X CTLA-4 bispecific molecules significantly enhanced T-cell responses. When
antibodies were used in combination, each antibody was added at the indicated concentration
so that the total concentration of antibody added is d.
Example 6
In Vivo Studies
A. Activity of a PD-l x CTLA-4 Bispecific Molecule in GVHD Murine Model
The activity of a representative PDl X CTLA-4 bispeciflc bivalent molecule,
DART D was assessed in a PBMC implanted NOG murine model of Graft Versus Host Disease
(GVHD). The study design is presented in Table 15.
Table 15
Group N/sex Treatment Dose Route/ Cell Implant(s)
(ug/kg) Schedule
DARTD IV/Q7Dx7 PBMC (1P, 1E7)
DART D IV/Q7D x 7 PBMC (IP, 1E7)
DART D IV/Q7D x 7 PBMC (IP, 1E7)
] CD3+ T cell counts were med via FACS on study day 14 and are plotted in
Figure 20A. Survival was monitored over the course of the study and is plotted as percent
survival in Figure 20B. sed T cell expansion and accelerated GVHD was seen in animal
treated with 500 ug/kg DART D, consistence with enhancement of T cell immune responses.
-l38-
B. Toxicology and cokinetic Study of PD-l x CTLA-4 Bispecific
Molecules
The safety profile of a representative PDl X CTLA-4 bispecific bivalent molecule,
DART D, and a representative PDl X CTLA-4 ific trivalent molecule, TRIDENT A, was
assessed in a non-GLP (Good Laboratory Practice) dosing study in cynomolgus monkeys. In
on, l markers pharmacodynamics activity were ed.
In this study the potential toxicity of the PD-l x CTLA—4 bispecific molecules, when
administered by multiple intravenous infusions was evaluated. The study design is presented
in Table 16.
Table 16
Group Test Article Dose (mg/kg) Number of
Animals
1M 1F
3M 3F
—3M 3F
TRIDENTA —— 2M 1F
A 2-week interval was thus provided between the 50 mg/kg dose and escalation to
75 mg/kg, The following parameters and nts were evaluated in this study: clinical signs,
body s, food consumption, body temperature, clinical pathology ters
(coagulation, clinical chemistry and hematology pre-dose and 23 hours post-dose for Groups
1-3, out to day 22 for Group 4), bioanalysis and toxicokinetic parameters, flow cytometry (pre-
dose and 23 hours post dose), cytokines (2, 6, 22 hours post-dose). Anti-Drug-Antibodies were
evaluated for Group 4 only on days 8, 15 and 22. Necropsy was performed 48 hours after the
3r01 dose for Groups 1-3 only. The in vivo binding and activity of the PD-l x CTLA-4 bispeciflc
molecules was also examined as described below.
All animals survived until scheduled euthanasia. No adverse clinical observations
in animals receiving 3 doses up to 75 mg/kg/week. In ular, no diarrhea was observed.
The histopathology was also rkable. Increases in globulin levels were observed in the
treatment groups and the organ weight of the spleen and thymus were observed to increase in
Groups 2—3 (see Table 17, Group 4 was not necropsied), as would be expected upon stimulation
of the immune system. The serum concentration-time profiles for each of the treatment groups
are shown in Figures 21A-21C and are tent with molecules comprising human Fc
regions in cynomolgus monkeys.
-l39-
Table 17
SleenzBod Weiht Th muszBod Wei_ht
-—-_0.080mean,n=2 0.035 mean,n=2
DARTD 0.239 mean, n=6 0.088 mean, n=6
DARTD 0.225 mean, n=6 0.084 mean, n=6
It has been reported that ses in absolute lymphocyte count (ALC) after
treatment with the anti-CTLA-4 antibody ipilimumab appear to correlate with clinical benefit
and overall survival (see, e. g., Ku, G.Y., et al. (2010) “Single-Institution ence With
Ipilimumab In AdvancedMelanoma Patients In The Compassionate Use Setting: Lymphocyte
Count After 2 Doses Correlates With Survival” Cancer 1 16(7): 1767-1775) indicating that ALC
may be a useful pharmacodynamic (PD) endpoint. The ALC counts were ed in each of
the above-described groups pre—treatment and post-treatment on days 2, 8, 9, 15 and 16.
Occupancy of DART D or TRIDENT A binding sites on PD-1+ T cells was determined by
measuring the mean fluorescent intensity (MFI) of anti-human IgG4 Alexa 488+ events in the
CD4+/PD-1+ and CD8+/PD—1+ T cell tions under two conditions for each monkey
blood sample. Under one ion, the MFI values obtained in the presence of excess DART
D or TRIDENT A were used to determine the maximal DART D or TRIDENT A binding
intensity on PD-1+ cells within each cell population. Under the second condition, the MFI
values obtained in the presence of excess negative control were used to determine the binding
intensity of PD-1+ cells within each cell population exhibited in the DART D or TRIDENT A-
treated animal at the time of sample collection. The difference n the two conditions was
used to calculate % occupancy of DART D or TRIDENT A binding sites on PD-1+ T cell
subsets in DART D or TRIDENT A-treated animals as follows:
MFI of Anti-HulgG4+ Events in
% Occupancy of DART D or TRIDENT A {the Presence of Excess AEX1367]
_ x100
Binding Sites On PD-l+ T Cell Subsets [ ce of Excess DART D or TRIDENT A]MFI ofAnti-HngG4+ Events in the
The absolute counts, and the percent change normalized to Day 1 are plotted in
Figure 22A (in thousands of cells /ul (th/ul)) and in Figure 22B (percent change in the ALC
normalized to Day 1 (D1)). Each of the DART D treatment groups exhibited an l drop in
ALC counts immediately after treatment followed by an se in ALC to levels well above
ne. A similar trend was observed for the TRIDENT A treatment group, which only
received only one lower dose.
—140—
In addition, CD4+ T cell eration and PD-l occupancy on T cells were
examined for the above-described Groups 1—3. Bn'efly, CD3+/PD-l+ T cells were analyzed by
FACS to evaluate the t cells bound by DART D. Forty microliters ofthe negative control
molecule (respiratory syncytial virus (RSV) X fluorescein IgG4,K Fc DART) or test article
(DART D or TRIDENT A) at 35 ug/mL were added to a 96 ell plate. One hundred
microliters of well-mixed anticoagulated whole blood were then added into each well,
thoroughly mixed using a pipette, and incubated in the dark for 45 to 75 minutes at ambient
temperature. One thousand microliters of 1x BD FACS Lysing solution were then added to
each well and mixed using a pipette; the plate was then incubated in the dark for an additional
to 20 minutes at ambient temperature. The plate was then centrifuged at 400 x g for 5
minutes and the supernatant was discarded. One thousand microliters of FACS buffer were
added in each well and mixed as a washing step. The plate was then fuged at 400 x g for
s and the supernatant was discarded. The cell pellet was resuspended with twenty
microliters of Panel 1 antibody mix and incubated for 30 to 60 minutes at ambient temperature.
The plate was washed as in us wash steps. At the end of incubation, the plate was washed
again and the cell pellet was finally resuspended in three-hundred microliters of FACS buffer
and the samples were analyzed with a BD FACSCanto 11 cell analyzer. The results of the
analysis are shown in Figures 23A-23B.
As shown in Figure 23A (for DART D administered at 50 mg/kg) and Figure
23B (for DART D administered at 75 mg/kg), PD-l ncy (i.e., binding by DART D) was
maximal hout the duration of treatment for Groups 2 and 3. Proliferation CD4+ T cells
were ted by FACS for co-expression of Ki-67 (a cellular marker for proliferation).
Twenty microliters of an antibody mixture A (containing antibodies that bind cell
surface markers: CD45, CD3, CD4, and CD8) were added into a 96 deep-well plate. Fifty
microliters of ixed anticoagulated whole blood were then added into each well, mixed
ghly using a pipette, and incubated in the dark for 15 to 45 minutes at ambient
temperature. Five hundred microliters of 1x BD FACS Lysing solution were then added to
each well and mixed using a pipette, the plate was then incubated in the dark for an additional
to 20 minutes at ambient temperature. The plate was centrifuged at 1200 rpm for 5 minutes
and the supernatant was discarded. Five hundred microliters of FACS buffer were then added
in each well and mixed as a washing step. The plate was then centrifuged at 1200 rpm for 5
minutes and the supernatant was discarded. The cell pellet was resuspend in antibody mixture
—141—
B ining antibodies that bind the ellular marker, Ki 67) or were resuspended in an
iso antibody preparation (containing isotype ls for the intracellular marker) and
incubated in the dark for 15 to 45 minutes. After washing, the cell pellet was resuspended in
three hundred iters of FACS buffer and the samples were analyzed with a BD
FACSCanto II cell analyzer. From a T Cell Intracellular ng Panel, the percentage of
CD4+ and CD8+ cells was determined as the fraction of total CD45+ leukocyte gated cells.
The cellular events of Ki 67+ in gated CD4+ cells were counted and the percentage of CD4+/Ki
67+ T cells (proliferative CD4 T cells) was determined as the fraction of total CD4+ cells. In
a similar manner, the percentage of CD8+/Ki 67+ T cells (proliferative CD8 T cells) was
determined as the on of total CD8+ cells. The results of the analysis are shown in Figures
24A-24B.
As shown in Figures 24A-24B, proliferation of CD4+ T cells was markedly
ed in treatment Groups 2 and 3 throughout the duration of treatment. The results of this
study indicate that administration of PD1 x CTLA-4 ific molecules is well tolerated in
cynomolgus monkeys at trations of up to 75 mg/kg. Well above the 5 mg/kg dosage
where adverse events have been reported for cynomolgus monkeys treated with Ipilimumab.
The molecules exhibited a favorable pharmacokinetic profile and a number of markers
pharmacodynamics activity were observed including increased lymphocyte count, increased
in levels, increased spleen and thymus organ weights, increased T cell proliferation (both
T cell counts and sion of Ki-67) and maximal PD-1 occupancy on T cells.
All ations and patents mentioned in this specification are herein
incorporated by reference to the same extent as if each individual publication or patent
application was specifically and individually indicated to be incorporated by reference in its
entirety. While the invention has been described in connection with specific embodiments
thereof, it will be understood that it is capable of further modifications and this application is
intended to cover any ions, uses, or adaptations of the invention following, in general, the
principles of the invention and ing such departures from the present disclosure as come
within known or customary practice within the art to which the invention pertains and as may
be applied to the essential features hereinbefore set forth.
Other aspects of the invention as described herein are defined in the following
paragraphs:
1. A bispecific molecule possessing both one or more e-binding sites
capable of immunospecific binding to (an) epitope(s) of PD-1 and one or more
epitope-binding sites capable of immunospecific binding to (an) epitope(s) of
CTLA-4, wherein said molecule comprises:
(A) a Heavy Chain Variable Domain and a Light Chain Variable Domain of
an antibody that binds PD-1; and
(B) a Heavy Chain Variable Domain and a Light Chain Variable Domain of
an antibody that binds CTLA-4;
wherein said molecule is:
(i) a diabody, said y being a covalently bonded complex that
ses two, three, four or five polypeptide chains; or
(ii) a trivalent binding molecule, said trivalent binding molecule being a
covalently bonded complex that comprises three, four, five, or more
polypeptide chains.
2. The bispecific molecule of paragraph 1, wherein said le exhibits an
activity that is enhanced ve to such activity ted by two monospecific
molecules one of which possesses said Heavy Chain Variable Domain and said
Light Chain Variable Domain of said antibody that binds PD-1 and the other of
which possesses said Heavy Chain Variable Domain and said Light Chain
Variable Domain of said antibody that binds .
3. The ific molecule of paragraph 1 or 2, wherein said molecule elicits fewer
immune-related adverse events (irAEs) when administered to a subject in need
thereof relative to such iREs elicited by the administration of a monospecific
antibody that binds CTLA-4.
4. The bispecific molecule of any one of paragraphs 1-3, wherein said molecule
comprises an Fc Region.
. The bispecific molecule of aph 4, wherein said Fc Region is a variant Fc
Region that comprises:
(A) one or more amino acid modifications that reduces the ty of the
variant Fc Region for an FcγR; and/or
(B) one or more amino acid modifications that enhances the serum half-life
of the variant Fc Region.
6. The bispecific molecule of paragraph 5, wherein said modifications that reduces
the affinity of the variant Fc Region for an FcγR comprise the substitution of
L234A; L235A; or L234A and L235A, wherein said numbering is that of the
EU index as in Kabat.
7. The bispecific molecule of paragraph 5 or 6, wherein said modifications that
that enhances the serum ife of the variant Fc Region comprise the
substitution of M252Y; M252Y and S254T; M252Y and T256E; M252Y,
S254T and T256E; or K288D and H435K, wherein said numbering is that of
the EU index as in Kabat.
8. The bispecific molecule of any one of paragraphs 1-7, n said molecule is
said y and comprises two epitope-binding sites capable of
immunospecific binding to an epitope of PD-1 and two epitope-binding sites
e of immunospecific binding to an epitope of CTLA-4.
9. The bispecific molecule of any one of paragraphs 1-7, wherein said molecule is
said trivalent binding molecule and comprises two epitope-binding sites capable
of immunospecific binding to an epitope of PD-1 and one epitope-binding site
capable of immunospecific binding to an epitope of CTLA-4.
. The ific molecule of any one of aphs 1-9, wherein said molecule is
capable of binding to PD-1 and CTLA-4 molecules present on the cell surface.
11. The bispecific molecule of any one of paragraphs 1-10, wherein said molecule
is capable of simultaneously binding to PD-1 and CTLA-4.
12. The bispecific molecule of any one of paragraphs 1-11, n said molecule
es the stimulation of immune cells.
13. The bispecific le of aph 12, wherein said stimulation of immune
cells results in:
(A) immune cell proliferation; and/or
(B) immune cell production and/or release of at least one cytokine; and/or
(C) immune cell production and/or release of at least one lytic molecule;
and/or
(D) immune cell expression of at least one activation marker.
14. The bispecific molecule of paragraph 12 or 13, wherein said immune cell is a
T-lymphocyte or an NK-cell.
. The ific molecule of any one of aphs 1-14, wherein said epitopebinding
sites capable of immunospecific binding to an epitope of PD-1
(A) the VH Domain of PD-1 mAb 1 (SEQ ID NO:47) and the VL Domain
of PD-1 mAb 1 (SEQ ID NO:48); or
(B) the VH Domain of PD-1 mAb 2 (SEQ ID NO:49) and the VL Domain
of PD-1 mAb 2 (SEQ ID NO:50); or
(C) the VH Domain of PD-1 mAb 3 (SEQ ID NO:51) and the VL Domain
of PD-1 mAb 3 (SEQ ID NO:52); or
(D) the VH Domain of PD-1 mAb 4 (SEQ ID NO:53) and the VL Domain
of PD-1 mAb 4 (SEQ ID NO:54); or
(E) the VH Domain of PD-1 mAb 5 (SEQ ID NO:55) and the VL Domain
of PD-1 mAb 5 (SEQ ID NO:56); or
(F) the VH Domain of PD-1 mAb 6 (SEQ ID NO:57) and the VL Domain
of PD-1 mAb 6 (SEQ ID NO:58); or
(G) the VH Domain of PD-1 mAb 6-I VH (SEQ ID NO:86) and the VL
Domain of PD-1 mAb 6-SQ VL (SEQ ID NO:87); or
(H) the VH Domain of PD-1 mAb 7 (SEQ ID NO:59) and the VL Domain
of PD-1 mAb 7 (SEQ ID NO:60); or
(I) the VH Domain of PD-1 mAb 8 (SEQ ID NO:61) and the VL Domain
of PD-1 mAb 8 (SEQ ID .
16. The bispecific molecule of any one of paragraphs 1-15, wherein said epitopebinding
site(s) capable of immunospecific binding to an epitope of CTLA-4
comprise:
(A) the VH Domain of CTLA-4 mAb 1 (SEQ ID NO:76) and the VL
Domain of CTLA-4 mAb 1 (SEQ ID NO:77); or
(B) the VH Domain of CTLA-4 mAb 2 (SEQ ID NO:78) and the VL
Domain of CTLA-4 mAb 2 (SEQ ID NO:79); or
(C) the VH Domain of CTLA-4 mAb 3 (SEQ ID NO:90) and the VL
Domain of CTLA-4 mAb 3 (SEQ ID .
17. The bispecific molecule of paragraph 16, wherein:
(A) said epitope-binding sites capable of immunospecific binding to an
epitope of PD-1 comprise the VH Domain of PD-1 mAb 6-I VH (SEQ
ID NO:86) and the VL Domain of PD-1 mAb 6-SQ (SEQ ID NO:87);
(B) said epitope-binding site(s) e of immunospecific binding to an
epitope of CTLA-4 comprise(s) the VH Domain of CTLA-4 mAb 3
(SEQ ID NO:90) and the VL Domain of CTLA-4 mAb 3 (SEQ ID
NO:91).
18. The bispecific molecule of any one of paragraphs 1-17, wherein said molecule
comprises:
(A) two polypeptide chains having SEQ ID NO:95, and two ptide
chain having SEQ ID NO:96; or
(B) two polypeptide chains having SEQ ID NO:97, and two polypeptide
chain having SEQ ID NO:98; or
(C) two polypeptide chains having SEQ ID NO:99, and two polypeptide
chain having SEQ ID ; or
(D) two polypeptide chains having SEQ ID NO:102, and two polypeptide
chain having SEQ ID NO:103; or
(E) two polypeptide chains having SEQ ID NO:101, and two polypeptide
chain having SEQ ID NO:100; or
(F) one polypeptide chains having SEQ ID NO:104, one polypeptide chain
having SEQ ID NO:105, one polypeptide chain having SEQ ID
NO:106, and one polypeptide chain having SEQ ID NO:107; or
(G) one polypeptide chains having SEQ ID NO:108, one polypeptide chain
having SEQ ID NO:105, one polypeptide chain having SEQ ID
NO:109, and one polypeptide chain having SEQ ID NO:107.
19. A pharmaceutical composition that comprises an effective amount of the
bispecific molecule of any of paragraphs 1-18 and a pharmaceutically
able carrier.
. The bispecific le of any one of paragraphs 1-18, wherein said molecule
is used to promote stimulation of an immune-mediated response of a subject in
need thereof.
21. The bispecific molecule of any one of paragraphs 1-18, wherein said molecule
is used in the treatment of a disease or condition associated with a suppressed
immune system.
22. The bispecific le of paragraph 21, wherein the disease or condition is
cancer or an infection.
23. The ific molecule of paragraph 22, wherein said cancer is characterized
by the presence of a cancer cell selected from the group consisting of a cell of:
an adrenal gland tumor, an AIDS-associated cancer, an alveolar soft part
sarcoma, an astrocytic tumor, bladder , bone cancer, a brain and spinal
cord cancer, a metastatic brain tumor, a breast cancer, a carotid body tumors, a
cervical cancer, a chondrosarcoma, a ma, a chromophobe renal cell
carcinoma, a clear cell carcinoma, a colon cancer, a colorectal cancer, a
cutaneous benign fibrous histiocytoma, a desmoplastic small round cell tumor,
an ependymoma, a Ewing’s tumor, an extraskeletal myxoid chondrosarcoma, a
fibrogenesis imperfecta ossium, a fibrous sia of the bone, a gallbladder
or bile duct , c cancer, a gestational trophoblastic disease, a germ
cell tumor, a head and neck cancer, hepatocellular oma, an islet cell
tumor, a Kaposi’s Sarcoma, a kidney cancer, a leukemia, a lipoma/benign
tous tumor, a liposarcoma/malignant lipomatous tumor, a liver cancer, a
lymphoma, a lung cancer, a medulloblastoma, a melanoma, a meningioma, a
multiple ine neoplasia, a multiple myeloma, a myelodysplastic
syndrome, a neuroblastoma, a neuroendocrine tumors, an ovarian cancer, a
pancreatic cancer, a papillary thyroid carcinoma, a parathyroid tumor, a
pediatric cancer, a eral nerve sheath tumor, a phaeochromocytoma, a
pituitary tumor, a prostate cancer, a posterious uveal melanoma, a rare
hematologic disorder, a renal metastatic cancer, a rhabdoid tumor, a
rhabdomysarcoma, a sarcoma, a skin , a soft-tissue sarcoma, a squamous
cell cancer, a stomach , a synovial a, a testicular cancer, a thymic
carcinoma, a thymoma, a thyroid metastatic cancer, and a uterine cancer.
24. The bispecific molecule of paragraph 22, wherein said infection is terized
by the presence of a bacterial, fungal, viral or protozoan pathogen.
Still further embodiments are within the scope of the following claims.
Claims (18)
1. A bispecific molecule, comprising: (A) one or more epitope-binding sites e of immunospecific binding to an epitope of PD-1 comprising the VH Domain of PD-1 mAb 6-I VH (SEQ ID NO:86) and the VL Domain of PD-1 mAb 6-SQ (SEQ ID NO:87); and (B) one or more epitope-binding sites capable of immunospecific binding to an epitope of CTLA-4 comprising the VH Domain of CTLA-4 mAb 3 (SEQ ID NO:90) and the VL Domain of CTLA-4 mAb 3 (SEQ ID NO:91).
2. The bispecific molecule of claim 1, wherein said le comprises an Fc .
3. The bispecific molecule of claim 2, wherein said Fc Region is a t Fc Region that comprises: (A) one or more amino acid cations that reduces the affinity of the variant Fc Region for an FcγR; and/or (B) one or more amino acid cations that enhances the serum half-life of the variant Fc Region.
4. The bispecific molecule of claim 3, wherein said modifications that reduces the affinity of the variant Fc Region for an FcγR comprise the substitution of L234A; L235A; or L234A and L235A, wherein said numbering is that of the EU index as in Kabat.
5. The bispecific molecule of claim 3 or claim 4, wherein said modifications that that enhances the serum half-life of the variant Fc Region comprise the substitution of M252Y; M252Y and S254T; M252Y and T256E; M252Y, S254T and T256E; or K288D and H435K, wherein said numbering is that of the EU index as in Kabat.
6. The bispecific molecule of any one of claims 1-5, which is an antibody, antibody fragment, singlechain binding molecule, diabody, or bispecific T-cell engaging antibody.
7. The bispecific molecule of claim 1, comprising two polypeptide chains each comprising SEQ ID NO:99 and two polypeptide chains each comprising SEQ ID .
8. The bispecific molecule of claim 1, comprising one polypeptide chain comprising SEQ ID NO:104, one polypeptide chain comprising SEQ ID NO:105, one polypeptide chain comprising SEQ ID NO:106, and one polypeptide chain comprising SEQ ID NO:107.
9. The bispecific molecule of claim 1, comprising two polypeptide chains each comprising SEQ ID NO:101 and two polypeptide chains each comprising SEQ ID .
10. The bispecific molecule of claim 1, comprising one polypeptide chain comprising SEQ ID NO:108, one polypeptide chain comprising SEQ ID NO:105, one polypeptide chain sing SEQ ID , and one polypeptide chain comprising SEQ ID NO:107.
11. A pharmaceutical composition that comprises an effective amount of the bispecific molecule of any one of claims 1-10 and a pharmaceutically acceptable carrier.
12. Use of the bispecific molecule of any one of claims 1-10, or the pharmaceutical composition of claim 11 for the manufacture of a medicament for promoting stimulation of an immune-mediated response or for treating a disease or condition associated with a suppressed immune .
13. The use of claim 12, wherein the disease or condition is cancer or an infection.
14. The use of claim 13, n said cancer is characterized by the presence of a cancer cell selected from the group consisting of a cell of: an adrenal gland tumor, an AIDS-associated cancer, an alveolar soft part sarcoma, an astrocytic tumor, bladder cancer, bone cancer, a brain and spinal cord cancer, a metastatic brain tumor, a breast cancer, a carotid body tumors, a cervical cancer, a chondrosarcoma, a chordoma, a chromophobe renal cell carcinoma, a clear cell carcinoma, a colon cancer, a colorectal cancer, a cutaneous benign fibrous histiocytoma, a desmoplastic small round cell tumor, an ependymoma, a s tumor, an extraskeletal myxoid osarcoma, a fibrogenesis imperfecta ossium, a fibrous dysplasia of the bone, a gallbladder or bile duct cancer, gastric cancer, a ional trophoblastic disease, a germ cell tumor, a head and neck , hepatocellular carcinoma, an islet cell tumor, a Kaposi’s Sarcoma, a kidney cancer, a leukemia, a lipoma/benign lipomatous tumor, a liposarcoma/malignant lipomatous tumor, a liver cancer, a lymphoma, a lung cancer, a medulloblastoma, a melanoma, a meningioma, a multiple endocrine neoplasia, a multiple a, a myelodysplastic syndrome, a neuroblastoma, a neuroendocrine tumors, an ovarian cancer, a pancreatic , a papillary thyroid carcinoma, a parathyroid tumor, a ric , a peripheral nerve sheath tumor, a phaeochromocytoma, a pituitary tumor, a prostate cancer, a posterior uveal melanoma, a rare logic disorder, a renal metastatic cancer, a rhabdoid tumor, a rhabdomyosarcoma, a sarcoma, a skin cancer, a issue sarcoma, a squamous cell cancer, a stomach cancer, a al sarcoma, a testicular cancer, a thymic carcinoma, a thymoma, a thyroid metastatic cancer, and a uterine cancer.
15. The use of claim 13, wherein the cancer is characterized by the presence of a cancer cell selected from the group consisting of a cell of: a colorectal cancer, a lung cancer, a al , a head and neck cancer, a prostate cancer, a sarcoma, and a thymoma.
16. The use of claim 13, wherein the cancer is terized by the ce of a cancer cell selected from the group consisting of a cell of: a colorectal cancer, a hepatocellular carcinoma, a glioma, a kidney cancer, a breast cancer, a multiple myeloma, a bladder cancer, a neuroblastoma, a sarcoma, a non-Hodgkin’s lymphoma, a non-small cell lung cancer, an ovarian cancer, a pancreatic cancer and a rectal cancer.
17. The use of claim 13, n the cancer is characterized by the presence of a cancer cell selected from the group ting of a cell of: a colorectal cancer, a gastric cancer, a melanoma, a prostate cancer, a pancreatic cancer, a renal cancer, a bladder , a mammary cancer, a lung cancer, a fibrosarcoma, a human mantle cell lymphoma, a Raji Burkitt’s lymphoma.
18. The use of claim 13, wherein said infection is characterized by the presence of a bacterial, fungal, viral or protozoan pathogen. K—coil {or E-coii) Polypeptide Chain 1 COOHWC Linker 22 Linker 2 Polypeptide Chain 2 COOH WI: C ------/S
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562266944P | 2015-12-14 | 2015-12-14 | |
NZ74302116 | 2016-12-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ782254A true NZ782254A (en) | 2022-05-27 |
Family
ID=81709906
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ782254A NZ782254A (en) | 2015-12-14 | 2016-12-12 | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof |
Country Status (1)
Country | Link |
---|---|
NZ (1) | NZ782254A (en) |
-
2016
- 2016-12-12 NZ NZ782254A patent/NZ782254A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11840571B2 (en) | Methods of using bispecific molecules having immunoreactivity with PD-1 and CTLA-4 | |
TWI773646B (en) | Lag-3-binding molecules and methods of use thereof | |
TWI691509B (en) | Pd-1-binding molecules and methods of use thereof | |
US20170233472A1 (en) | ROR1-Binding Molecules, and Methods of Use Thereof | |
TW201831511A (en) | Bispecific Binding Molecules That Are Capable of Binding CD137 and Tumor Antigens, and Uses Thereof | |
KR20190015520A (en) | Combination Therapy | |
WO2016122701A1 (en) | Anti-dr5 antibodies and molecules comprising dr5-binding domains thereof | |
TW201938192A (en) | Bispecific CD16-binding molecules and their use in the treatment of disease | |
WO2020041404A1 (en) | Pd-l1-binding molecules and use of the same for the treatment of disease | |
JP7378567B2 (en) | LAG-3 binding molecules and methods of use thereof | |
NZ782254A (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
EA043373B1 (en) | BISPECIFIC MOLECULES WITH IMMUNOREACTIVITY AGAINST PD-1 AND CTLA-4, AND METHODS OF THEIR APPLICATION | |
TW202000231A (en) | Variant CD3-Binding Domains and their use in combination therapies for the treatment of disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 DEC 2023 BY CPA GLOBAL Effective date: 20221027 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 DEC 2024 BY CPA GLOBAL Effective date: 20231026 |